
==== Front
Int J Mol Sci
Int J Mol Sci
ijms
International Journal of Molecular Sciences
1422-0067
MDPI

10.3390/ijms22179207
ijms-22-09207
Review
Tau Protein Interaction Partners and Their Roles in Alzheimer’s Disease and Other Tauopathies
Sinsky Jakub
Pichlerova Karoline
https://orcid.org/0000-0001-5427-2042
Hanes Jozef *
Amadoro Giuseppina Academic Editor
Institute of Neuroimmunology, Slovak Academy of Sciences, Dubravska Cesta 9, 845 10 Bratislava, Slovakia; jakub.sinsky@savba.sk (J.S.); karoline.pichlerova@savba.sk (K.P.)
* Correspondence: jozef.hanes@savba.sk
26 8 2021
9 2021
22 17 920702 8 2021
25 8 2021
© 2021 by the authors.
2021
https://creativecommons.org/licenses/by/4.0/ Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Tau protein plays a critical role in the assembly, stabilization, and modulation of microtubules, which are important for the normal function of neurons and the brain. In diseased conditions, several pathological modifications of tau protein manifest. These changes lead to tau protein aggregation and the formation of paired helical filaments (PHF) and neurofibrillary tangles (NFT), which are common hallmarks of Alzheimer’s disease and other tauopathies. The accumulation of PHFs and NFTs results in impairment of physiological functions, apoptosis, and neuronal loss, which is reflected as cognitive impairment, and in the late stages of the disease, leads to death. The causes of this pathological transformation of tau protein haven’t been fully understood yet. In both physiological and pathological conditions, tau interacts with several proteins which maintain their proper function or can participate in their pathological modifications. Interaction partners of tau protein and associated molecular pathways can either initiate and drive the tau pathology or can act neuroprotective, by reducing pathological tau proteins or inflammation. In this review, we focus on the tau as a multifunctional protein and its known interacting partners active in regulations of different processes and the roles of these proteins in Alzheimer’s disease and tauopathies.

tau protein
interaction partners
Alzheimer’s disease
tauopathies
==== Body
pmc1. Introduction

Proteins are essential macromolecules that play important roles in almost any cellular process. They usually do not function alone but rather as complexes with other molecules, mainly with proteins. Protein-protein interactions (PPIs) are elementary for many processes and it is proposed that their dysfunction or deregulation is located upstream, leading to various pathological conditions [1]. In Alzheimer’s disease and other tauopathies, tau protein undergoes pathological modifications that lead to the formation of paired helical filaments (PHF) and neurofibrillary tangles (NT) which belong to the main hallmarks of these diseases. The conversion of physiological tau into its pathological forms and their participation in disease etiology have not been fully understood yet and are still under investigation. In physiological conditions, tau interacts with many protein partners which maintain their proper structure and function. Under pathological conditions, proteins interacting with tau can also participate in its non-physiological modifications leading to the development of neurodegenerative diseases. Interaction partners of tau protein and involved molecular pathways can either initiate and drive the tau pathology or can have neuroprotective roles, by reducing pathological tau changes or inflammation.

Tau protein belongs to the family of microtubule-associated proteins (MAPs) [2,3] and can influence axonal transport and growth [4], neuronal polarization [5], and thus the normal function of neurons and the brain (Figure 1) [6,7].

In humans, tau protein is expressed mainly in neurons [8], and in lower amounts in oligodendrocytes and astrocytes [9,10,11,12]. Besides the central nervous system (CNS), tau is expressed by peripheral neurons [13], and more recently, tau immunoreactivity was also found in the human submandibular gland and sigmoid colon tissues [14]. Human tau protein is encoded by MAPT gene localized on chromosome 17q21 and consists of 16 exons. In the adult human brain, six tau isoforms are expressed ranging from 352 to 441 amino acids (see Figure 2). Three decades ago, it was proposed that individual tau isoforms may have different functions since they are differently expressed in the fetal and developed brain [15,16,17]. Now, it is known that alternative splicing even varies across neuronal cell types and during neuronal maturation [18,19].

Tau protein is distinctly divided into the N-terminal part, proline-rich region (PRR), microtubule-binding domain (MTBD), and C-terminus. The N-terminal domain length is dependent on alternative splicing of exons 2 and 3 which encode acidic amino acids. In MTBD, the splicing-dependent manner of exon 10 results in either 3 (3R) or 4 (4R) microtubule-binding repeats which are essential for binding of tau to individual tubulin heterodimers, and through this interaction tau stabilizes microtubules (MT) [20].

Despite the MT-stabilizing function of tau, its removal or modification had no significant impact on microtubule stability, cellular function, or cognition in mouse models [21,22,23,24,25]. It was shown that the MT-stabilizing function of tau protein is replaceable by microtubule-associated proteins MAP1a [22,26] or MAP1b [5]. However, experiments performed by several other groups on tau-knockout mice revealed that tau can influence the regulation of neuronal activity [27], synaptic plasticity [28], neurogenesis [29], iron export from neurons [30], and long-term depression of synapses [31,32]. Along with other animal disease models where the tau levels were reduced, it was found that depletion of tau protein had a protective effect on neurons against amyloid-beta (Aβ) induced excitotoxicity or by other excitotoxins in mice over-expressing amyloid precursor protein (APP) and presenilin 1 [33,34,35,36,37]. In chemically induced seizure models, hyperexcitability of neurons was reduced in mice with attenuated tau expression [38]. This suggests that endogenous tau is integral for regulating, or rather, upregulating neuronal hyperexcitability in diseased animals. In addition, in mice with impaired function of voltage-dependent sodium and potassium channels, the depletion of tau protein had a protective effect on neurons [39]. These studies suggest that tau protein may play a role in the regulation of neuronal network activity in both pathological and physiological conditions. Moreover, this is also supported by the evidence that tau protein has several additional roles in neurons and the brain [6].

In pathological conditions, the accumulation of insoluble tau aggregates occurs inside neurons, in extracellular space [40,41], and other brain cells such as astrocytes and oligodendrocytes [42,43]. The formation of this stable material is the consequence of abnormally modified and truncated tau proteins which self-aggregate and gradually mature to paired helical filaments (PHF) and neurofibrillary tangles (NFT) which are common hallmarks of several neurodegenerative diseases [44]. The formation of PHFs and NFTs is associated with the engulfment of the cytosol of neurons, failure in intracellular trafficking, and gradual disruption of basic physiological processes that end in apoptosis and neuronal death [45,46,47]. The formation of these aggregates is accompanied by inflammation which on one hand could help in their clearance, but on the other, can exacerbate the pathological processes [48,49,50]. Tau pathology is the main cause of dementia in Alzheimer’s disease and other neurodegenerative diseases, including frontotemporal dementia [51], argyrophilic grain disease [52], corticobasal degeneration [53,54], progressive supranuclear palsy [55], and several other diseases [44]. These disorders, where the accumulation of abnormal tau protein in the brain occurs, are referred to as tauopathies.

2. Roles of Tau Protein in Physiology and Pathology

2.1. Tau and Axonal Transport

Tau protein is enriched in axons where it binds microtubules through its MTBD and participates in their stabilization and regulation. Tau protein’s “free” flanking N-terminal and C-terminal regions interact with various classes of proteins involved in the regulation of cytoskeleton [56,57] and motor proteins kinesins and dyneins [58,59]. Thus, tau participates in the regulation of intraneuronal transport and modulation of microtubule dynamics, which ensures flexible reorganization of cytoskeleton and synaptic transmission. Tau can modulate functions of motor proteins by competitive inhibition of interactions of dynein and kinesin with microtubules, facilitating dynein binding to microtubules, or regulation of transport-vesicle releasing from motor proteins [60,61].

2.2. Tau Protein in Synapses

Besides axons, tau protein occurs also in pre- and post-synapses and in smaller amounts also in dendrites [31,32,33]. Tau protein can be directly translated in synapses and this translation is regulated by synaptic activity [62]. Furthermore, synaptic activity mediates tau protein release into extracellular space including synaptic clefts [63,64,65,66]. When discussing tau in the neuronal synapse, it is important to mention that synapses are complex biological structures also comprising astrocytes. These physiological structures composed of neuronal synapses and astrocyte protrusions are referred to as tripartite synapses [67,68]. Through these protrusions, astrocytes maintain the proper function of synapses through astrocyte–lactate shuttle, glutamate and GABA uptake from the synaptic cleft, growth factors release, and other processes [69]. In tauopathies, tau protein aggregates damage these tripartite synapses and disturb the normal function of neuronal networks [70]. Furthermore, the microglia, which constantly scan the surroundings with their processes, interact regularly with synapses [71,72]. Along with the fact that tau proteins are released during synaptic activity under both, physiological and pathological conditions, the microglia themselves also can mediate the inter-cellular spreading of the tau protein [73]. Released extracellular tau could be capable of interactions with proteins present in the synaptic clefts, thus influencing synaptic functions.

The structure of synapses is determined by the actin filaments, microtubules, and proteins modulating the membrane shape. It was shown that tau can mediate changes in the dendritic cytoskeleton and regulate synaptic plasticity and signaling [74,75]. Tau protein is known to interact with proteins regulating cytoskeleton and membrane curvature which are essential for synapse formation and sustainability [56,76,77,78,79]. Tau binds actin via its PRR, and at the same time also binds microtubules through its MTBD and serves as a crosslinker between microtubules and actin filaments and thus helps to organize the cytoskeleton network [20,80,81]. Furthermore, tau regulates the function of synaptic and extrasynaptic NMDA receptors (NMDARs) which mediate Na+ and Ca2+ influx into neurons and regulate membrane polarization [82].

2.3. Tau Protein in the Nucleus of Neurons

Tau is localized in the nucleus of neurons, more precisely, in nucleolar organized regions of the nucleolus [83,84,85,86]. Since nucleolus is the center of ribosomal RNA (rRNA) synthesis and processing, several studies which described localization of tau in parts of nucleolus suggest that tau can be involved in rRNA-coding DNA transcription and rRNA processing [86,87]. Tau can directly bind DNA [88] and RNA [89] and protects them from oxidative damage [90,91] which helps to maintain DNA and RNA integrity [92]. Furthermore, tau-DNA interaction is modulated by tau phosphorylation, which strongly reduces the ability of tau to bind DNA [93]. Hyperphosphorylation, which is one of the major hallmarks of the pathological forms of tau, may also influence its nucleocytoplasmic transport. According to the recent study, hyperphosphorylated tau directly interacts with a subunit of nuclear pore complex—nucleoporin NUP98 causes its mislocalization and disrupts the nucleocytoplasmic transport [94].

2.4. Big Tau

Big tau was initially known from studies on rats and mice where tau proteins were detected in their tissues, as well as, in cell lines derived from these species. This high-molecular-weight form of a rat and murine tau has an apparent molecular weight of ~110 kDa and possesses 733 or 752 amino acids (aa), respectively [95,96], as a result of the involvement of exon 4a and alternatively spliced exon 6 of MAPT gene in its transcript [97,98]. It was shown that Big tau is expressed only in the peripheral nervous system (PNS), neurons of the optic nerve, but also in specific CNS neurons with long axons projecting to the periphery [96,99]. In human sequence databases, Big tau is also designated as the PNS tau. Human Big tau (Figure 3) has not been confirmed experimentally in human tissues or human-derived cell lines so far, and its specific function remains unanswered. In light of the known functions of brain tau protein, several benefits of Big tau due to its increased length were proposed. The most important is the increased spacing between microtubules observed in processes of Sf9 cells overexpressing Big tau, which may reduce the energy required for axonal transport [100]. Furthermore, the elongated N-terminus of Big tau was proposed to reduce the rate of phosphorylation of motor proteins, and not mitigating their activity, thus supporting uninterrupted axonal transport [97,101].

2.5. Extracellular Tau Protein

Mounting evidence shows that pathological forms of tau protein spread from diseased to healthy cells and transform physiological tau to its misfolded pathological forms which in turn self-aggregate and form PHF and NFT [102,103]. It was shown that neuronal activity, accompanied by synaptic transmission, mediates tau protein release into extracellular space, mainly in an exosome-bound form, but also in a soluble form, and that this process occurs under both physiological and pathological conditions [63,64,65,66]. One of the suggested pathways of pathological tau spreading is connected to the resident macrophages of CNS–microglia [73]. Microglia have both phagocytic and secretion properties and can play a key role in the spreading of tau pathology [104]. Microglial exosomes serve as a medium for intercellular transport of cytokines, miRNAs, and other regulating factors [105]. The fact that microglia can be involved in the spreading of pathological tau forms is supported by several experiments. The group of Asai showed that depletion of the microglia in mouse brain significantly slowed propagation of tau between cells and that tau spreading was mediated by microglial exosomes [106]. Another research group demonstrated that reactive, inflammatory microglia can contribute to the spreading of tau pathology [73].

3. Tau Interaction Partners (TIPs), Their Biological Functions and Related Molecular Pathways

The understanding of tau function and behavior is mainly based on genetic experiments such as in-site mutagenesis, overexpression, or depletion of tau protein in animal or cellular models [107,108,109]. Moreover, studying physical protein-protein interactions [PPIs] significantly broadened the knowledge about tau protein function and its relationship to various physiological processes [7]. Since PPIs are elementary for many processes and it is supposed that their dysfunction or deregulation is located upstream of various pathological conditions, it is important to understand the tau protein interactome and dynamics [1].

Studies that focused on tau protein forms present in PHF and NFT showed that tau present in pathological lesions can be phosphorylated, truncated, glycosylated, nitrated, and ubiquitinated [110,111,112,113,114,115,116,117]. Therefore, it is likely that proteins involved in molecular pathways connected to the above-mentioned posttranslational modifications can have an impact on the pathological processes in tauopathies. The proteins and other compounds identified in NFT are listed in Table 1. Their presence in NFT could be the consequence of their physiological or pathological interactions with tau [118,119,120]. However, their presence in NFT can also result from a damaged fine-balanced chaperone system, altered nature of individual proteins due to pathological conditions (oxidation, modifications, etc.), or nucleocytoplasmic coagulation of proteins [121].

Physiological IPs play different roles in cells, and they are a part of various molecular pathways like energy metabolism, chaperone complex, apoptosis, organization of the cytoskeleton, and signaling pathways. Under pathological conditions, abnormal interactions of tau with its partners may occur as a consequence of the deregulation of any molecular pathway. Vice versa, newly emerging pathological forms of tau proteins within the cell can deregulate or block physiological processes in the cell and interact with proteins that do not occur under physiological conditions.

PPIs are summarized in several databases, however, all of them contain many hypothetical, predicted, or experimentally non-validated interactions. The following PPI databases are the best known (with the number of Homo Sapiens interactions in brackets): BioGRID (789073) [149], GPS-Prot (395501) [150], DIP (9141) [151], IntAct (703717) [152], MINT (10143) [153], STRING (12628534) [154] and IID (1099176) [155]. We reviewed all of them and found that the BioGRID (Biological General Repository for Interaction Datasets) was the most representative regarding TIPs (reporting up to date 245 TIPs). After a detailed review of all listed studies reporting the interactions, we excluded the non-validated interaction partners, which were derived mainly from large-scale interaction studies with no additional validation experiments. We then examined the resulting 153 experimentally validated TIPs by reviewing the scientific literature and protein databases. TIPs can be divided into several groups according to their molecular functions and their impact on tau protein physiology and pathology (Figure 4).

3.1. Tau as a Substrate for Kinases and Phosphatases

Phosphorylation and dephosphorylation of tau protein are physiological processes that regulate the binding of tau to microtubules. Increased phosphorylation of tau MTBD causes the release of tau from microtubules [116,156,157,158,159]. Under pathological conditions, tau protein is hyperphosphorylated, unable to bind microtubules, and subsequently aggregates and forms PHF and NFT. In AD, several pathological phosphorylations were identified [117,160,161,162,163,164], and the overall phosphorylation of tau is elevated by approximately four-fold in comparison to a healthy brain. This ratio may be even higher due to post-mortem delay of analyzed brain samples where tau dephosphorylation by phosphatases occurs [116,165]. The longest isoform of human tau protein has 85 potential phosphorylation sites of which 71 were experimentally documented [160,163,166,167,168]. This represents 19.3% of tau amino acids available for phosphorylation/dephosphorylation.

Among the known, and validated TIPs, 65 of them are involved in phosphorylation and/or dephosphorylation. Fifty-four of them are protein kinases (Table 2), seven phosphatases (Table 3), and four important kinase or phosphatase modulating proteins (Table 4). The protein kinases, which represent the majority of TIPs, were extensively reviewed by Martin et al. [169] and partially by Guo et al. [18]. The phosphatases, including PP2A, which contributes to approximately 70% of brain dephosphorylation activity [170], were deeply reviewed in Martin et al. [171] and by Guo et al. [18].

3.2. Tau-Interacting Partners Involved in Acetylation and Deacetylation of Proteins

Acetylation affects around 80–90% of all translated human proteins [241]. Acetylases are enzymes with acetyltransferase and deacetylase activity, and their role is the addition or removal of an acetyl group to the N-terminal or lysine residues of proteins. Acetylation of proteins regulates many processes, for example, transcription and memory consolidation by histone acetylation [242,243], localization in the cell [244], modulation of PPIs, and others [245]. Acetylation of tau protein on the Lys280, Lys281, and Lys311 residues impairs tau binding to microtubules [246,247], which leads to increased pools of cytosolic tau available for pathological aggregation. Tau itself possesses intrinsic acetyltransferase activity that allows tau self-acetylation [248]. Tau acetylation occurs before tau fibrillization into PHF suggesting that it could be an upstream pathological event. Besides AD, acetylated tau at the Lys280 is also present in PHF from patients with corticobasal degeneration [247]. In AD, deregulation of acetylation of both nuclear and cytoplasmic non-histone proteins occurs. Acetylated-tau is present through all of the stages of AD, peaking in the end stages of the disease [249]. Moreover, acetylation of tau inhibits its degradation, and along with increasing the concentration of unbound tau, it contributes to tau aggregation and pathology [250].

Currently, four proteins acetylases are validated as TIPs: CREB-binding protein (CBP) [251], histone acetyltransferase p300 (p300 HAT) [246,250,252], NAD-dependent protein deacetylase sirtuin-1 (SIRT1) [250] and histone deacetylase 6 (HDAC6) [253].

CBP and p300 HAT are highly homologous enzymes, which regulate transcription via chromatin remodeling and also acetylate non-histone proteins [247,254,255]. Both enzymes can acetylate up to 19 sites in tau protein located in the PRR and MTBD. The loss or over-expression of CBP and p300 HAT is responsible for neuronal death, which suggests that only the balanced and specific activity of these acetyltransferases is neuroprotective [256].

HDAC6 is a deacetylase mainly found in the cytoplasm, but also in smaller amounts in the nucleus [257]. Its main function is the deacetylation of several cytoplasmic proteins. Under pathological conditions, the HDAC6 is overexpressed, along with increased translocation to the nucleus, resulting in a decreased levels of brain-derived neurotrophic factor, a critical factor for synaptic repair and plasticity, leading to synaptic loss [258]. The overexpression of HDAC6 in AD can result in lower levels of acetylated tubulin [253], and thus impairment of transport, or increase in oxidative stress by deacetylation of peroxyredoxins resulting in lowering their ability to eliminate oxidative response products [259]. Furthermore, overexpression of HDAC6 elevates the burden of tau [260], which might also play a role in neuroinflammation [261,262]. HDAC6 can also deacetylate lysine residues in MTBD of tau which enhances tau phosphorylation, and aggregation [252].

The deacetylase SIRT1 links transcriptional regulation to the energy homeostasis of the cell. It plays a role in different processes like cell cycle, response to DNA damage, metabolism, apoptosis, and autophagy [263,264]. The expression of SIRT1 is decreased in aged neurons, and under neuropathological conditions [265,266]. SIRT1 deacetylates lysine residues in the PRR of tau protein [250] and has a neuroprotective role during neuronal injury and neurodegeneration [267]. Deletion of the Sirt1 gene in the mouse model of tau exacerbated their mortality, synapse loss, and cognition deficits. After induced expression of Sirt1 in the same model, the spread of tau pathology in the brain was attenuated [268]. In AD, SIRT1 levels are decreased and negatively correlated with the accumulation of pathological tau acetylated at Lys174 [265]. Deficiency of SIRT1 leads to synapse loss, impaired memory and spatial learning [269], elevated levels of proinflammatory cytokines, and accumulation of hyperphosphorylated tau due to low tau turnover [250]. Thus, the interaction of SIRT1 with tau protein has neuroprotective effects.

3.3. Tau-Interacting Partners Involved in Glycosylation

Only one protein from this group was experimentally validated for interaction with tau: the O-linked N-acetylglucosamine transferase (OGT) [270]. OGT is a glycosyltransferase that catalyzes the addition of a β-N-acetylglucosamine (GlcNAc) moiety to threonine or serine residues via an O-glycosidic linkage [271]. In a healthy brain, the tau phosphorylation sites are protected by O-GlcNAc modification. Thus, a competitive modification of Ser and Thr residues between O-GlcNAcylation and phosphorylation occurs. In vitro glycosylation of tau at Ser356 slowed tau aggregation [272]. In AD, impaired glucose metabolism leads to the reduction of UDP-GlcNAc, thereby decrease in O-GlcNAc levels, thus facilitating the tau phosphorylation and aggregation [273,274]. After the phosphorylation of tau, the chance of tau being O-GlcNAcylated is lower [275].

3.4. Interactions of Tau with Ubiquitin-Proteasome System and Chaperone System

Two major degradation pathways are known: the ubiquitin-proteasome and the lysosomal pathway, and these pathways are tightly regulated with molecular chaperones [276]. It is proposed that a fine-balanced chaperone system, which participates in correct protein folding and degradation of misfolded proteins could play an important role in the accumulation of disordered toxic tau species. Indeed, it has been shown that the chaperone system is impaired in tau pathology [277]. However, it is unclear whether this event is upstream or downstream of tau pathology.

3.4.1. Tau-Interacting Proteins Involved in the Ubiquitin-Proteasome Pathway

The ubiquitin-proteasome pathway of protein degradation involves the attachment of ubiquitin moieties to proteins which ensures their targeting to proteasomal degradation [278]. The process of ubiquitination starts by activation of ubiquitin by ubiquitin-activating enzymes (E1). Subsequently, the activated ubiquitin is transferred to a ubiquitin-conjugating enzyme (E2) and then attached to the target protein by ubiquitin ligases (E3) [279]. Some of the experimentally detected E2 ubiquitin-conjugating enzymes (UBE) interacting and ubiquitinating tau protein are UBE2D2 [280], UBE2D3 [281], and UBE2W [280,281,282,283]. The UBE2W is likely specific to intrinsically disordered proteins, such as tau, because of its partly disordered and flexible C-terminal domain. This flexibility allows recognition of disordered N-terminal domains of proteins and promotes ubiquitination [284].

One of the E3 ubiquitin-protein ligases that interact and modify tau proteins is parkin [285,286]. Parkin regulates mitochondrial trafficking, mitophagy, endosomal sorting, synaptic transmission, programmed necrosis, ER stress, inflammation, and cellular homeostasis [287,288,289,290]. Despite its various important cellular processes, there is not enough evidence about its direct involvement in tau pathology.

Other E3 ubiquitin-protein ligases reported to interact with tau are CHIP [281,291], axotrophin [292], and TRAF6 [293]. The CHIP ligase targets misfolded chaperone substrates to proteasomal degradation [294], and along with HSP70 chaperones, facilitates ubiquitination and degradation of tau protein which enhances cell survival [280]. Studies show that CHIP overexpression can promote tau aggregation [285], and ubiquitination of tau by axotrophin significantly reduces the affinity of tau protein to microtubules [292].

E3 ubiquitin-protein ligase TRAF6 acts in cooperation with Sequestosome-1 (SQSTM1) via complex formation. SQSTM1 is a multifunctional TIP [293,295] that regulates the elongation of ubiquitin chains on the surface of substrates and intensifies their targeting signal [296,297,298]. The SQSTM1 is essential for the shuttling of tau to proteasomal degradation because TRAF6 alone is not capable to polyubiquitinate tau [293]. Furthermore, SQSTM1 also functions as a receptor for selective macroautophagy of polyubiquitinated proteins and aggregates [299,300].

The neddylation is a process similar to ubiquitination; however, instead of ubiquitin, the NEDD8 is attached to proteins [301]. NEDD8 by itself and its protein conjugates are targeted to proteasomal degradation by NEDD8 ultimate buster 1 (NUB1), which was also identified as a tau-interacting protein [302,303]. The work of Richet et al. [303] showed that in SK-N-SH cells, NUB1 disrupts the interaction of tau with GSK3β kinase thus lowering pathological phosphorylation and aggregation of tau. The same group also recently showed that SQSTM1 specifically interacts with NUB1. Using the SH-SY5Y neuroblastoma cell model, it was demonstrated that NUB1 reduced the levels of insoluble tau aggregates. NUB1 also increased the autophagy-lysosomal pathway which facilitated the release of tau from SH-SY5Y cells [304]. These data suggest that NUB1 enhances the viability of diseased neurons at the expense of facilitating tau spreading between cells.

3.4.2. Tau-Interacting Proteins Involved in Chaperone System

The chaperone system is composed mainly of heat shock proteins (HSPs), which are involved during stress conditions. These proteins mainly function as molecular chaperones and regulate several diverse cellular processes, including protein folding, targeting, transport, degradation, and signal transduction. Under stress conditions, they assist in protein refolding and suppress aggregation, which promotes the maintenance of cellular homeostasis. HSPs are classified into the following families according to their molecular size: HSP90, HSP70, HSP60, HSP40, and small HSPs.

HSP70 chaperones assist in the stabilization and folding of many substrates and are found in most cellular compartments [305]. In humans, 11 genes encoding HSP70 family members have been identified [306]. The four chaperones of this family are known to interact with tau: HSPA1A [307], HSPA4 [307], HSPA5 [308] and HSPA8 [309]. All HSP70 proteins have a conserved N-terminal ATPase domain that binds and hydrolyses ATP and a C-terminal substrate-binding domain. The co-chaperone of HSP70, BAG family molecular chaperone regulator 1 (BAG1), serves as a nucleotide-exchange factor and promotes the release of ADP from HSP70 chaperones [310]. BAG1 was also found to interact with tau; however, only in complex with HSP70. Despite this indirect interaction, BAG1 is an important regulator in tau pathology because of its inhibitory effect on ubiquitin-independent 20S proteasomal degradation [311]. However, HSP70 chaperones are potent inhibitors of tau aggregation by preventing the formation of tau oligomers and PHF. It has been shown that HSP70 chaperones protect neuronal functions against the toxic effects of tau aggregates and oligomers [312].

Another co-chaperone of HSP70s interacting with tau is the DnaJ homolog subfamily A member 1 (DNAJA1). It was demonstrated that the over-expression of DNAJA1 mediated ubiquitin-dependent clearance of tau, while DNAJA1 knockdown facilitated tau accumulation [313].

The HSP90 heat shock protein family is an essential component of the eukaryotic cytosol where they stabilize misfolded proteins and regulate the activity of various signaling proteins, including steroid hormone receptors, tyrosine kinases, nitric oxide synthase, and calcineurin [314]. Two HSP90 proteins are known to interact with tau: HSP90α [315,316,317] and its co-chaperone and activator AHSA1 [318], which triggers the ATPase activity of HSP90α thus increasing its activity [319]. The interaction of tau with both these proteins is pathological. HSP90 and its activator AHSA1 can mediate tau oligomerization and aggregation [320,321,322].

Heat shock protein β-1 (HSPB1), which belongs to the family of small HSPs, preferentially interacts with hyperphosphorylated tau in the human brain [323]. In the cell model, it decreased hyperphosphorylated tau levels, increased the abundance of dephosphorylated tau, and suppressed tau-mediated cell death [324].

The Clusterin (CLU) is a chaperone that prevents the aggregation of misfolded proteins [325]. It is present in two main forms: the secreted (sCLU) and intracellular (iCLU). Total levels of both sCLU and iCLU are significantly increased in AD, and these levels are proportional to overall levels of insoluble Aβ and tau aggregates [326]. iCLU was identified as a TIP, which also interacts with another TIP: BIN1 (see Section 3.7). It was shown that expressions of both iCLU and BIN1 were associated with misfolded tau in AD [327]. Expression of certain coding CLU variants linked to AD risk led to increased levels of iCLU. Therefore, the iCLU and BIN1 interaction might impact Tau function in neurons, and could be involved in the etiology of tau pathology in AD.

Protein isomerization is an essential physiological process involved in protein folding and maturation [328]. Two types of isomerization in proteins are known: prolyl cis-trans isomerization and disulfide isomerization. The prolyl cis-trans isomerization shifts the proline peptide bonds between cis and trans conformation, thus causing changes in protein secondary structure [329]. The 2N4R tau contains 43 proline residues, the majority of which are located in its PRR. Thus, isomerization of the proline peptide bonds between cis-trans conformation can influence tau protein structure and behavior [330,331]. Moreover, the proline cis-trans isomerization also regulates tau protein phosphorylation. Deregulation of this process causes phosphorylation of tau protein at AD-specific phospho-sites [332].

Five peptidyl-prolyl cis-trans isomerases: FKBP1A [315], FKBP4 [333], FKBP5 [318], PIN1 [334], cyclophilin D (CypD), and one protein disulfide-isomerase (PDI), are known to interact with tau. PDI is responsible for proper protein folding by both enzymatic and chaperone activity. It catalyzes the rearrangement of the formed disulfide bonds to correct positions [335]. It was shown that tau aggregation is significantly prevented by the binding of PDI to monomeric tau proteins [336]. Furthermore, the PDI strongly inhibits the tau seeding process which precedes tau aggregation [337,338]. In AD, PDI is S-nitrosylated which causes inhibition of this enzyme [339,340].

The peptidyl-prolyl cis-trans isomerases play an important role in protein folding through the isomerization of proline peptide bonds between cis and trans conformation. Their functional effects on tau protein and related pathology were extensively discussed in reviews of Blair et al. [341] and Peak et al. [342]. They play different roles in tau pathology, they can either facilitate tau aggregation, like FKBP4 and FKBP5, or can be neuroprotective, like PIN1 or FKBP12.

Cyclophilin D (CypD) [343], besides its peptidyl-prolyl activity, also participates as a regulator of the mitochondrial permeability transition pore in mitochondria, which is responsible for the Ca2+ release [344,345,346]. Mitochondrial damage and Ca2+ imbalance are pathological features of AD [347,348,349]. It was suggested that increased expression of CypD could play an important role in the neurodegenerative process as in AD. It was shown that Aβ interacts with CypD [350,351], and induces mitochondrial and neuronal stress. Recent studies also demonstrated a link between mitochondrial dysfunction and tau pathology as a contributor to AD [352,353].

3.5. Interactions of Tau with Proteins Regulating Programmed Cell Death

The apoptosis, one of the consequences of the developed Aβ and tau pathology [354], is an important physiological cell process mediated by various proteins including caspases, the cysteine aspartyl proteases [355]. Interactions of tau with caspases were confirmed by the study of Gamblin et al., where the authors suggest that caspases involved in Aβ-induced neuronal apoptosis could contribute to pathological cleavage of tau. They showed that tau is cleaved at Asp421 in vitro by caspases-1,-3,-6,-7, and -8, and the same cleavage product of tau is produced in primary rat cortical neurons after treatment with fibrillar Aβ [112]. This cleavage of tau with caspases generates pathological truncated tau species which can aggregate, lead to neurofibrillary pathology, and contribute to neuronal death [356,357]. Although the caspase activation precedes the formation of neurofibrillary tangles, the soluble tau species are the caspase activators that augments tau truncation, thus contributing to NFT formation [45,358].

Caspase-1 is activated by proteolytic cleavage by other caspases, and it is a part of a pathway called pyroptosis: a lytic and inflammatory form of programmed cell death [359].

Caspase-3 is involved in the activation cascade responsible for the execution of apoptosis. When caspase-3 is activated, it cleaves its substrates caspase-6, -7, and -9 which simultaneously activates them. In the AD brain, caspase-cleaved tau colocalizes with both intracellular Aβ and activated caspase-3 [113]. Through the cleavage of Ser/Thr Kinase 1 (Akt), caspase-3 regulates tau phosphorylation via the GSK3β kinase pathway [360]. Furthermore, upregulation of active caspase-3 led to the accumulation of caspase-3-cleaved tau in the traumatic brain injury model [361]. These data suggest that abnormal activation of caspase-3 may lead to progressive tau pathology.

Caspase-6 cleaves tau at three different sites in comparison to other caspases: Asp13 [362], Asp402 [363] and Asp421 [364]. Cleaved tau colocalized with active caspase-6 within NFTs in AD. Furthermore, active caspase-6 was identified in the mild stage of AD which supports its role in the early stages of tau pathology [365,366]. Caspase-6 (along with caspases-3 and -8) cleaves amyloid precursor protein (APP) at Asp664 releasing C-terminal p31 cytotoxic fragment which can induce apoptotic pathway cascade [367,368,369,370].

Caspase-7 is the effector caspase in programmed cell death which induces the Gasdermin-D-independent pore formation [371]. It cleaves tau at Asp421 [113]. In the study by Ayers et al., the individuals homozygous for AD-risk APOE4 allele and had loss-of-function mutation in the CASP7 gene did not develop the AD [372], this implicates the neurotoxic role of caspase-7. However, a genetic association study identified a different, rare missense variant of the CASP7 gene to be robustly associated with familial late-onset AD [373].

Caspase-8 is the most upstream protease in the activation cascade of caspases [374]. It activates caspase-3 by proteolytic cleavage [375]. Furthermore, it has been shown that in the brain of AD patients, the active form of caspase-8 is abundantly present in NFT-bearing neurons [376]. In contrast, a gene association study that found two mutations in the CASP8 gene: K148R and I298V also showed in vitro that mutation I298V had an attenuating effect on caspase-8 activity [377]. Interestingly, de Calignon et al. noted that after the formation of NFT in neurons, the caspase activity is suppressed [45].

The next TIP involved in apoptosis is the neuronal pentraxin-1 (NPTX1) [77]. Under physiological conditions, the NPTX1 is released from synapses into the synaptic cleft, binds extracellularly to AMPA glutamate receptors (AMPARs), and stabilizes them on dendritic surfaces [378,379]. Thus, the secreted NPTX1 binds and recruits AMPARs, promoting the formation of an active synapse [380,381]. It has been shown that under potassium deprivation and reduced neuronal activity, NPTX1 protein is overexpressed along with other proteins involved in programmed cell death [382,383]. Furthermore, exposure to Aβ also increased NPTX1 expression leading to reduced neurite outgrowth and increased apoptosis. Moreover, NPTX1 overexpression alone reproduces the effects of Aβ on neurite damage and apoptosis [384].

3.6. Proteolytic Cleavage and Truncation of Tau Protein

Protein degradation is an important physiological process, which is responsible for the removal of aged, damaged, or misfolded proteins with the possibility of their constituents being recycled in the process [385]. Proteolytic cleavage of specific proteins is the common denominator of many neurodegenerative diseases including huntingtin protein in Huntington’s disease [386,387], α-synuclein in Parkinson’s disease and Lewy body dementia [388], ataxins in cerebral ataxia [389,390], prion protein in prionosis [391,392] and tau protein in Alzheimer’s disease, as mentioned in Section 1 [117]. Experiments deciphering PHF showed that the “minimal protease-resistant” core of paired helical filaments are mainly composed of tau proteins and that the majority of them are truncated [393,394,395]. A general consequence of proteolysis is the production of various fragments with a toxic gain-of-function that can be translocated into an inappropriate cell compartment [358,396]. Pathological tau protein fragments can either switch on the cell death cascade or induce and drive protein aggregation. Mounting evidence supports the idea that truncated protein fragments are upstream in the pathological cascade and can form the initial seeds for the aggregation in neurodegenerative diseases [45,397,398,399]. For example, the cleavage of tau monomers to truncated fragments supports its mounting into oligomers and PHF [117].

Two calcium-regulated thiol-proteases are known to interact with tau: calpain-1 [400] and calpain-2 [401], and they are major isoforms of calpains in the brain. Calpains can cleave tau in vitro [402]. Calpain-1 participates in long-term potentiation and acts neuroprotective on neurons. On the other hand, calpain-2 activation limits neuronal potentiation leads to silencing of neuronal activity, and neuronal death [403]. Calpain-1 showed an increase in activity in AD from Braak stage III to the late stages of the disease [404]. Activation of both calpains leads to the production of 10.7-kDa tau fragment in neurons (tau 125∓230, related to 2N4R tau), which is neurotoxic [405,406]. Additionally, calpain-1 cleaves tau at Arg242, and this fragment is observed in brains with tauopathy [407]. Furthermore, a recent study by Cicognola et al. showed that in tauopathy, calpain-2 cleaves tau at Lys224 [408], a fragment enriched in CSF tau pool in pathological conditions [409].

In addition to thiol-proteases, legumain [410,411] and ubiquitin thioesterase OTUB1 [412] are also known as TIPs. The legumain is predominantly localized in lysosomes and it is a multifunctional enzyme that can have endopeptidase, carboxypeptidase, or ligase activity depending on their milieu [413]. Increased levels of the active legumain along with a higher amount of proteolytically truncated tau were found in the cytoplasm of neurons in AD [410,414]. Ubiquitin thioesterase OTUB1 belongs to the deubiquitination family proteins. It is involved in the processing of poly-ubiquitin precursors, as well as ubiquitinated proteins [415]. OTUB1 was shown to be involved in the deubiquitination of tau protein thus preventing its degradation [416]. Furthermore, expression of OTUB1 in primary neurons increased tau levels, enhanced tau aggregation, and contributed to tau pathology [412].

Cathepsin D (CTSD) is the lysosomal aspartic acid protease involved in cleavage and activation of ADAM30 which leads to amyloid precursor protein (APP) degradation and thus preventing the formation of Aβ peptides and plaque load [417]. The study of Khurana et al., examined the relationship between CTSD and tau in vivo using the Drosophila model of AD and showed that CTSD is upregulated with age and has a neuroprotective effect. The deletion of the Ctsd gene in this model increased the generation of Asp421-cleaved tau protein and exacerbated tau toxicity. Additionally, the authors showed that ablation or silencing of the Ctsd gene also in mice and sheep resulted in the truncation of tau at Asp421 and caspase-3 activation [418]. CTSD has many cellular functions including activation of enzymes, such as ADAM30, and various enzymatic precursors [419], degradation of intracellular proteins [420,421], activation and degradation of hormones and growth factors [422,423], processing of enzyme activators and inhibitors [424], processing of brain-resident proteins, such as tau [425], myelin [426] or Aβ [427], and regulation of apoptosis [428]. It was shown that genetic variation in the CTSD gene is a risk factor for AD [429].

Human high-temperature requirement serine protease A1 (HTRA1) and thrombin are two serine proteases known to cleave tau protein [400]. HTRA1 is able to degrade tau aggregates and fibrils, and patients with elevated expression of HTRA1 had lower amounts of accumulated tau protein in the brain [400,430]. Thrombin, an extracellular protease, cleaves tau protein at various arginine and lysine residues. Its proteolytic activity is inhibited by the phosphorylation of its substrates. PHFs isolated from the AD brain were more resistant to thrombin cleavage than those that were dephosphorylated [431].

The 26S proteasome complex, which comprises 19S regulatory particle (19S RP) and 20S core particle (20S CP) [432], interacts directly with tau protein [433]. Furthermore, two of nine subunits of the base complex of 19S RP are TIPs: the 26S proteasome regulating subunit 7 (PSMC2) [293] and 26S proteasome non-ATPase regulatory subunit 2 (PSMD2) [77]. The main role of 19S RP is the degradation of ubiquitinated proteins in an ATP-dependent manner [434,435,436]. The PSMC2 subunit is a motor protein with ATPase activity. The PSMD2 recognizes and binds ubiquitin bound Usp14, a ubiquitin-specific protease, which cleaves polyubiquitin chains from substrates before entering the 26S proteasome core [437,438]. However, in tauopathies, the ubiquitin-dependent proteasomal system is impaired [75] and tau protein aggregates may inhibit proteasome function [439,440]. Furthermore, pathological protein aggregates may have a suppressive effect on the proteasome system, as demonstrated by Thibaudeau et al. who showed that Aβ oligomers can bind to the 20S CP [432] and thus impair substrate entry into the 26S proteasome [441].

Only one metalloprotease that can degrade tau has been reported so far, the puromycin-sensitive aminopeptidase (PSA) [442]. It was shown that PSA more efficiently degraded soluble tau from the normal human brain when compared to soluble or PHF tau purified from AD brain, very likely due to post-translational modifications and/or aggregation of tau. PSA is upregulated in patients with tauopathies [443], but its role in tau pathology is not known yet.

Presenilin-1 (PSEN1) is a part of the γ-secretase complex, which cleaves integral membrane proteins such as Notch receptors and APP [444,445]. Mutations in this gene are risk factors for developing familial Alzheimer’s disease [446,447]. It has been shown that PSEN1 facilitates the phosphorylation of tau protein through direct interaction with tau and glycogen synthase kinase 3β (GSK3β) and thus guiding the GSK3β into close proximity with tau for phosphorylation [448]. Moreover, two AD-characteristic mutations in PSEN1 increased its binding to GSK3β and enhanced the phosphorylation of tau protein [449]. However, the exact mechanism as to how PSEN1 contributes to tau pathology remains unanswered.

3.7. Proteins Involved in the Regulation of the Cytoskeleton and Intracellular Transport

Cytoskeleton regulating proteins are essential for maintaining and regulating the shape and function of the cytoskeleton, axons, dendrites, and synapses [450]. Furthermore, they are important for axonal growth, cellular transport, and axonal signal transmission [451,452]. The cytoskeleton proteins show abnormalities during tauopathies, like the inhibition of assembly or deformation of microtubules and invaginations of the nuclear membrane [453,454]. Cytoskeleton constituents, such as tubulins (4 isoforms) [292,455,456,457] and actin (3 isoforms) [80], which polymerize into filaments and microtubules (MTs) are stabilized and co-organized by microtubule-associated proteins (MAPs) or actin-binding proteins (ABPs) [81].

Another cytoskeleton-regulating TIP is the microtubule-associated protein 2 (MAP2) [458], which belongs to the category of microtubule-binding proteins. Strong MAP2 immunoreactivity was observed mainly in dendrites of neurons and occasionally in neuronal soma. MAP2 regulates the spacing between MTs in dendrites and is involved in dendrite arborization and growth [459]. The induction of long-term potentiation in cultured primary rat neurons and mice hippocampal slices caused translocation of MAP2 from dendritic shafts to dendritic spines and heads. This suggests that MAP2 is involved in processes of synaptic plasticity and learning [460]. The other function of MAP2 is the regulation of axonal transport. It was observed that in sensory neurons MAP2 coordinates the functions of molecular motors kinesin-1 and kinesin-3, where it inhibits slow kinesin-1 and thus allowing fast kinesin-3 to drive cargo transport from the soma into the axon [461]. The importance of physiological interaction of tau with MAP2 has not been revealed yet, however, it was shown that hyperphosphorylated tau protein isolated from AD brain inhibits MAP2-promoted MT assembly [458].

The microtubule dynamics rely on the assembly or disintegration of tubulins on plus-ends of microtubules [462]. These dynamics are regulated by the presence or absence of factors and proteins such as the GTP-bound tubulin dimers [463], tau protein [464,465], or plus-end tracking proteins [466]. The two plus-end tracking proteins are known to directly interact with tau, the microtubule-associated protein RP/EB family member 1 (MAPRE1) [467] and 3 (MAPRE3) [467]. They promote and regulate MT nucleation and elongation [468,469]. Moreover, the MAPRE1 and MAPRE3 also regulate the minus-end of MTs and mediate the tethering of MTs to the Golgi apparatus [469]. Tau protein, through interaction with MAPRE1 and MAPRE3, inhibits their binding to MTs and this inhibition is abolished by tau phosphorylation at Ser262 [470]. Furthermore, MAPRE1 and MAPRE3 could be directly involved in tau secretion from the cells [471]. These data suggest the existence of a tight relationship between tau and end-binding proteins.

The next TIP from the class of cytoskeleton-regulating proteins is amphiphysin II [327,472,473], which controls the plasma membrane curvature, shaping, and remodeling [474]. Amphiphysin II is abundantly expressed in the brain and muscle cells [475]. Using genome-wide association studies, the variations in its gene (BIN1) were identified as the second most risky genetic factor for sporadic Alzheimer’s disease [476]. It was shown that under pathological conditions amphiphysin II expression is elevated [473,477]. However, the direct function of amphiphysin II in tau pathology remains unknown.

Protein kinase C and casein kinase substrate in neurons 1 (PACSIN1) is a flexible adaptor protein that contains important SH3 and F-BAR domains which are known to interact with many proteins. The F-BAR domain regulates membrane deformation and shaping of the neuronal plasma membrane [478,479]. PACSIN1 interacts with the proline-rich region (PRR) of tau through its SH3 domain, and by this interaction, it coordinates the remodeling of the MT cytoskeleton [79]. Moreover, PACSIN1 plays a role in the reorganization of the actin cytoskeleton thus facilitating the membrane fission during endocytosis [480]. It plays a role in neurodevelopment and during this process, it is upregulated [481]. The PACSIN1 is the key regulator of endocytic removal of developmental NMDARs and their replacement with mature NMDARs [482], which comprise different subunits, and thus possess other synaptic attachment and kinetic properties [483,484,485]. Through this replacement of developmental/mature NMDARs, PACSIN1 regulates the formation of new synaptic connections and is important for learning and memory creation.

One of the novel TIPs that we have recently identified is the brain-specific angiogenesis inhibitor 1-associated protein 2 (BAIAP2) [77]. It is the adapter protein that links membrane-bound small G-proteins to cytoplasmic effector proteins. The BAIAP2 binds and deforms the membranes by its I-BAR domain and may be involved in the formation of membrane curvatures, which are present for example in synapses or dendrites [76,78]. I-BAR domain is also capable of binding and bundling the actin filaments [486]. The SH3 domain of BAIAP2 binds various effectors, whereby many of them are actin modulatory proteins that participate in the nucleation of branched actin filament networks [487,488]. Furthermore, the BAIAP2 participates in the outgrowth of neuronal processes [489] and may be involved in insulin-mediated neurite development and synaptic plasticity [490,491]. BAIAP2 in CNS is located mainly in axonal synapses and dendritic spines and regulates their morphology, as was revealed by electron microscopy [492]. Moreover, their association with psychiatric disorders has been revealed, such as schizophrenia [493,494], autism spectrum disorders [495,496], and attention deficit hyperactivity disorder [497].

The intracellular transport, which is tightly dependent on the cytoskeleton, is commonly impaired in AD. One of the tau-associated proteins implicated in intracellular transport is the hook microtubule-tethering protein 3 (HOOK3), which is expressed predominantly in neurons. HOOK3 belongs to a family of cytoplasmic linkers that participate in endosomal transport. The HOOK3 was shown to associate mainly with tau aggregates, and weak interaction with monomeric soluble tau was also reported [498].

The regulators of nucleocytoplasmic transport are also represented among the TIPs by the GTP-binding nuclear protein RAN [77] and by the nuclear pore complex protein NUP98. The RAN belongs to the Ras superfamily [499], and its GTP-bound form (RAN-GTP) is required for mitotic spindle assembly, and thus for cell proliferation [500,501]. Both RAN and NUP98 mediate the transport of proteins and RNA between the nucleus and cytosol through the nuclear pore complex (NPC) [502,503,504]. A study focusing on nucleocytoplasmic transport in AD showed that hyperphosphorylated tau interacts directly with the FG domain of NUP98 and causes the disruption of nucleocytoplasmic transport. Upon interaction with hyperphosphorylated tau, NUP98 becomes mislocalized to the cytoplasm and promotes tau aggregation into NFT. As NUP98 also interacts with RAN and regulates the RAN-GTP/GDP exchange through NPC, mislocalization of NUP98 results in disruption of nucleocytoplasmic equilibrium of RAN, its depletion in the nucleus and nucleocytoplasmic transport failure [94]. The impact of pathological forms of tau protein on RAN function is currently unknown.

Next TIP, the apolipoprotein E (APOE) [505] associates with lipid particles and plays a role in lipoprotein-mediated lipid transport [506,507,508]. APOE has three common isoforms: APOE2, APOE3, and APOE4 [509], with different levels of lipidation and related functions. Individuals possessing the APOE4 allele have significantly smaller APOE-containing particles compared to individuals without an APOE4 allele [510]. Carrying the APOE4 allele is considered a genetic risk factor for AD, with the increase of risk by three-fold for one allele, and lower age of onset for AD [511]. APOE in the healthy brain plays a neuroprotective role, by binding tau and blocking the phosphorylation sites for kinases [512]. However, only APOE3 and APOE2 can bind tau, not APOE4 [505]. A study proposed genetic interaction between APOE and tau in the development of AD, in a way where the polymorphic tau G allele represents an additional risk factor in the individuals carrying the APOE4 allele, with a five-fold increased risk of AD development [513]. In clinical AD, Aβ mediates the association of APOE with PHF, which correlates with cognitive decline [514].

The motor protein kinesin-1 was also identified as a tau-interacting protein. More precisely, its two light chains, the kinesin light chain 1 (KLC1) and 2 (KLC2) were identified as TIPs [60,515]. KLC1 and KLC2 are present in the complex with the kinesin-1 heavy chain and are responsible for the binding of cargo membrane vesicles, which kinesin-1 motor complex transports along the axon from the neuronal soma to synapses. By interacting with tau protein, both KLC1 and KLC2 participate in the axonal transport of tau in healthy neurons [60]. Whereas the KLC1 is enriched in neurons, the KLC2 is ubiquitously expressed across the various tissues [516]. In the healthy brain, the KLC1 also participates in the transport of amyloid precursor protein (APP) through its attachment to the KLC ligand calsyntenin-1 [517,518], a transmembrane protein present in membranes of APP-containing vesicles in the Golgi [519]. The phosphorylation of KLC1 on Ser460 reduces the interaction of KLC1 and calsyntenin-1 thus leading to reduced axonal transport [520]. In the AD brain, the levels of the KLC1 are reduced and the phosphorylation of the Ser460 is increased which results in the inhibition of axonal transport of APP [521]. Similarly, the levels of the KLC2 are also decreased in the frontal cortex of AD patients [522]. In the animal model expressing pathological tau proteins, a simultaneous reduction of kinesin light chain expression slowed axonal transport and increased the accumulation of hyperphosphorylated tau and tau aggregates [523].

Another TIP is the dynactin subunit 1 (DCTN1) [61]. This protein is part of the dynactin complex which is responsible for recruiting and tethering the dynein motor complex to MTs [524,525]. Interaction of tau with DCTN1 enhances the binding of the dynactin complex to MTs [61]. Direct involvement of DCTN1 in tau pathology has not been revealed yet.

The mitochondrial import receptor subunit TOM20 homolog (TOMM20) is the part of the translocase of the outer mitochondrial membrane (TOM), a protein complex responsible for the recognition and translocation of cytosolically synthetized proteins into the intermembrane space of the mitochondria [526]. The evidence of TOMM20 as TIPs arises from the study by Amadoro et al. which showed that TOMM20 binds caspase-truncated tau [343]. In AD, the reduced immunoreactivity of TOMM20 was observed. The decreased levels of TOMM20 can lead to an impairment of the recognition and binding of proteins intended for translocation into mitochondria [527,528]. This could contribute to the damage of oxidative phosphorylation as seen in AD. Additionally, the TOM complex can bind and translocate Aβ peptides which results in the accumulation of Aβ in mitochondrial cristae [529].

The ADP/ATP translocase 1 (ANT1) is an ADP-ATP antiporter located at the mitochondrial inner membrane and mediates the import of ADP into the mitochondrial matrix for ATP synthesis in exchange for the export of ATP [530]. Its ANT1 gene is involved in the maintenance and replication of mitochondrial DNA [531], and its mutations are associated with different mitochondrial disorders affecting the brain [532]. Similarly, as in the case of TOMM20, the caspase-truncated tau fragment can bind ANT1, which either alone or in association with other synaptotoxins can induce synapse decay [343]. The interaction of truncated tau with ANT1 also inhibits its ADP/ATP exchange activity which is one of the factors triggering mitochondrial dysfunction.

The excitatory amino acid transporter 2 (EAAT2) was also identified as TIP and was shown to preferentially interact with tau phosphorylated at AD-characteristic phospho-sites. Furthermore, EAAT2 is recruited into NFT which suggests some role for EAAT2 in tau pathology [533].

Alpha-synuclein (α-syn) [534] is mainly distributed in the presynaptic terminals of neurons [535]. In the healthy brain, α-syn has many different functions like modulation of vesicle trafficking [536], the suppression of apoptosis [537], modulation of synaptic plasticity [538], or chaperone activity [539]. In pathological conditions, α-syn aggregates and forms Lewy bodies, which are typical hallmarks of Parkinson´s disease and other synucleinopathies. In around 50% of AD cases, α-syn pathology is also reported [540,541]. It was shown that the α-syn monomers assemble into amyloid-like fibrils which are able to interact with tau, resulting in inhibition of microtubule assembly and their stabilization. The tau subsequently aggregates which could promote the pathological pathway in synergy [542,543]. α-syn also increases the GSK3-mediated phosphorylation of tau that can further enhance the progress of disease [544]. Furthermore, it was proposed that pathological α-syn is able for cell-to-cell transmission, similar to prion diseases [543].

3.8. Tau-Interacting Proteins Involved in DNA Replication and Transcription

Neurons are post-mitotic cells, which are unable to further divide, and are in the resting phase of the cell cycle [545]. In tauopathies, like AD, several changes influence the processes of replication and transcription. It was found that translocation of tau to the nucleus, where it binds and protects DNA under physiological conditions, is reduced upon its hyperphosphorylation; thereby, heterochromatin organization is disrupted leading to cell cycle re-entry and neuronal death [546]. Furthermore, dysregulated gene expression and rRNA synthesis occur resulting in the rise of altered protein synthesis [547,548]. From the group of DNA replication and transcription proteins only two are currently verified as TIPs: the apoptosis-antagonizing transcription factor (AATF) [549] and mothers against decapentaplegic homolog 2 (SMAD2) [550].

AATF is a transcriptional regulator involved in cell proliferation. AATF binds the retinoblastoma protein (Rb) and inhibits its function. The role of Rb is growth suppression via expressional regulation of genes required for DNA synthesis and cell progression [551]. AATF is also an inhibitor of Aβ production in cells undergoing apoptosis by binding and blocking the pro-apoptotic WT1 regulator (PAWR) activity in the regulation of APP processing [115]. On the other hand, AATF participates in neurodegeneration due to its capability to stimulate DNA synthesis and induce quiescent cells to re-enter the cell cycle. AATF–tau association is also shown to be modulated during the onset of neuronal apoptosis in the cytoplasm of cerebral granule neurons, and this interaction is progressively lost in apoptosis [549]. However, the consequences of AATF interaction with tau have not been examined so far.

SMAD2 acts in a complex of SMAD2/SMAD2/SMAD4 or SMAD2/SMAD3/SMAD4 as a transcriptional co-activator on SMAD-binding elements of DNA. SMAD2 is a part of the TGFβ signaling pathway, and along with other SMAD proteins, it is the most important effector of this cascade. TGFβ activates the phosphorylation of SMAD2 and SMAD3 and starts the assembly and translocation of the SMAD2/SMAD3 complex into the nucleus [552]. In AD, SMAD2 is also a part of the TGFβ/SMAD2/STAT3 signaling pathway which is activated by APOE, the important risk factor for AD, and increases the amyloidogenic processing of APP leading to Aβ formation and contributes to cognitive decline [553]. Inversely, SMAD2 plays a role in CX3CL1/TGFβ/SMAD2 pathways which control adult neurogenesis [554]. Thus, SMAD2 signaling pathways can contribute either to neurodegeneration or neuroprotection. Furthermore, it was shown that the interaction of hyperphosphorylated tau with phosphorylated SMAD2 resulted in reduced translocation of SMAD2 into the nucleus [555].

3.9. Tau-Interacting Proteins Involved in RNA Processing and Translation

The group of RNA processing and translational proteins is a part of the large protein family, called RNA-binding proteins (RBPs), which are active in the processes like mRNA maturation including splicing, targeting, degradation, and translation of the RNA [556,557]. In AD, several changes to RBPs, and thus to the processing and translational machinery occur. The activity of the spliceosome in AD is impaired resulting in a lower splicing efficiency and production of mRNAs with introns. Splicing deficiency in AD leads to an altered expression of protein-encoding genes like APP which can be detrimental [558]. Furthermore, impaired alternative splicing leads to a dendritic loss in primary neurons and weakened memory in mice [559]. Two proteins from the group of RBPs were validated as TIPs: the U1 70 kDa small nuclear ribonucleoprotein (SNRNP70) [560] and the T-cell-restricted intracellular antigen-1 (TIA1) [561].

The SNRNP70 is a component of the U1 small nuclear ribonucleoprotein (snRNP) complex which is responsible for the recognition of the pre-mRNA 5’ splice-site and the subsequent assembly of the spliceosome [562]. In AD, SNRNP70 is internally cleaved, and its 40 kDa fragment participates in the formation of protein aggregates and was found in close proximity with NFTs [558]. Moreover, this fragment exerts toxic effects on neurons [563]. The truncated, aggregated forms of SNRNP70 are able to bind and sequester the soluble SNRNP70 into insoluble aggregates [564]. The SNRNP70 aggregation occurs earlier in AD and its levels correlate more with Aβ plaques compared to pathological tau aggregates. It was shown that in AD, the LC1/BAD domain of SNRNP70 interacts with tau, a process that does not occur under physiological conditions [560], and it causes mislocalization of SNRNP70 from the nucleus to the cytoplasmic phospho-tau aggregates. These pathological changes of SNRNP70 affect the whole U1 snRNP complex, leading to the loss of the spliceosome function and thus impaired splicing of pre-mRNAs [558,565].

TIA1 is a protein with several different functions in neurons. It plays a role in the regulation of RNA localization and utilization, splicing [566], dendritic arborization [561], and it is also one of the primary stress granule proteins active in stress response [567]. In the healthy brain, tau participates in translational stress response by the promotion of stress granule (SG) formation, which allows adaptation of the protein synthesis and thus copes with stress. Under neuropathological conditions, TIA1 aggregates with pathological tau proteins and creates abnormal SGs; however, the clear consequences of these abnormal SGs are unknown [561]. Tau and TIA1 have a reciprocal effect on themselves. Tau can facilitate the assembly of TIA1 stress granules, and TIA1 facilitates the aggregation of phosphorylated and altered tau [568], and the binding of TIA1 to tau oligomers promotes their stabilization and accumulation. Furthermore, reduction of TIA1 levels prevents tau oligomers propagation and toxicity. TIA1 regulates the toxicity of tau oligomers by the determination of their amount and thus the response of neurons to toxic tau oligomers by binding them into stress granules [569]. However, TIA1 can also stabilize prefibrillar tau aggregates and inhibit their further assembly into large fibrils [570].

3.10. Signal Transduction Mediators Interacting with Tau

Signaling pathways in the cells regulate many different, important, and basic processes, like cell growth, proliferation [571], metabolism, cell-to-cell communication, regeneration [572], apoptosis, and stress response. Signaling pathways comprise four categories of components: surface or intracellular receptors, enzymes, transcription factors, and signal mediators [573,574]. In tauopathies, changes in signaling pathways occur, such as the cell cycle pathway, response to stress, and Ca2+ signaling pathway. For example, oxidative stress in neurons can provoke stress responses and induce several signaling pathways, like the stress-activated protein kinase pathways (JNK-SAPK and p38-SAPK2). These pathways result in either stress adaptation or apoptosis, thus their outcomes can be neuroprotective or neurodegenerative [575]. Changes in the Ca2+ signaling pathways occur in AD, where they lead to progressive decline in memory and apoptosis [576]. Currently, eleven proteins that are components of signaling pathways were experimentally confirmed as TIPs.

The 14-3-3 adaptor proteins regulate a wide range of pathological and physiological processes [577]. They are involved in neuronal migration, neuromorphogenesis, synaptogenesis, and development of the nervous system, including neurogenesis and differentiation [578]. They also participate in neurodevelopmental disorders by the regulation of the subcellular localization and activity of target proteins [579]. In pathological conditions, they can participate in the development of neurodegeneration or can be neuroprotective. For example, 14-3-3 zeta facilitates GSK3β-dependent tau phosphorylation by the affinity enhancement of GSK3β for tau [580]. 14-3-3 zeta-bound proteins are also resistant against protein phosphatases, which enhance the strength and duration of kinase-dependent signals under pathological conditions. The 14-3-3 proteins bound to tau favor tau phosphorylation and aggregation [581]. They were found also in NFT [582]. However, they also play a neuroprotective role by inhibiting the cell cycle activation and preventing neuronal death [583]. A more comprehensive description of the interaction of 14-3-3 proteins with tau was recently reviewed by Chen et al. [584].

The next TIP involved in signaling is the growth factor receptor-bound protein 2 (GRB2) [235], an adapter protein that plays a key role in Ras-mediated growth factor signaling, proliferation, and cell cycle. GRB2 also presents an important link between cellular signaling and neuronal cytoskeleton [235]. In a healthy brain, GRB2 is localized in the neuronal body and its projections, while in the AD, it disappears from projections and is restricted only to neuronal soma [585]. GRB2 interacts with tyrosine-phosphorylated APP in AD [586]. GRB2 is involved in the activation of the mitogen-activated protein kinase (MAPK) pathway leading to abnormal tau phosphorylation [587]. However, the direct consequence of tau interaction with GRB2 is unknown.

The prosaposin receptor Gpr37-like 1 (GPR37L1) [77] is the G-protein coupled receptor exclusively expressed in the nervous system and is abundant in the human brain [588]. It possesses functional similarity to the prosaposin receptor GPR37 (GPR37), which is a substrate for E3 ubiquitin-protein ligase parkin. Both receptors, GPR37 and GPR37L1 bind the neurotrophic protein prosaposin and its active fragment prosaptide, which causes the endocytosis of both receptors upon binding and activation of the ERK phosphorylation pathway. Prosaposin as the neurotrophic factor promotes cell survival, neurite outgrowth, and differentiation [589]. One study revealed that GPR37L1 is a constitutively active receptor-independent from prosaposin binding and that its activity is down-regulated by ADAM metalloprotease [590]. The GPR37L1 was only recently identified as TIP [77], however, the consequence of its interaction with tau protein has not been elucidated.

Hepatocyte growth factor-regulated tyrosine kinase substrate (HGS) [591] is involved in intracellular signal transduction mediated by cytokines and growth factors and is a part of the ESCRT-0 sorting complex. HGS is essential for the binding of ubiquitylated cargo into multi-vesicular bodies (MVBs), which are important for the lysosomal recycling of plasma membrane proteins [592]. Furthermore, HGS is also an effector of the small GTPase Rab35, which catalyzes the ESCRT-0 complex recruitment and MVBs formation [593]. The Rab35 and the ESCRT-0 machinery are active in the regulation of total tau turnover and specific phospho-tau species by lysosomal degradation since tau proteins are present in HGS-positive early endosomes [591]. In AD, impairment of tau proteostasis occurs, which is linked to neuronal and synaptic dysfunction. In the early stages of AD, abnormalities of the endolysosomal pathway, like high levels of lysosomal hydrolases and endosomal enlargement [594], and dysregulation of the hypothalamic-pituitary-adrenal axis occur, which lead to elevated glucocorticoid levels [595]. Moreover, the high glucocorticoid levels impair tau degradation by the downregulation of Rab35 expression, which suppresses the sorting of tau into the ESCRT pathway and the formation of the HGS-positive endosomes containing tau. In addition, HGS levels are significantly decreased in AD, which suggests that molecular components critical for membrane protein sorting in the endocytic pathway are altered [596]. This results in the accumulation of ubiquitinated tau and related neuronal death [591].

JNK-interacting protein 1 (JIP1) mediates the JNK signaling and MAPK kinase cascade activation. JIP1 binds to the kinesin-I motor complex and regulates the release of cargo from the kinesin at the transport destination. Phosphorylated tau interacts with JIP1 and re-localizes it from axons to neuronal soma. This interaction was shown to be pathological because it competes with the binding of JIP1 to kinesin leading to failure of JIP1-mediated phosphorylation of the kinesin motor complex and damage of the anterograde axonal transport [597].

LIM and senescent cell antigen-like-containing domain protein 1 (LIMS1) are required for the formation of multi-protein complexes and facilitate cell proliferation, migration, and survival [598]. During neuronal development, LIMS1 is necessary for the maintenance of neuronal polarity and communication in synapses [599]. In a healthy brain, the levels of LIMS1 are nearly undetectable, while during neurodegeneration it is robustly expressed [600]. In the study by Ozdemir et al., authors propose that LIMS1 plays a role in tau hyperphosphorylation and the stabilization of abnormally hyperphosphorylated tau [598].

The phospholipase C-gamma-1 (PLCG1) is essential for the production of diacylglycerol and inositol 1,4,5-triphosphate, the second messenger signaling molecules [601]. PLCG1 participates in the pathways of growth factor neutrophins in neurons and is involved in the development of the brain, cytoskeleton organization, and synaptic plasticity [602]. PLCG1, along with protein kinase D1, participate in the neuroprotective function of APOE-containing lipoproteins, through anti-apoptotic signaling [603]. In AD, PLCG1 levels are lower than in a healthy brain [604]. Tau protein interacts directly with the SH3 domain of PLCG1 by the PXXP motif in the proline-rich region and this interaction is regulated by phosphorylation of tau [235]. This suggests that tau may be involved in the regulation of signal transduction mediated by PLCG1.

4. Current Therapeutic Approaches Targeting Tau and Its Interacting Partners

The modulation of the interaction between Tau and its partners has been applied for the development of therapeutics for AD and PSP. The modulators in clinical trials can be divided into four groups, such as inhibitors of phosphorylation, acetylation, and de-glycosylation and molecule-activated dephosphorylation. The drugs in clinical studies and their outcome are summarized in Table 5.

Several more drugs which have TIPs as targets are currently in the preclinical phases of development. Most of them have the same targets as modulators in clinical trials. Among them are inhibitors targeting Cdk5 kinase [619], two inhibitors of caspases [620,621,622], several HDAC6 specific inhibitors [623,624,625,626], and modulators of chaperones Hsp90 [627] and Hsp70 [628,629]. All of them showed modulation of tau protein modifications (phosphorylation, acetylation, etc.) and thus influencing their interaction with tau protein.

5. Conclusions

The exact causes of tau pathology in Alzheimer’s disease (AD) and other tauopathies have not been well understood and are under the broad current research. Besides tau pathology, the next widely accepted model of AD progression is the Aβ hypothesis, which is considered to be upstream of tau pathology by many researchers [630,631]. However, other insights on the initiation of tau pathology have been proposed, such as the impaired cholesterol metabolism [632], deregulated endocytosis [473,633], or overactivated microglia [634]. On the other hand, the pathological accumulation of tau proteins well correlates with the cognitive decline in individuals suffering from AD [635]. Furthermore, the recently developed positron emission tomography (PET) tracers raised against Aβ and tau, showed that both types of pathologies initially start in different brain regions [636,637]. Moreover, it is suggested that the accumulation of the Aβ occurs 20–30 years before the clinical onset of AD [638]. These seemingly contradictory facts demonstrate the need for a better understanding of the precise molecular mechanisms of upstream pathological processes in AD and other tauopathies.

Since protein-protein interactions (PPIs) represent a core part of each molecular pathway and biological process [639], it is important to study the interactome of proteins involved in diseases such as AD. Key players of affected molecular pathways could be suitable targets for drug development and disease-modifying therapies. The pathological modifications of tau protein which include abnormal phosphorylation, truncation, acetylation, glycosylation, or ubiquitination are performed by various classes of enzymes interacting with tau. Therefore, it is proposed that interaction partners of tau protein and their corresponding molecular pathways may be responsible for the development of pathological forms of tau [640]. In this review, we summarized the current knowledge about the role of tau protein in physiology and pathology and reviewed the TIPs. We discussed the functions of individual TIPs in neurodegeneration and pointed out the several discrepancies and gaps in knowledge of their roles in tau pathology. We believe that this review will encourage basic research on TIPs and/or the targets for the development of effective therapies against tauopathies.

Author Contributions

Conceptualization, J.H.; writing—original draft preparation, J.S., K.P. and J.H.; writing—review and editing, J.S., K.P. and J.H.; supervision, J.H. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by the Slovak Research and Development Agency (grant nos. APVV-16-0531 and APVV-18-0302), the Scientific Grant Agency of the Ministry of Education of the Slovak Republic (grant nos. VEGA 2/0123/21 and VEGA 2/0150/19), and the SAS Grants for PhD Students (grant no. APP0040).

Data Availability Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

Figure 1 Schematic representation of physiological tau protein functions in neurons. The axonal tau (A) stabilizes microtubules (MTs), and it can also bind actin filaments thus facilitating cytoskeleton networking. Furthermore, tau regulates MT dynamics by interacting with end-binding (EB) proteins. The EB proteins promote and regulate MT nucleation and elongation. Tau inhibits the EB protein binding to MTs and this inhibition is reversed by tau phosphorylation. Tau also competitively inhibits the interaction of dynein and kinesin to MTs and thus influences the intraneuronal transport and cargo release. In the synapses (B), tau protein can be directly translated, and during neuronal activity, it is released into the synaptic cleft. Through linking the MTs and actin filaments, tau can influence synaptic plasticity. Moreover, tau is a known interacting partner of the BAR domain-containing proteins such as BAIAP2, PACSIN1, and BIN1, that ensure the curvature and shaping of the neuronal membrane. Tau may play a role in the removal of developmental NMDARs and their replacement for mature NMDARs in dendrites (dashed arrows) as it is a known substrate of the protein kinase C (PKC), which is activated by the G protein-coupled receptors (GPCR). The PACSIN1 recruits clathrin and dynamin endocytic machinery to the developmental NMDARs and thus mediates their removal. The developmental/mature NMDARs exchange is important for the formation of new synaptic connections. ER—endoplasmic reticulum. In the nucleus (C), tau interacts with DNA and RNA, maintains their integrity, and protects them from oxidative damage. Furthermore, tau may be involved in rRNA-coding DNA transcription and rRNA processing. Created with BioRender.com.

Figure 2 Schematic representation of six human tau protein isoforms and their domains. The N-terminal part is more acidic due to N1 and N2 inserts. The microtubule-binding domain (MTBD) is composed of repeats R1–R4. The number of repeats and N-terminal inserts varies according to the type of tau protein isoform.

Figure 3 Schematic representation of human Big tau. Its counterparts in rat and mouse possess 752 or 733 aa and share 74.9% or 74.2% identity, respectively. Exons 4a and 6 are responsible for differentiation from the brain tau protein.

Figure 4 Overview of validated TIPs distributed according to their function. In brackets: the number of validated TIPs for the particular group.

ijms-22-09207-t001_Table 1 Table 1 Overview of proteins and substances found mounted in paired helical filaments and neurofibrillary tangles.

Category	Proteins/Substances	Reference	
Tubulin interacting proteins	microtubule-associated protein 2	[122]	
microtubule-associated protein 1B	[123,124]	
neurofilament proteins, vimentin	[125]	
heparansulfate proteoglycans	[126,127]	
amyloid precursor protein	[128,129]	
Kinases and other cytosol enzymes	casein kinase II	[130]	
extracellular signal-related kinase-2	[131]	
glycogen synthase kinase-3	[132]	
phospholipase C-δ	[133]	
Stress molecules	advanced glycation end products	[134,135,136]	
malondialdehyde	[137]	
heme oxygenase-1	[136]	
Amyloid and amyloid-binding proteins	complement proteins (Clq, C3, C4d and C5b-9)	[138,139]	
vitronectin	[140]	
apolipoprotein-E	[141,142]	
Others	C-series of gangliosides	[124]	
ubiquitin and ubiquitin ligases	[143,144,145]	
synaptophysin	[146]	
anti-thrombin III	[147]	
lactotransferrin	[148]	

ijms-22-09207-t002_Table 2 Table 2 Overview of protein kinases interacting with tau protein and their roles in pathology.

Protein	Roles in Tau Pathology	References	
ABL1	involved in formation of apoptotic complex	[172]	
AKT1	neuroprotective activity; inactivates pro-apoptotic proteins and promotes cell survival	[173]	
BRSK (1, 2)	unknown role in tau pathology	-	
CAMK2A	involved in hyperphosphorylation of tau in AD	[174,175]	
CDK (1, 5)	accelerate tau hyperphosphorylation and formation of NFT; act neuroprotective by apoptosis inhibition	[176,177]	
CDK2	inhibits tau-mediated tubulin polymerization by tau phosphorylation	[178]	
CSNK1 (A1, D)	involved in formation of Aβ; colocalize with NFT, suggesting a role in tau aggregation	[179,180]	
DYRK1A	overexpressed in AD; facilitates further tau phosphorylation by GSK3B	[181,182]	
DYRK2	overexpressed in AD; involved in activation of apoptosis	[181,183]	
FYN	facilitates formation of NFT by tau hyperphosphorylation; activates PTK2B; potentiates Aβ-induced synapse damage	[184,185,186]	
GSK3 (A, B)	responsible for hyperphosphorylation of tau; involved in activation of apoptosis; exacerbate tau pathology when activated by Aβ	[187,188,189]	
CHEK (1, 2)	unknown role in tau pathology	-	
LCK	it is downregulated in AD; unknown role in tau pathology	[190,191]	
LRRK2	contradictory reports: enhances abnormal tau phosphorylation and promote tauopathy or, no impact on tau pathology was shown	[192,193,194,195]	
MAP2K7	colocalize with hyperphosphorylated tau; contribute to Aβ accumulation	[196,197]	
MAPK (1, 3, 8–14)	overactivated in AD; involved in abnormal tau phosphorylation	[198,199]	
MARK (1–3)	phosphorylate tau aggregates; colocalizes with NFT	[200]	
MARK4	phosphorylate tau aggregates; mutation causes tau hyperphosphorylation, aggregation and tau-mediated neurodegeneration; colocalizes with NFT	[200,201]	
PHKG1	unknown role in tau pathology	-	
PKN1	regulates tau phosphorylation; colocalize with NFT	[202,203]	
PRKACA	abnormally phosphorylate α-Synuclein-bound tau; facilitates further phosphorylation of tau by GSK3 kinase; colocalize with NFT; important for regulation of alternative splicing of exon 10 in MAPT	[204,205,206,207]	
PRKC (A, B, E, G, I, Z)	neuroprotective role through inhibition of GSK3 kinase and reduced tau phosphorylation	[208,209]	
PTK2B	hyperphosphorylates tau; is regulated by FYN kinase; colocalize with pathological tau proteins in brains of AD patients	[185,210]	
RPS6K (A1, A3, A5, B1)	their attenuation is neuroprotective; possibly upregulate tau translation; contribute to tau aggregation and synapse damage; inhibit apoptosis	[211,212,213]	
SGK1	upregulated in AD; enhances tau hyperphosphorylation by GSK3B activation	[214]	
SIK1	unknown role in tau pathology	-	
SRC	unknown role in tau pathology	-	
SRPK (1, 2)	involved in regulation of alternative splicing of exon 10 in MAPT, where impaired splicing of exon 10 can lead to tauopathy	[215,216]	
SYK	accumulation of pathological tau proteins cause overactivation of SYK, which further hyperphosphorylates tau and exacerbate pathology; contributes to the neuroinflammation; inhibits autophagic tau degradation; contributes to neuronal loss	[217,218,219]	
TTBK1	enhances tau phosphorylation and aggregation; involved in neurodegeneration	[220,221]	

ijms-22-09207-t003_Table 3 Table 3 Overview of protein phosphatases interacting with tau protein and their roles in pathology.

Protein	Roles in Tau Pathology	References	
PPP1C (A, B, C)	downregulated in AD; neuroprotective function by reducing hyperphosphorylated tau levels;	[170,222]	
PPP2C (A, B)	downregulated in AD what induces tau hyperphosphorylation; neuroprotective; regulate autophagic degradation of proteins	[170,222,223,224]	
PPP5C	downregulated in AD what contributes to increased levels of hyperphosphorylated tau; dephosphorylates AD phospho-tau; protects against Aβ toxicity	[225,226,227]	
PTPN11	upregulated in AD; unknown role in tau pathology	[228]	

ijms-22-09207-t004_Table 4 Table 4 Overview of proteins participating in the regulation of kinases or phosphatases known to interact with tau protein and their roles in pathology.

Protein	Roles in Tau Pathology	References	
PTPA	regulatory subunit of PPP2C (A, B); decreased expression in AD; enhances tau dephosphorylation; neuroprotective; regulate autophagic degradation of proteins	[223,224,229,230]	
CDC37	regulates tau phosphorylation, enhances phospho-tau stability at HSP90 scaffold, preventing its degradation, preserves CDK5 and AKT kinases	[231]	
PIK3R1	key unit of PI3K, part of the PI3K/AKT1/GSK3B signaling pathway, which is downregulated in AD, plays a role in insulin signaling pathway where it might exacerbate AD pathology	[232,233,234,235]	
S100B	inhibits tau phosphorylation; enhances tau dephosphorylation by PPP5C; overexpression of S100B causes apoptosis, tau hyperphosphorylation, and inflammation	[236,237,238,239,240]	

ijms-22-09207-t005_Table 5 Table 5 Compounds in clinical trials targeting tau interactions with its PPIs.

Name	Function	Phase (Disease)	Efficacy	Source	
Dasatinib	Ab1 and Src kinase inhibitor	Phase I and II	Recruiting	NCT04063124	
Epigallocatechin gallate	DYRK1A kinase inhibitor	Phase II (AD)	No results posted	NCT00951834	
Lithium chloride	GSK-3 kinase inhibitor	Phase II (AD/PSP)	No effect	NCT00088387
[605]	
Nilotinib	Ab1 kinase inhibitor	Phase II (AD/PD)	Unknown	NCT02947893
[606]	
Saracatinib	Ab1, Src kinase inhibitor	Phase II (AD)	No effect	NCT02167256
[607,608]	
Tideglusib	GSK-3 kinase inhibitor	Phase II (AD/PSP)	No effect	NCT01350362
[609,610,611,612]	
Valproate	GSK-3 kinase inhibitor	Phase III (AD)	No effect	NCT00071721
[613,614,615]	
Memantine	PPP2CA activator	Phase IV (AD)	No effect	NCT00469456
[616]	
Sodium selenate	PPP2CA activator	Phase II (AD)	Small positive effects	[617]	
Salsalate	Acetylation inhibitor	Phase I (AD/PSP)	Ongoing	NCT03277573
[618]	
Minocycline	CDK5 kinase/caspase-3 inhibitor	Phase II (AD)	No effect	NCT01463384	
Nicotinamide	HDAC inhibitor	Phase II	Recruiting	NCT03061474	
Phenylbutyrate	HDAC inhibitor	Phase II	Ongoing	NCT03533257	
Vorinostat	HDAC inhibitor	Phase I	Recruiting	NCT03056495	

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Uversky V.N. Intrinsic disorder, protein–protein interactions, and disease Adv. Protein Chem. Struct. Biol. 2018 110 85 121 29413001
2. Weingarten M.D. Lockwood A.H. Hwo S.-Y. Kirschner M.W. A protein factor essential for microtubule assembly Proc. Natl. Acad. Sci. USA 1975 72 1858 1862 10.1073/pnas.72.5.1858 1057175
3. Cleveland D.W. Hwo S.-Y. Kirschner M.W. Physical and chemical properties of purified tau factor and the role of tau in microtubule assembly J. Mol. Biol. 1977 116 227 247 10.1016/0022-2836(77)90214-5 146092
4. Ferreira A. Busciglio J. Cáceres A. Microtubule formation and neurite growth in cerebellar macroneurons which develop in vitro: Evidence for the involvement of the microtubule-associated proteins, MAP-1a, HMW-MAP2 and Tau Dev. Brain Res. 1989 49 215 228 10.1016/0165-3806(89)90023-0 2509111
5. Takei Y. Teng J. Harada A. Hirokawa N. Defects in axonal elongation and neuronal migration in mice with disrupted tau and map1b genes J. Cell Biol. 2000 150 989 1000 10.1083/jcb.150.5.989 10973990
6. Sotiropoulos I. Galas M.C. Silva J.M. Skoulakis E. Wegmann S. Maina M.B. Blum D. Sayas C.L. Mandelkow E.M. Mandelkow E. Atypical, non-standard functions of the microtubule associated Tau protein Acta Neuropathol. Commun. 2017 5 91 10.1186/s40478-017-0489-6 29187252
7. Wang Y. Mandelkow E. Tau in physiology and pathology Nat. Rev. Neurosci. 2016 17 5 21 10.1038/nrn.2015.1 26631930
8. Binder L.I. Frankfurter A. Rebhun L.I. The distribution of tau in the mammalian central nervous system J. Cell Biol. 1985 101 1371 1378 10.1083/jcb.101.4.1371 3930508
9. LoPresti P. Szuchet S. Papasozomenos S.C. Zinkowski R.P. Binder L.I. Functional implications for the microtubule-associated protein tau: Localization in oligodendrocytes Proc. Natl. Acad. Sci. USA 1995 92 10369 10373 10.1073/pnas.92.22.10369 7479786
10. Müller R. Heinrich M. Heck S. Blohm D. Richter-Landsberg C. Expression of microtubule-associated proteins MAP2 and tau in cultured rat brain oligodendrocytes Cell Tissue Res. 1997 288 239 249 10.1007/s004410050809 9082959
11. Komori T. Tau-positive dial Inclusions in Progressive Supranuclear Palsy, Corticobasal Degeneration and Pick’s Disease Brain Pathol. 1999 9 663 679 10.1111/j.1750-3639.1999.tb00549.x 10517506
12. Maragakis N.J. Rothstein J.D. Mechanisms of disease: Astrocytes in neurodegenerative disease Nat. Clin. Pract. Neurol. 2006 2 679 689 10.1038/ncpneuro0355 17117171
13. Trojanowski J.Q. Schuck T. Schmidt M.L. Lee V. Distribution of tau proteins in the normal human central and peripheral nervous system J. Histochem. Cytochem. 1989 37 209 215 10.1177/37.2.2492045 2492045
14. Dugger B.N. Hoffman B.R. Scroggins A. Serrano G.E. Adler C.H. Shill H.A. Belden C.M. Sabbagh M.N. Caviness J.N. Dunckley E.D. Tau immunoreactivity in peripheral tissues of human aging and select tauopathies Neurosci. Lett. 2019 696 132 139 10.1016/j.neulet.2018.12.031 30579993
15. Goedert M. Jakes R. Expression of separate isoforms of human tau protein: Correlation with the tau pattern in brain and effects on tubulin polymerization EMBO J. 1990 9 4225 4230 10.1002/j.1460-2075.1990.tb07870.x 2124967
16. Kosik K.S. Orecchio L.D. Bakalis S. Neve R.L. Developmentally regulated expression of specific tau sequences Neuron 1989 2 1389 1397 10.1016/0896-6273(89)90077-9 2560640
17. Buee L. Bussiere T. Buee-Scherrer V. Delacourte A. Hof P.R. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders Brain Res. Brain Res. Rev. 2000 33 95 130 10.1016/S0165-0173(00)00019-9 10967355
18. Guo T. Noble W. Hanger D.P. Roles of tau protein in health and disease Acta Neuropathol. 2017 133 665 704 10.1007/s00401-017-1707-9 28386764
19. Lee G. Cowan N. Kirschner M. The primary structure and heterogeneity of tau protein from mouse brain Science 1988 239 285 288 10.1126/science.3122323 3122323
20. Kadavath H. Hofele R.V. Biernat J. Kumar S. Tepper K. Urlaub H. Mandelkow E. Zweckstetter M. Tau stabilizes microtubules by binding at the interface between tubulin heterodimers Proc. Natl. Acad. Sci. USA 2015 112 7501 7506 10.1073/pnas.1504081112 26034266
21. Dawson H.N. Ferreira A. Eyster M.V. Ghoshal N. Binder L.I. Vitek M.P. Inhibition of neuronal maturation in primary hippocampal neurons from tau deficient mice J. Cell Sci. 2001 114 Pt 6 1179 1187 10.1242/jcs.114.6.1179 11228161
22. Harada A. Oguchi K. Okabe S. Kuno J. Terada S. Ohshima T. Sato-Yoshitake R. Takei Y. Noda T. Hirokawa N. Altered microtubule organization in small-calibre axons of mice lacking tau protein Nature 1994 369 488 491 10.1038/369488a0 8202139
23. Tan D.C.S. Yao S. Ittner A. Bertz J. Ke Y.D. Ittner L.M. Delerue F. Generation of a New Tau Knockout (tauDeltaex1) Line Using CRISPR/Cas9 Genome Editing in Mice J. Alzheimer’s Dis. 2018 62 571 578 10.3233/JAD-171058 29480201
24. Terwel D. Lasrado R. Snauwaert J. Vandeweert E. Van Haesendonck C. Borghgraef P. Van Leuven F. Changed conformation of mutant Tau-P301L underlies the moribund tauopathy, absent in progressive, nonlethal axonopathy of Tau-4R/2N transgenic mice J. Biol. Chem. 2005 280 3963 3973 10.1074/jbc.M409876200 15509565
25. Tucker K.L. Meyer M. Barde Y.A. Neurotrophins are required for nerve growth during development Nat. Neurosci. 2001 4 29 37 10.1038/82868 11135642
26. DiTella M. Feiguin F. Carri N. Kosik K. Caceres A. MAP-1B/TAU functional redundancy during laminin-enhanced axonal growth J. Cell Sci. 1996 109 467 477 10.1242/jcs.109.2.467 8838670
27. Lei P. Ayton S. Moon S. Zhang Q. Volitakis I. Finkelstein D.I. Bush A.I. Motor and cognitive deficits in aged tau knockout mice in two background strains Mol. Neurodegener. 2014 9 29 10.1186/1750-1326-9-29 25124182
28. Ahmed T. Van der Jeugd A. Blum D. Galas M.C. D’Hooge R. Buee L. Balschun D. Cognition and hippocampal synaptic plasticity in mice with a homozygous tau deletion Neurobiol. Aging 2014 35 2474 2478 10.1016/j.neurobiolaging.2014.05.005 24913895
29. Hong X.P. Peng C.X. Wei W. Tian Q. Liu Y.H. Yao X.Q. Zhang Y. Cao F.Y. Wang Q. Wang J.Z. Essential role of tau phosphorylation in adult hippocampal neurogenesis Hippocampus 2010 20 1339 1349 10.1002/hipo.20712 19816983
30. Lei P. Ayton S. Finkelstein D.I. Spoerri L. Ciccotosto G.D. Wright D.K. Wong B.X. Adlard P.A. Cherny R.A. Lam L.Q. Tau deficiency induces parkinsonism with dementia by impairing APP-mediated iron export Nat. Med. 2012 18 291 295 10.1038/nm.2613 22286308
31. Kimura T. Whitcomb D.J. Jo J. Regan P. Piers T. Heo S. Brown C. Hashikawa T. Murayama M. Seok H. Microtubule-associated protein tau is essential for long-term depression in the hippocampus Philos. Trans. R. Soc. Lond. B Biol. Sci. 2014 369 20130144 10.1098/rstb.2013.0144 24298146
32. Regan P. Piers T. Yi J.H. Kim D.H. Huh S. Park S.J. Ryu J.H. Whitcomb D.J. Cho K. Tau phosphorylation at serine 396 residue is required for hippocampal LTD J. Neurosci. 2015 35 4804 4812 10.1523/JNEUROSCI.2842-14.2015 25810511
33. Ittner L.M. Ke Y.D. Delerue F. Bi M. Gladbach A. van Eersel J. Wolfing H. Chieng B.C. Christie M.J. Napier I.A. Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer’s disease mouse models Cell 2010 142 387 397 10.1016/j.cell.2010.06.036 20655099
34. Leroy K. Ando K. Laporte V. Dedecker R. Suain V. Authelet M. Heraud C. Pierrot N. Yilmaz Z. Octave J.N. Lack of tau proteins rescues neuronal cell death and decreases amyloidogenic processing of APP in APP/PS1 mice Am. J. Pathol. 2012 181 1928 1940 10.1016/j.ajpath.2012.08.012 23026200
35. Roberson E.D. Halabisky B. Yoo J.W. Yao J. Chin J. Yan F. Wu T. Hamto P. Devidze N. Yu G.Q. Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease J. Neurosci. 2011 31 700 711 10.1523/JNEUROSCI.4152-10.2011 21228179
36. Roberson E.D. Scearce-Levie K. Palop J.J. Yan F. Cheng I.H. Wu T. Gerstein H. Yu G.Q. Mucke L. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model Science 2007 316 750 754 10.1126/science.1141736 17478722
37. Bi M. Gladbach A. van Eersel J. Ittner A. Przybyla M. van Hummel A. Chua S.W. van der Hoven J. Lee W.S. Muller J. Tau exacerbates excitotoxic brain damage in an animal model of stroke Nat. Commun. 2017 8 473 10.1038/s41467-017-00618-0 28883427
38. De Vos S.L. Goncharoff D.K. Chen G. Kebodeaux C.S. Yamada K. Stewart F.R. Schuler D.R. Maloney S.E. Wozniak D.F. Rigo F. Antisense reduction of tau in adult mice protects against seizures J. Neurosci. 2013 33 12887 12897 10.1523/JNEUROSCI.2107-13.2013 23904623
39. Gheyara A.L. Ponnusamy R. Djukic B. Craft R.J. Ho K. Guo W. Finucane M.M. Sanchez P.E. Mucke L. Tau reduction prevents disease in a mouse model of Dravet syndrome Ann. Neurol. 2014 76 443 456 10.1002/ana.24230 25042160
40. Braak H. Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes Neurobiol. Aging 1995 16 271 278 10.1016/0197-4580(95)00021-6 7566337
41. Braak H. Braak E. Neuropathological stageing of Alzheimer-related changes Acta Neuropathol. 1991 82 239 259 10.1007/BF00308809 1759558
42. Lin W.-L. Lewis J. Yen S.-H. Hutton M. Dickson D.W. Filamentous tau in oligodendrocytes and astrocytes of transgenic mice expressing the human tau isoform with the P301L mutation Am. J. Pathol. 2003 162 213 218 10.1016/S0002-9440(10)63812-6 12507904
43. Perea J.R. López E. Díez-Ballesteros J.C. Ávila J. Hernández F. Bolós M. Extracellular monomeric tau is internalized by astrocytes Front. Neurosci. 2019 13 442 10.3389/fnins.2019.00442 31118883
44. Kovacs G.G. Tauopathies Handb. Clin. Neurol. 2018 145 355 368
45. De Calignon A. Fox L.M. Pitstick R. Carlson G.A. Bacskai B.J. Spires-Jones T.L. Hyman B.T. Caspase activation precedes and leads to tangles Nature 2010 464 1201 1204 10.1038/nature08890 20357768
46. Ross C.A. Poirier M.A. Protein aggregation and neurodegenerative disease Nat. Med. 2004 10 S10 S17 10.1038/nm1066 15272267
47. Cowan C.M. Mudher A. Are tau aggregates toxic or protective in tauopathies? Front. Neurol. 2013 4 114 10.3389/fneur.2013.00114 23964266
48. Kitazawa M. Oddo S. Yamasaki T.R. Green K.N. La Ferla F.M. Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer’s disease J. Neurosci. 2005 25 8843 8853 10.1523/JNEUROSCI.2868-05.2005 16192374
49. Hansen D.V. Hanson J.E. Sheng M. Microglia in Alzheimer’s disease J. Cell Biol. 2018 217 459 472 10.1083/jcb.201709069 29196460
50. Friedman B.A. Srinivasan K. Ayalon G. Meilandt W.J. Lin H. Huntley M.A. Cao Y. Lee S.-H. Haddick P.C. Ngu H. Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer’s disease not evident in mouse models Cell Rep. 2018 22 832 847 10.1016/j.celrep.2017.12.066 29346778
51. Rademakers R. Cruts M. van Broeckhoven C. The role of tau (MAPT) in frontotemporal dementia and related tauopathies Hum. Mutat. 2004 24 277 295 10.1002/humu.20086 15365985
52. Tolnay M. Probst A. Argyrophilic grain disease Handb. Clin. Neurol. 2008 89 553 563 18631777
53. Mahapatra R.K. Edwards M.J. Schott J.M. Bhatia K.P. Corticobasal degeneration Lancet Neurol. 2004 3 736 743 10.1016/S1474-4422(04)00936-6 15556806
54. Arai T. Ikeda K. Akiyama H. Nonaka T. Hasegawa M. Ishiguro K. Iritani S. Tsuchiya K. Iseki E. Yagishita S. Identification of amino-terminally cleaved tau fragments that distinguish progressive supranuclear palsy from corticobasal degeneration Ann. Neurol. 2004 55 72 79 10.1002/ana.10793 14705114
55. Hauw J.J. Verny M. Delaere P. Cervera P. He Y. Duyckaerts C. Constant neurofibrillary changes in the neocortex in progressive supranuclear palsy. Basic differences with Alzheimer’s disease and aging Neurosci. Lett. 1990 119 182 186 10.1016/0304-3940(90)90829-X 1704110
56. Brandt R. Léger J. Lee G. Interaction of tau with the neural plasma membrane mediated by tau’s amino-terminal projection domain J. Cell Biol. 1995 131 1327 1340 10.1083/jcb.131.5.1327 8522593
57. Brandt R. Trushina N.I. Bakota L. Much More Than a Cytoskeletal Protein: Physiological and Pathological Functions of the Non-microtubule Binding Region of Tau Front. Neurol. 2020 11 1 14 10.3389/fneur.2020.590059 32116995
58. Dixit R. Ross J.L. Goldman Y.E. Holzbaur E.L. Differential regulation of dynein and kinesin motor proteins by tau Science 2008 319 1086 1089 10.1126/science.1152993 18202255
59. Konzack S. Thies E. Marx A. Mandelkow E.M. Mandelkow E. Swimming against the tide: Mobility of the microtubule-associated protein tau in neurons J. Neurosci. 2007 27 9916 9927 10.1523/JNEUROSCI.0927-07.2007 17855606
60. Utton M.A. Noble W.J. Hill J.E. Anderton B.H. Hanger D.P. Molecular motors implicated in the axonal transport of tau and α-synuclein J. Cell Sci. 2005 118 4645 4654 10.1242/jcs.02558 16176937
61. Magnani E. Fan J. Gasparini L. Golding M. Williams M. Schiavo G. Goedert M. Amos L.A. Spillantini M.G. Interaction of tau protein with the dynactin complex EMBO J. 2007 26 4546 4554 10.1038/sj.emboj.7601878 17932487
62. Kobayashi S. Tanaka T. Soeda Y. Takashima A. Enhanced tau protein translation by hyper-excitation Front. Aging Neurosci. 2019 11 322 10.3389/fnagi.2019.00322 31824301
63. Yamada K. Holth J.K. Liao F. Stewart F.R. Mahan T.E. Jiang H. Cirrito J.R. Patel T.K. Hochgräfe K. Mandelkow E.-M. Neuronal activity regulates extracellular tau in vivo J. Exp. Med. 2014 211 387 393 10.1084/jem.20131685 24534188
64. Wang Y. Balaji V. Kaniyappan S. Krüger L. Irsen S. Tepper K. Chandupatla R. Maetzler W. Schneider A. Mandelkow E. The release and trans-synaptic transmission of Tau via exosomes Mol. Neurodegener. 2017 12 1 25 10.1186/s13024-016-0143-y 28049533
65. Sato C. Barthelemy N.R. Mawuenyega K.G. Patterson B.W. Gordon B.A. Jockel-Balsarotti J. Sullivan M. Crisp M.J. Kasten T. Kirmess K.M. Tau Kinetics in Neurons and the Human Central Nervous System Neuron 2018 97 1284 1298.e7 10.1016/j.neuron.2018.02.015 29566794
66. Pooler A.M. Phillips E.C. Lau D.H. Noble W. Hanger D.P. Physiological release of endogenous tau is stimulated by neuronal activity EMBO Rep. 2013 14 389 394 10.1038/embor.2013.15 23412472
67. Araque A. Parpura V. Sanzgiri R.P. Haydon P.G. Tripartite synapses: Glia, the unacknowledged partner Trends Neurosci. 1999 22 208 215 10.1016/S0166-2236(98)01349-6 10322493
68. Perea G. Navarrete M. Araque A. Tripartite synapses: Astrocytes process and control synaptic information Trends Neurosci. 2009 32 421 431 10.1016/j.tins.2009.05.001 19615761
69. Halassa M.M. Fellin T. Haydon P.G. The tripartite synapse: Roles for gliotransmission in health and disease Trends Mol. Med. 2007 13 54 63 10.1016/j.molmed.2006.12.005 17207662
70. Piacentini R. Li Puma D.D. Mainardi M. Lazzarino G. Tavazzi B. Arancio O. Grassi C. Reduced gliotransmitter release from astrocytes mediates tau-induced synaptic dysfunction in cultured hippocampal neurons Glia 2017 65 1302 1316 10.1002/glia.23163 28519902
71. Tremblay M.-È. Lowery R.L. Majewska A.K. Microglial interactions with synapses are modulated by visual experience PLoS Biol. 2010 8 e1000527 10.1371/journal.pbio.1000527 21072242
72. Wake H. Moorhouse A.J. Jinno S. Kohsaka S. Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals J. Neurosci. 2009 29 3974 3980 10.1523/JNEUROSCI.4363-08.2009 19339593
73. Maphis N. Xu G. Kokiko-Cochran O.N. Jiang S. Cardona A. Ransohoff R.M. Lamb B.T. Bhaskar K. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain Brain 2015 138 1738 1755 10.1093/brain/awv081 25833819
74. Mondragon-Rodriguez S. Trillaud-Doppia E. Dudilot A. Bourgeois C. Lauzon M. Leclerc N. Boehm J. Interaction of endogenous tau protein with synaptic proteins is regulated by N-methyl-D-aspartate receptor-dependent tau phosphorylation J. Biol. Chem. 2012 287 32040 32053 10.1074/jbc.M112.401240 22833681
75. Tai H.C. Serrano-Pozo A. Hashimoto T. Frosch M.P. Spires-Jones T.L. Hyman B.T. The synaptic accumulation of hyperphosphorylated tau oligomers in Alzheimer disease is associated with dysfunction of the ubiquitin-proteasome system Am. J. Pathol. 2012 181 1426 1435 10.1016/j.ajpath.2012.06.033 22867711
76. Suetsugu S. Toyooka K. Senju Y. Subcellular Membrane Curvature Mediated by the BAR Domain Superfamily Proteins Semin. Cell Dev. Biol. 2010 21 340 349 10.1016/j.semcdb.2009.12.002 19963073
77. Sinsky J. Majerova P. Kovac A. Kotlyar M. Jurisica I. Hanes J. Physiological tau interactome in brain and its link to tauopathies J. Proteome Res. 2020 19 2429 2442 10.1021/acs.jproteome.0c00137 32357304
78. Safari F. Suetsugu S. The BAR domain superfamily proteins from subcellular structures to human diseases Membranes 2012 2 91 117 10.3390/membranes2010091 24957964
79. Liu Y. Lv K. Li Z. Yu A.C. Chen J. Teng J. PACSIN1, a Tau-interacting protein, regulates axonal elongation and branching by facilitating microtubule instability J. Biol. Chem. 2012 287 39911 39924 10.1074/jbc.M112.403451 23035120
80. He H.J. Wang X.S. Pan R. Wang D.L. Liu M.N. He R.Q. The proline-rich domain of tau plays a role in interactions with actin BMC Cell Biol. 2009 10 1 12 10.1186/1471-2121-10-81 19134226
81. Elie A. Prezel E. Guerin C. Denarier E. Ramirez-Rios S. Serre L. Andrieux A. Fourest-Lieuvin A. Blanchoin L. Arnal I. Tau co-organizes dynamic microtubule and actin networks Sci. Rep. 2015 5 9964 10.1038/srep09964 25944224
82. Pallas-Bazarra N. Draffin J. Cuadros R. Antonio Esteban J. Avila J. Tau is required for the function of extrasynaptic NMDA receptors Sci. Rep. 2019 9 9116 10.1038/s41598-019-45547-8 31235881
83. Lu J. Li T. He R. Bartlett P.F. Gotz J. Visualizing the microtubule-associated protein tau in the nucleus Sci. China Life Sci. 2014 57 422 431 10.1007/s11427-014-4635-0 24643416
84. Liu C. Gotz J. Profiling murine tau with 0N, 1N and 2N isoform-specific antibodies in brain and peripheral organs reveals distinct subcellular localization, with the 1N isoform being enriched in the nucleus PLoS ONE 2013 8 e84849 10.1371/journal.pone.0084849 24386422
85. Maina M.B. Bailey L.J. Wagih S. Biasetti L. Pollack S.J. Quinn J.P. Thorpe J.R. Doherty A.J. Serpell L.C. The involvement of tau in nucleolar transcription and the stress response Acta Neuropathol. Commun. 2018 6 70 10.1186/s40478-018-0565-6 30064522
86. Sjoberg M.K. Shestakova E. Mansuroglu Z. Maccioni R.B. Bonnefoy E. Tau protein binds to pericentromeric DNA: A putative role for nuclear tau in nucleolar organization J. Cell Sci. 2006 119 Pt 10 2025 2034 10.1242/jcs.02907 16638814
87. Thurston V.C. Zinkowski R.P. Binder L.I. Tau as a nucleolar protein in human nonneural cells in vitro and in vivo Chromosoma 1996 105 20 30 10.1007/BF02510035 8662255
88. Wei Y. Qu M.H. Wang X.S. Chen L. Wang D.L. Liu Y. Hua Q. He R.Q. Binding to the minor groove of the double-strand, tau protein prevents DNA from damage by peroxidation PLoS ONE 2008 3 e2600 10.1371/journal.pone.0002600 18596978
89. Kampers T. Friedhoff P. Biernat J. Mandelkow E.M. Mandelkow E. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments FEBS Lett. 1996 399 344 349 10.1016/S0014-5793(96)01386-5 8985176
90. Violet M. Delattre L. Tardivel M. Sultan A. Chauderlier A. Caillierez R. Talahari S. Nesslany F. Lefebvre B. Bonnefoy E. A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions Front. Cell Neurosci. 2014 8 84 10.3389/fncel.2014.00084 24672431
91. Sultan A. Nesslany F. Violet M. Begard S. Loyens A. Talahari S. Mansuroglu Z. Marzin D. Sergeant N. Humez S. Nuclear tau, a key player in neuronal DNA protection J. Biol. Chem. 2011 286 4566 4575 10.1074/jbc.M110.199976 21131359
92. Mansuroglu Z. Benhelli-Mokrani H. Marcato V. Sultan A. Violet M. Chauderlier A. Delattre L. Loyens A. Talahari S. Begard S. Loss of Tau protein affects the structure, transcription and repair of neuronal pericentromeric heterochromatin Sci. Rep. 2016 6 33047 10.1038/srep33047 27605042
93. Qi H. Cantrelle F.X. Benhelli-Mokrani H. Smet-Nocca C. Buee L. Lippens G. Bonnefoy E. Galas M.C. Landrieu I. Nuclear magnetic resonance spectroscopy characterization of interaction of Tau with DNA and its regulation by phosphorylation Biochemistry 2015 54 1525 1533 10.1021/bi5014613 25623359
94. Eftekharzadeh B. Daigle J.G. Kapinos L.E. Coyne A. Schiantarelli J. Carlomagno Y. Cook C. Miller S.J. Dujardin S. Amaral A.S. Tau protein disrupts nucleocytoplasmic transport in Alzheimer’s disease Neuron 2018 99 925 940.e7 10.1016/j.neuron.2018.07.039 30189209
95. Goedert M. Spillantini M. Crowther R. Cloning of a big tau microtubule-associated protein characteristic of the peripheral nervous system Proc. Natl. Acad. Sci. USA 1992 89 1983 1987 10.1073/pnas.89.5.1983 1542696
96. Taleghany N. Oblinger M. Regional distribution and biochemical characteristics of high molecular weight tau in the nervous system J. Neurosci. Res. 1992 33 257 265 10.1002/jnr.490330209 1453489
97. Fischer I. Baas P.W. Resurrecting the mysteries of big tau Trends Neurosci. 2020 43 493 504 10.1016/j.tins.2020.04.007 32434664
98. Mercken M. Fischer I. Kosik K. Nixon R. Three distinct axonal transport rates for tau, tubulin, and other microtubule-associated proteins: Evidence for dynamic interactions of tau with microtubules in vivo J. Neurosci. 1995 15 8259 8267 10.1523/JNEUROSCI.15-12-08259.1995 8613759
99. Boyne L. Tessler A. Murray M. Fischer I. Distribution of Big tau in the central nervous system of the adult and developing rat J. Comp. Neurol. 1995 358 279 293 10.1002/cne.903580209 7560287
100. Frappier T.F. Georgieff I.S. Brown K. Shelanski M.L. τ Regulation of Microtubule-Microtubule Spacing and Bundling J. Neurochem. 1994 63 2288 2294 10.1046/j.1471-4159.1994.63062288.x 7964749
101. Kanaan N.M. Morfini G. Pigino G. LaPointe N.E. Andreadis A. Song Y. Leitman E. Binder L.I. Brady S.T. Phosphorylation in the amino terminus of tau prevents inhibition of anterograde axonal transport Neurobiol. Aging 2012 33 826.e15 826.e30 10.1016/j.neurobiolaging.2011.06.006 21794954
102. Frost B. Jacks R.L. Diamond M.I. Propagation of tau misfolding from the outside to the inside of a cell J. Biol. Chem. 2009 284 12845 12852 10.1074/jbc.M808759200 19282288
103. Clavaguera F. Duyckaerts C. Haïk S. Prion-like properties of Tau assemblies Curr. Opin. Neurobiol. 2020 61 49 57 10.1016/j.conb.2019.11.022 31923760
104. Banati R.B. Gehrmann J. Schubert P. Kreutzberg G.W. Cytotoxicity of microglia Glia 1993 7 111 118 10.1002/glia.440070117 8423058
105. Paolicelli R.C. Bergamini G. Rajendran L. Cell-to-cell communication by extracellular vesicles: Focus on microglia Neuroscience 2019 405 148 157 10.1016/j.neuroscience.2018.04.003 29660443
106. Asai H. Ikezu S. Tsunoda S. Medalla M. Luebke J. Haydar T. Wolozin B. Butovsky O. Kügler S. Ikezu T. Depletion of microglia and inhibition of exosome synthesis halt tau propagation Nat. Neurosci. 2015 18 1584 10.1038/nn.4132 26436904
107. Ebneth A. Godemann R. Stamer K. Illenberger S. Trinczek B. Mandelkow E.-M. Mandelkow E. Overexpression of tau protein inhibits kinesin-dependent trafficking of vesicles, mitochondria, and endoplasmic reticulum: Implications for Alzheimer’s disease J. Cell Biol. 1998 143 777 794 10.1083/jcb.143.3.777 9813097
108. Denk F. Wade-Martins R. Knock-out and transgenic mouse models of tauopathies Neurobiol. Aging 2009 30 1 13 10.1016/j.neurobiolaging.2007.05.010 17590238
109. Blair L.J. Frauen H.D. Zhang B. Nordhues B.A. Bijan S. Lin Y.-C. Zamudio F. Hernandez L.D. Sabbagh J.J. Selenica M.-L.B. Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy Acta Neuropathol. Commun. 2015 3 1 22 10.1186/s40478-015-0186-2 25627031
110. Ledesma M.D. Bonay P. Avila J. τ Protein from Alzheimer’s disease patients is glycated at its tubulin-binding domain J. Neurochem. 1995 65 1658 1664 10.1046/j.1471-4159.1995.65041658.x 7561862
111. Du Yan S. Yan S.F. Chen X. Fu J. Chen M. Kuppusamy P. Smith M.A. Perry G. Godman G.C. Nawroth P. Non-enzymatically glycated tau in Alzheimer’s disease induces neuronal oxidant stress resulting in cytokine gene expression and release of amyloid β-peptide Nat. Med. 1995 1 693 699 10.1038/nm0795-693 7585153
112. Gamblin T.C. Chen F. Zambrano A. Abraha A. Lagalwar S. Guillozet A.L. Lu M. Fu Y. Garcia-Sierra F. LaPointe N. Caspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer’s disease Proc. Natl. Acad. Sci. USA 2003 100 10032 10037 10.1073/pnas.1630428100 12888622
113. Rissman R.A. Poon W.W. Blurton-Jones M. Oddo S. Torp R. Vitek M.P. LaFerla F.M. Rohn T.T. Cotman C.W. Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology J. Clin. Investig. 2004 114 121 130 10.1172/JCI200420640 15232619
114. Jadhav S. Zilka N. Novak M. Protein truncation as a common denominator of human neurodegenerative foldopathies Mol. Neurobiol. 2013 48 516 532 10.1007/s12035-013-8440-8 23516100
115. Guo Q. Xie J. AATF inhibits aberrant production of amyloid β peptide 1-42 by interacting directly with Par-4 J. Biol. Chem. 2004 279 4596 4603 10.1074/jbc.M309811200 14627703
116. Köpke E. Tung Y.-C. Shaikh S. Alonso A.d.C. Iqbal K. Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease J. Biol. Chem. 1993 268 24374 24384 10.1016/S0021-9258(20)80536-5 8226987
117. Novak M. Truncated tau protein as a new marker for Alzheimer’s disease Acta Virol. 1994 38 173 189 7817900
118. Yen S.-h. Liu W.-K. Hall F.L. Yan S.-D. Stern D. Dickson D.W. Alzheimer neurofibrillary lesions: Molecular nature and potential roles of different components Neurobiol. Aging 1995 16 381 387 10.1016/0197-4580(95)00022-7 7566347
119. Armstrong R.A. Lantos P.L. Cairns N.J. What determines the molecular composition of abnormal protein aggregates in neurodegenerative disease? Neuropathology 2008 28 351 365 10.1111/j.1440-1789.2008.00916.x 18433435
120. Goldman R.D. Steinert P.M. Cellular and Molecular Biology of Intermediate Filaments Springer Science & Business Media New York, NY, USA 2013
121. Samson A.L. Ho B. Au A.E. Schoenwaelder S.M. Smyth M.J. Bottomley S.P. Kleifeld O. Medcalf R.L. Physicochemical properties that control protein aggregation also determine whether a protein is retained or released from necrotic cells Open Biol. 2016 6 160098 10.1098/rsob.160098 27810968
122. Kosik K.S. Duffy L.K. Dowling M.M. Abraham C. McCluskey A. Selkoe D.J. Microtubule-associated protein 2: Monoclonal antibodies demonstrate the selective incorporation of certain epitopes into Alzheimer neurofibrillary tangles Proc. Natl. Acad. Sci. USA 1984 81 7941 7945 10.1073/pnas.81.24.7941 6083566
123. Hasegawa M. Arai T. Ihara Y. Immunochemical evidence that fragments of phosphorylated MAP5 (MAP1B) are bound to neurofibrillary tangles in Alzheimer’s disease Neuron 1990 4 909 918 10.1016/0896-6273(90)90144-5 2361014
124. Takahashi H. Hirokawa K. Ando S. Obata K. Immunohistological study on brains of Alzheimer’s disease using antibodies to fetal antigens, C-series gangliosides and microtubule-associated protein 5 Acta Neuropathol. 1991 81 626 631 10.1007/BF00296372 1909079
125. Anderton B.H. Breinburg D. Downes M.J. Green P.J. Tomlinson B. Ulrich J. Wood J.N. Kahn J. Monoclonal antibodies show that neurofibrillary tangles and neurofilaments share antigenic determinants Nature 1982 298 84 86 10.1038/298084a0 6178036
126. Snow A. Mar H. Nochlin D. Sekiguchi R. Kimata K. Koike Y. Wight T. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer’s disease and Down’s syndrome Am. J. Pathol. 1990 137 1253 2146882
127. Perry G. Siedlak S.L. Richey P. Kawai M. Cras P. Kalaria R.N. Galloway P.G. Scardina J.M. Cordell B. Greenberg B.D. Association of heparan sulfate proteoglycan with the neurofibrillary tangles of Alzheimer’s disease J. Neurosci. 1991 11 3679 3683 10.1523/JNEUROSCI.11-11-03679.1991 1941102
128. Huang Y. Herman M.M. Liu J. Katsetos C.D. Wills M.R. Savory J. Neurofibrillary lesions in experimental aluminum-induced encephalopathy and Alzheimer’s disease share immunoreactivity for amyloid precursor protein, Aβ, α1-antichymotrypsin and ubiquitin-protein conjugates Brain Res. 1997 771 213 220 10.1016/S0006-8993(97)00780-4 9401741
129. Perry G. Richey P.L. Siedlak S.L. Smith M.A. Mulvihill P. DeWitt D.A. Barnett J. Greenberg B.D. Kalaria R.N. Immunocytochemical evidence that the beta-protein precursor is an integral component of neurofibrillary tangles of Alzheimer’s disease Am. J. Pathol. 1993 143 1586 7504885
130. Baum L. Masliah E. Iimoto D.S. Hansen L.A. Halliday W.C. Saitoh T. Casein kinase II is associated with neurofibrillary tangles but is not an intrinsic component of paired helical filaments Brain Res. 1992 573 126 132 10.1016/0006-8993(92)90121-O 1576530
131. Trojanowski J.Q. Mawal-Dewan M. Schmidt M.L. Martin J. Lee V.M.-Y. Localization of the mitogen activated protein kinase ERK2 in Alzheimer’s disease neurofibrillary tangles and senile plaque neurites Brain Res. 1993 618 333 337 10.1016/0006-8993(93)91286-2 8374766
132. Hanger D.P. Hughes K. Woodgett J.R. Brion J.-P. Anderton B.H. Glycogen synthase kinase-3 induces Alzheimer’s disease-like phosphorylation of tau: Generation of paired helical filament epitopes and neuronal localisation of the kinase Neurosci. Lett. 1992 147 58 62 10.1016/0304-3940(92)90774-2 1336152
133. Shimohama S. Homma Y. Suenaga T. Fujimoto S. Taniguchi T. Araki W. Yamaoka Y. Takenawa T. Kimura J. Aberrant accumulation of phospholipase C-delta in Alzheimer brains Am. J. Pathol. 1991 139 737 1928298
134. Smith M.A. Taneda S. Richey P.L. Miyata S. Yan S.-D. Stern D. Sayre L.M. Monnier V.M. Perry G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology Proc. Natl. Acad. Sci. USA 1994 91 5710 5714 10.1073/pnas.91.12.5710 8202552
135. Yan S. Chen X. Schmidt A. Brett J. Godman G. Zou Y. Scott C. Caputo C. Frappier T. Smith M. Glycated tau protein in Alzheimer disease: A mechanism for induction of oxidant stress Proc. Natl. Acad. Sci. USA 1994 91 7787 7791 10.1073/pnas.91.16.7787 8052661
136. Sasaki N. Fukatsu R. Tsuzuki K. Hayashi Y. Yoshida T. Fujii N. Koike T. Wakayama I. Yanagihara R. Garruto R. Advanced glycation end products in Alzheimer’s disease and other neurodegenerative diseases Am. J. Pathol. 1998 153 1149 1155 10.1016/S0002-9440(10)65659-3 9777946
137. Gella A. Durany N. Oxidative stress in Alzheimer disease Cell Adhes. Migr. 2009 3 88 93 10.4161/cam.3.1.7402 19372765
138. McGeer P. Akiyama H. Itagaki S. McGeer E. Activation of the classical complement pathway in brain tissue of Alzheimer patients Neurosci. Lett. 1989 107 341 346 10.1016/0304-3940(89)90843-4 2559373
139. Itagaki S. Akiyama H. Saito H. McGeer P.L. Ultrastructural localization of complement membrane attack complex (MAC)-like immunoreactivity in brains of patients with Alzheimer’s disease Brain Res. 1994 645 78 84 10.1016/0006-8993(94)91640-3 8062101
140. Akiyama H. Kawamata T. Dedhar S. McGeer P. Immunohistochemical localization of vitronectin, its receptor and beta-3 integrin in Alzheimer brain tissue J. Neuroimmunol. 1991 32 19 28 10.1016/0165-5728(91)90067-H 1705945
141. Namba Y. Tomonaga M. Kawasaki H. Otomo E. Ikeda K. Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer’s disease and kuru plaque amyloid in Creutzfeldt-Jakob disease Brain Res. 1991 541 163 166 10.1016/0006-8993(91)91092-F 2029618
142. Yamaguchi H. Nakazato Y. Shoji M. Okamoto K. Ihara Y. Morimatsu M. Hirai S. Secondary deposition of beta amyloid within extracellular neurofibrillary tangles in Alzheimer-type dementia Am. J. Pathol. 1991 138 699 1705753
143. Mori H. Kondo J. Ihara Y. Ubiquitin is a component of paired helical filaments in Alzheimer’s disease Science 1987 235 1641 1644 10.1126/science.3029875 3029875
144. Iwatsubo T. Hasegawa M. Esaki Y. Ihara Y. Lack of ubiquitin immunoreactivities at both ends of neuropil threads. Possible bidirectional growth of neuropil threads Am. J. Pathol. 1992 140 277 1310831
145. Nakamura M. Kaneko S. Dickson D.W. Kusaka H. Aberrant accumulation of BRCA1 in Alzheimer disease and other tauopathies J. Neuropathol. Exp. Neurol. 2020 79 22 33 10.1093/jnen/nlz107 31750914
146. Arima K. Nakamura M. Sunohara N. Nishio T. Ogawa M. Hirai S. Kawai M. Ikeda K. Immunohistochemical and ultrastructural characterization of neuritic clusters around ghost tangles in the hippocampal formation in progressive supranuclear palsy brains Acta Neuropathol. 1999 97 565 576 10.1007/s004010051032 10378375
147. Kalaria R. Golde T. Kroon S. Perry G. Serine protease inhibitor antithrombin III and its messenger RNA in the pathogenesis of Alzheimer’s disease Am. J. Pathol. 1993 143 886 8362984
148. Kawamata T. Tooyama I. Yamada T. Walker D.G. McGeer P.L. Lactotransferrin immunocytochemistry in Alzheimer and normal human brain Am. J. Pathol. 1993 142 1574 8494052
149. Oughtred R. Rust J. Chang C. Breitkreutz B.J. Stark C. Willems A. Boucher L. Leung G. Kolas N. Zhang F. The BioGRID database: A comprehensive biomedical resource of curated protein, genetic, and chemical interactions Protein Sci. 2021 30 187 200 10.1002/pro.3978 33070389
150. Fahey M.E. Bennett M.J. Mahon C. Jäger S. Pache L. Kumar D. Shapiro A. Rao K. Chanda S.K. Craik C.S. GPS-Prot: A web-based visualization platform for integrating host-pathogen interaction data BMC Bioinform. 2011 12 1 13 10.1186/1471-2105-12-298
151. Salwinski L. Miller C.S. Smith A.J. Pettit F.K. Bowie J.U. Eisenberg D. The database of interacting proteins: 2004 update Nucleic Acids Res. 2004 32 Suppl. 1 D449 D451 10.1093/nar/gkh086 14681454
152. Orchard S. Ammari M. Aranda B. Breuza L. Briganti L. Broackes-Carter F. Campbell N.H. Chavali G. Chen C. Del-Toro N. The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases Nucleic Acids Res. 2014 42 D358 D363 10.1093/nar/gkt1115 24234451
153. Licata L. Briganti L. Peluso D. Perfetto L. Iannuccelli M. Galeota E. Sacco F. Palma A. Nardozza A.P. Santonico E. MINT, the molecular interaction database: 2012 update Nucleic Acids Res. 2012 40 D857 D861 10.1093/nar/gkr930 22096227
154. Szklarczyk D. Gable A.L. Lyon D. Junge A. Wyder S. Huerta-Cepas J. Simonovic M. Doncheva N.T. Morris J.H. Bork P. STRING v11: Protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets Nucleic Acids Res. 2019 47 D607 D613 10.1093/nar/gky1131 30476243
155. Kotlyar M. Pastrello C. Malik Z. Jurisica I. IID 2018 update: Context-specific physical protein–protein interactions in human, model organisms and domesticated species Nucleic Acids Res. 2019 47 D581 D589 10.1093/nar/gky1037 30407591
156. Ksiezak-Reding H. Liu W.-K. Yen S.-H. Phosphate analysis and dephosphorylation of modified tau associated with paired helical filaments Brain Res. 1992 597 209 219 10.1016/0006-8993(92)91476-U 1472994
157. Biernat J. Gustke N. Drewes G. Mandelkow E.M. Mandelkow E. Phosphorylation of Ser262 strongly reduces binding of tau to microtubules: Distinction between PHF-like immunoreactivity and microtubule binding Neuron 1993 11 153 163 10.1016/0896-6273(93)90279-Z 8393323
158. Goedert M. Jakes R. Crowther R.A. Cohen P. Vanmechelen E. Vandermeeren M. Cras P. Epitope mapping of monoclonal antibodies to the paired helical filaments of Alzheimer’s disease: Identification of phosphorylation sites in tau protein Biochem. J. 1994 301 Pt 3 871 877 10.1042/bj3010871 7519852
159. Zheng-Fischhofer Q. Biernat J. Mandelkow E.M. Illenberger S. Godemann R. Mandelkow E. Sequential phosphorylation of Tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation Eur. J. Biochem. 1998 252 542 552 10.1046/j.1432-1327.1998.2520542.x 9546672
160. Wegmann S. Biernat J. Mandelkow E. A current view on Tau protein phosphorylation in Alzheimer’s disease Curr. Opin. Neurobiol. 2021 69 131 138 10.1016/j.conb.2021.03.003 33892381
161. Hasegawa M. Morishima-Kawashima M. Takio K. Suzuki M. Titani K.A. Ihara Y. Protein sequence and mass spectrometric analyses of tau in the Alzheimer’s disease brain J. Biol. Chem. 1992 267 17047 17054 10.1016/S0021-9258(18)41890-X 1512244
162. Brici D. Götz J. Nisbet R.M. A novel antibody targeting tau phosphorylated at serine 235 detects neurofibrillary tangles J. Alzheimer’s Dis. 2018 61 899 905 10.3233/JAD-170610 29332046
163. Neddens J. Temmel M. Flunkert S. Kerschbaumer B. Hoeller C. Loeffler T. Niederkofler V. Daum G. Attems J. Hutter-Paier B. Phosphorylation of different tau sites during progression of Alzheimer’s disease Acta Neuropathol. Commun. 2018 6 1 15 10.1186/s40478-018-0557-6 29298724
164. Hanger D.P. Betts J.C. Loviny T.L. Blackstock W.P. Anderton B.H. New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer’s disease brain using nanoelectrospray mass spectrometry J. Neurochem. 1998 71 2465 2476 10.1046/j.1471-4159.1998.71062465.x 9832145
165. Matsuo E.S. Shin R.W. Billingsley M.L. Van deVoorde A. O’Connor M. Trojanowski J.Q. Lee V.M. Biopsy-derived adult human brain tau is phosphorylated at many of the same sites as Alzheimer’s disease paired helical filament tau Neuron 1994 13 989 1002 10.1016/0896-6273(94)90264-X 7946342
166. Drepper F. Biernat J. Kaniyappan S. Meyer H.E. Mandelkow E.M. Warscheid B. Mandelkow E. A combinatorial native MS and LC-MS/MS approach reveals high intrinsic phosphorylation of human Tau but minimal levels of other key modifications J. Biol. Chem. 2020 295 18213 18225 10.1074/jbc.RA120.015882 33106314
167. Mair W. Muntel J. Tepper K. Tang S. Biernat J. Seeley W.W. Kosik K.S. Mandelkow E. Steen H. Steen J.A. FLEXITau: Quantifying post-translational modifications of tau protein in vitro and in human disease Anal. Chem. 2016 88 3704 3714 10.1021/acs.analchem.5b04509 26877193
168. Tepper K. Biernat J. Kumar S. Wegmann S. Timm T. Hübschmann S. Redecke L. Mandelkow E.-M. Müller D.J. Mandelkow E. Oligomer formation of tau protein hyperphosphorylated in cells J. Biol. Chem. 2014 289 34389 34407 10.1074/jbc.M114.611368 25339173
169. Martin L. Latypova X. Wilson C.M. Magnaudeix A. Perrin M.-L. Yardin C. Terro F. Tau protein kinases: Involvement in Alzheimer’s disease Ageing Res. Rev. 2013 12 289 309 10.1016/j.arr.2012.06.003 22742992
170. Liu F. Grundke-Iqbal I. Iqbal K. Gong C.X. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation Eur. J. Neurosci. 2005 22 1942 1950 10.1111/j.1460-9568.2005.04391.x 16262633
171. Martin L. Latypova X. Wilson C.M. Magnaudeix A. Perrin M.-L. Terro F. Tau protein phosphatases in Alzheimer’s disease: The leading role of PP2A Ageing Res. Rev. 2013 12 39 49 10.1016/j.arr.2012.06.008 22771380
172. Alvarez A.R. Sandoval P.C. Leal N.R. Castro P.U. Kosik K.S. Activation of the neuronal c-Abl tyrosine kinase by amyloid-β-peptide and reactive oxygen species Neurobiol. Dis. 2004 17 326 336 10.1016/j.nbd.2004.06.007 15474370
173. Franke T.F. Kaplan D.R. Cantley L.C. PI3K: Downstream AKTion blocks apoptosis Cell 1997 88 435 437 10.1016/S0092-8674(00)81883-8 9038334
174. Litersky J.M. Johnson G.V. Jakes R. Goedert M. Lee M. Seubert P. Tau protein is phosphorylated by cyclic AMP-dependent protein kinase and calcium/calmodulin-dependent protein kinase II within its microtubule-binding domains at Ser-262 and Ser-356 Biochem. J. 1996 316 655 660 10.1042/bj3160655 8687413
175. Singh T.J. Wang J.-Z. Novak M. Kontzekova E. Grundke-Iqbal I. Iqbal K. Calcium/calmodulin-dependent protein kinase II phosphorylates tau at Ser-262 but only partially inhibits its binding to microtubules FEBS Lett. 1996 387 145 148 10.1016/0014-5793(96)00485-1 8674537
176. Patrick G.N. Zukerberg L. Nikolic M. de La Monte S. Dikkes P. Tsai L.-H. Conversion of p35 to p25 deregulates Cdk5 activity and promotes neurodegeneration Nature 1999 402 615 622 10.1038/45159 10604467
177. Piedrahita D. Hernández I. López-Tobón A. Fedorov D. Obara B. Manjunath B. Boudreau R.L. Davidson B. LaFerla F. Gallego-Gómez J.C. Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer’s mice J. Neurosci. 2010 30 13966 13976 10.1523/JNEUROSCI.3637-10.2010 20962218
178. Amniai L. Barbier P. Sillen A. Wieruszeski J.-M. Peyrot V. Lippens G. Landrieu I. Alzheimer disease specific phosphoepitopes of Tau interfere with assembly of tubulin but not binding to microtubules FASEB J. 2009 23 1146 1152 10.1096/fj.08-121590 19074508
179. Flajolet M. He G. Heiman M. Lin A. Nairn A.C. Greengard P. Regulation of Alzheimer’s disease amyloid-β formation by casein kinase I Proc. Natl. Acad. Sci. USA 2007 104 4159 4164 10.1073/pnas.0611236104 17360493
180. Schwab C. DeMaggio A.J. Ghoshal N. Binder L.I. Kuret J. McGeer P.L. Casein kinase 1 delta is associated with pathological accumulation of tau in several neurodegenerative diseases Neurobiol. Aging 2000 21 503 510 10.1016/S0197-4580(00)00110-X 10924763
181. Kimura R. Kamino K. Yamamoto M. Nuripa A. Kida T. Kazui H. Hashimoto R. Tanaka T. Kudo T. Yamagata H. The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between β-amyloid production and tau phosphorylation in Alzheimer disease Hum. Mol. Genet. 2007 16 15 23 10.1093/hmg/ddl437 17135279
182. Ryoo S.-R. Jeong H.K. Radnaabazar C. Yoo J.-J. Cho H.-J. Lee H.-W. Kim I.-S. Cheon Y.-H. Ahn Y.S. Chung S.-H. DYRK1A-mediated Hyperphosphorylation of Tau J. Biol. Chem. 2007 282 34850 34857 10.1074/jbc.M707358200 17906291
183. Taira N. Nihira K. Yamaguchi T. Miki Y. Yoshida K. DYRK2 is targeted to the nucleus and controls p53 via Ser46 phosphorylation in the apoptotic response to DNA damage Mol. Cell 2007 25 725 738 10.1016/j.molcel.2007.02.007 17349958
184. Briner A. Götz J. Polanco J.C. Fyn kinase controls tau aggregation in vivo Cell Rep. 2020 32 108045 10.1016/j.celrep.2020.108045 32814048
185. Li C. Götz J. Pyk2 is a novel tau tyrosine kinase that is regulated by the tyrosine kinase fyn J. Alzheimer’s Dis. 2018 64 205 221 10.3233/JAD-180054 29782321
186. Chin J. Palop J.J. Yu G.-Q. Kojima N. Masliah E. Mucke L. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice J. Neurosci. 2004 24 4692 4697 10.1523/JNEUROSCI.0277-04.2004 15140940
187. Takashima A. GSK-3 is essential in the pathogenesis of Alzheimer’s disease J. Alzheimer’s Dis. 2006 9 309 317 10.3233/JAD-2006-9S335 16914869
188. Hernández F. de Barreda E.G. Fuster-Matanzo A. Lucas J.J. Avila J. GSK3: A possible link between beta amyloid peptide and tau protein Exp. Neurol. 2010 223 322 325 10.1016/j.expneurol.2009.09.011 19782073
189. Mines M.A. Beurel E. Jope R.S. Regulation of cell survival mechanisms in Alzheimer’s disease by glycogen synthase kinase-3 Int. J. Alzheimer’s Dis. 2011 2011 10.4061/2011/861072 21629713
190. Hata R. Masumura M. Akatsu H. Li F. Fujita H. Nagai Y. Yamamoto T. Okada H. Kosaka K. Sakanaka M. Up-regulation of calcineurin Aβ mRNA in the Alzheimer’s disease brain: Assessment by cDNA microarray Biochem. Biophys. Res. Commun. 2001 284 310 316 10.1006/bbrc.2001.4968 11394878
191. Scales T.M. Derkinderen P. Leung K.-Y. Byers H.L. Ward M.A. Price C. Bird I.N. Perera T. Kellie S. Williamson R. Tyrosine phosphorylation of tau by the SRC family kinases lck and fyn Mol. Neurodegener. 2011 6 1 11 10.1186/1750-1326-6-12 21211002
192. Ujiie S. Hatano T. Kubo S.-I. Imai S. Sato S. Uchihara T. Yagishita S. Hasegawa K. Kowa H. Sakai F. LRRK2 I2020T mutation is associated with tau pathology Parkinsonism Relat. Disord. 2012 18 819 823 10.1016/j.parkreldis.2012.03.024 22525366
193. Ohta E. Nihira T. Uchino A. Imaizumi Y. Okada Y. Akamatsu W. Takahashi K. Hayakawa H. Nagai M. Ohyama M. I2020T mutant LRRK2 iPSC-derived neurons in the Sagamihara family exhibit increased Tau phosphorylation through the AKT/GSK-3β signaling pathway Hum. Mol. Genet. 2015 24 4879 4900 10.1093/hmg/ddv212 26056228
194. Henderson M.X. Changolkar L. Trojanowski J.Q. Lee V.M. LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons J. Parkinson’s Dis. 2021 11 1187 1196 10.3233/JPD-212562 33720852
195. Bailey R.M. Covy J.P. Melrose H.L. Rousseau L. Watkinson R. Knight J. Miles S. Farrer M.J. Dickson D.W. Giasson B.I. LRRK2 phosphorylates novel tau epitopes and promotes tauopathy Acta Neuropathol. 2013 126 809 827 10.1007/s00401-013-1188-4 24113872
196. Zhu X. Raina A.K. Rottkamp C.A. Aliev G. Perry G. Boux H. Smith M.A. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer’s disease J. Neurochem. 2001 76 435 441 10.1046/j.1471-4159.2001.00046.x 11208906
197. Shen C. Chen Y. Liu H. Zhang K. Zhang T. Lin A. Jing N. Hydrogen peroxide promotes Aβ production through JNK-dependent activation of γ-secretase J. Biol. Chem. 2008 283 17721 17730 10.1074/jbc.M800013200 18436531
198. Atzori C. Ghetti B. Piva R. Srinivasan A.N. Zolo P. Delisle M.B. Mirra S.S. Migheli A. Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis J. Neuropathol. Exp. Neurol. 2001 60 1190 1197 10.1093/jnen/60.12.1190 11764091
199. Swatton J.E. Sellers L.A. Faull R.L. Holland A. Iritani S. Bahn S. Increased MAP kinase activity in Alzheimer’s and Down syndrome but not in schizophrenia human brain Eur. J. Neurosci. 2004 19 2711 2719 10.1111/j.0953-816X.2004.03365.x 15147305
200. Chin J.Y. Knowles R.B. Schneider A. Drewes G. Mandelkow E.-M. Hyman B.T. Microtubule-affinity regulating kinase (MARK) is tightly associated with neurofibrillary tangles in Alzheimer brain: A fluorescence resonance energy transfer study J. Neuropathol. Exp. Neurol. 2000 59 966 971 10.1093/jnen/59.11.966 11089574
201. Oba T. Saito T. Asada A. Shimizu S. Iijima K.M. Ando K. MARK4 with an Alzheimer’s disease-related mutation promotes tau hyperphosphorylation directly and indirectly and exacerbates neurodegeneration bioRxiv 2020 10.1101/2020.05.20.107284
202. Kawamata T. Taniguchi T. Mukai H. Kitagawa M. Hashimoto T. Maeda K. Ono Y. Tanaka C. A protein kinase, PKN, accumulates in Alzheimer neurofibrillary tangles and associated endoplasmic reticulum-derived vesicles and phosphorylates tau protein J. Neurosci. 1998 18 7402 7410 10.1523/JNEUROSCI.18-18-07402.1998 9736660
203. Taniguchi T. Kawamata T. Mukai H. Hasegawa H. Isagawa T. Yasuda M. Hashimoto T. Terashima A. Nakai M. Ono Y. Phosphorylation of tau is regulated by PKN J. Biol. Chem. 2001 276 10025 10031 10.1074/jbc.M007427200 11104762
204. Jensen P.H. Hager H. Nielsen M.S. Højrup P. Gliemann J. Jakes R. α-Synuclein binds to tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356 J. Biol. Chem. 1999 274 25481 25489 10.1074/jbc.274.36.25481 10464279
205. Liu S.J. Zhang J.Y. Li H.L. Fang Z.Y. Wang Q. Deng H.M. Gong C.X. Grundke-Iqbal I. Iqbal K. Wang J.Z. Tau becomes a more favorable substrate for GSK-3 when it is prephosphorylated by PKA in rat brain J. Biol. Chem. 2004 279 50078 50088 10.1074/jbc.M406109200 15375165
206. Jicha G.A. Weaver C. Lane E. Vianna C. Kress Y. Rockwood J. Davies P. cAMP-dependent protein kinase phosphorylations on tau in Alzheimer’s disease J. Neurosci. 1999 19 7486 7494 10.1523/JNEUROSCI.19-17-07486.1999 10460255
207. Shi J. Qian W. Yin X. Iqbal K. Grundke-Iqbal I. Gu X. Ding F. Gong C.-X. Liu F. Cyclic AMP-dependent protein kinase regulates the alternative splicing of tau exon 10: A mechanism involved in tau pathology of Alzheimer disease J. Biol. Chem. 2011 286 14639 14648 10.1074/jbc.M110.204453 21367856
208. Wang Z.F. Li H.L. Li X.C. Zhang Q. Tian Q. Wang Q. Xu H. Wang J.Z. Effects of endogenous β-amyloid overproduction on tau phosphorylation in cell culture J. Neurochem. 2006 98 1167 1175 10.1111/j.1471-4159.2006.03956.x 16762022
209. Isagawa T. Mukai H. Oishi K. Taniguchi T. Hasegawa H. Kawamata T. Tanaka C. Ono Y. Dual effects of PKNα and protein kinase C on phosphorylation of tau protein by glycogen synthase kinase-3β Biochem. Biophys. Res. Commun. 2000 273 209 212 10.1006/bbrc.2000.2926 10873588
210. Dourlen P. Fernandez-Gomez F. Dupont C. Grenier-Boley B. Bellenguez C. Obriot H. Caillierez R. Sottejeau Y. Chapuis J. Bretteville A. Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology Mol. Psychiatry 2017 22 874 883 10.1038/mp.2016.59 27113998
211. Caccamo A. Branca C. Talboom J.S. Shaw D.M. Turner D. Ma L. Messina A. Huang Z. Wu J. Oddo S. Reducing ribosomal protein S6 kinase 1 expression improves spatial memory and synaptic plasticity in a mouse model of Alzheimer’s disease J. Neurosci. 2015 35 14042 14056 10.1523/JNEUROSCI.2781-15.2015 26468204
212. An W.-L. Cowburn R.F. Li L. Braak H. Alafuzoff I. Iqbal K. Iqbal I.-G. Winblad B. Pei J.-J. Up-regulation of phosphorylated/activated p70 S6 kinase and its relationship to neurofibrillary pathology in Alzheimer’s disease Am. J. Pathol. 2003 163 591 607 10.1016/S0002-9440(10)63687-5 12875979
213. Pei J.-J. Björkdahl C. Zhang H. Zhou X. Winblad B. p70 S6 kinase and tau in Alzheimer’s disease J. Alzheimer’s Dis. 2008 14 385 392 10.3233/JAD-2008-14405 18688088
214. Elahi M. Motoi Y. Shimonaka S. Ishiguro K. Imai Y. Hattori N. High-fat diet-induced activation of SGK1 contributes to Alzheimer’s disease pathogenesis by promoting tau pathology bioRxiv 2020 10.1101/2020.05.14.095471
215. Liu F. Gong C.-X. Tau exon 10 alternative splicing and tauopathies Mol. Neurodegener. 2008 3 1 10 10.1186/1750-1326-3-8 18179689
216. Zhang Y. Wu F. Iqbal K. Gong C.-X. Hu W. Liu F. Subacute to chronic Alzheimer-like alterations after controlled cortical impact in human tau transgenic mice Sci. Rep. 2019 9 1 13 10.1038/s41598-019-40678-4 30626917
217. Schweig J.E. Yao H. Beaulieu-Abdelahad D. Ait-Ghezala G. Mouzon B. Crawford F. Mullan M. Paris D. Alzheimer’s disease pathological lesions activate the spleen tyrosine kinase Acta Neuropathol. Commun. 2017 5 1 25 10.1186/s40478-017-0472-2 28057070
218. Schweig J.E. Yao H. Jin C. Crawford F. Mullan M. Paris D. Neuronal Spleen tyrosine kinase (SYK) mediates cytokine release in Transgenic Tau P301S mice organotypic brain slice cultures Neurosci. Lett. 2020 729 134992 10.1016/j.neulet.2020.134992 32334108
219. Schweig J.E. Yao H. Coppola K. Jin C. Crawford F. Mullan M. Paris D. Spleen tyrosine kinase (SYK) blocks autophagic Tau degradation in vitro and in vivo J. Biol. Chem. 2019 294 13378 13395 10.1074/jbc.RA119.008033 31324720
220. Xu J. Sato S. Okuyama S. Swan R.J. Jacobsen M.T. Strunk E. Ikezu T. Tau-tubulin kinase 1 enhances prefibrillar tau aggregation and motor neuron degeneration in P301L FTDP-17 tau-mutant mice FASEB J. 2010 24 2904 2915 10.1096/fj.09-150144 20354135
221. Dillon G.M. Henderson J.L. Bao C. Joyce J.A. Calhoun M. Amaral B. King K.W. Bajrami B. Rabah D. Acute inhibition of the CNS-specific kinase TTBK1 significantly lowers tau phosphorylation at several disease relevant sites PLoS ONE 2020 15 e0228771 10.1371/journal.pone.0228771 32255788
222. Gong C.X. Singh T.J. Grundke-Iqbal I. Iqbal K. Phosphoprotein phosphatase activities in Alzheimer disease brain J. Neurochem. 1993 61 921 927 10.1111/j.1471-4159.1993.tb03603.x 8395566
223. Kins S. Crameri A. Evans D.R. Hemmings B.A. Nitsch R.M. Götz J. Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice J. Biol. Chem. 2001 276 38193 38200 10.1074/jbc.M102621200 11473109
224. McKenzie-Nickson S. Chan J. Perez K. Hung L.W. Cheng L. Sedjahtera A. Gunawan L. Adlard P.A. Hayne D.J. McInnes L.E. Modulating protein phosphatase 2A rescues disease phenotype in neurodegenerative tauopathies ACS Chem. Neurosci. 2018 9 2731 2740 10.1021/acschemneuro.8b00161 29920069
225. Sanchez-Ortiz E. Hahm B.K. Armstrong D.L. Rossie S. Protein phosphatase 5 protects neurons against amyloid-β toxicity J. Neurochem. 2009 111 391 402 10.1111/j.1471-4159.2009.06337.x 19686245
226. Gong C.X. Liu F. Wu G. Rossie S. Wegiel J. Li L. Grundke-Iqbal I. Iqbal K. Dephosphorylation of microtubule-associated protein tau by protein phosphatase 5 J. Neurochem. 2004 88 298 310 10.1111/j.1471-4159.2004.02147.x 14690518
227. Liu F. Iqbal K. Grundke-Iqbal I. Rossie S. Gong C.-X. Dephosphorylation of tau by protein phosphatase 5: Impairment in Alzheimer’s disease J. Biol. Chem. 2005 280 1790 1796 10.1074/jbc.M410775200 15546861
228. Kim Y. Liu G. Leugers C.J. Mueller J.D. Francis M.B. Hefti M.M. Schneider J.A. Lee G. Tau interacts with SHP2 in neuronal systems and in Alzheimer’s disease brains J. Cell Sci. 2019 132 jcs229054 10.1242/jcs.229054 31201283
229. Chao Y. Xing Y. Chen Y. Xu Y. Lin Z. Li Z. Jeffrey P.D. Stock J.B. Shi Y. Structure and mechanism of the phosphotyrosyl phosphatase activator Mol. Cell 2006 23 535 546 10.1016/j.molcel.2006.07.027 16916641
230. Luo Y. Nie Y.-J. Shi H.-R. Ni Z.-F. Wang Q. Wang J.-Z. Liu G.-P. PTPA activates protein phosphatase-2A through reducing its phosphorylation at tyrosine-307 with upregulation of protein tyrosine phosphatase 1B Biochim. Biophys. Acta Mol. Cell Res. 2013 1833 1235 1243 10.1016/j.bbamcr.2013.02.005
231. Jinwal U.K. Trotter J.H. Abisambra J.F. Koren J. Lawson L.Y. Vestal G.D. O’Leary J.C. Johnson A.G. Jin Y. Jones J.R. The Hsp90 kinase co-chaperone Cdc37 regulates tau stability and phosphorylation dynamics J. Biol. Chem. 2011 286 16976 16983 10.1074/jbc.M110.182493 21367866
232. Cheng W. Chen W. Wang P. Chu J. Asiatic acid protects differentiated PC12 cells from Aβ25–35-induced apoptosis and tau hyperphosphorylation via regulating PI3K/Akt/GSK-3β signaling Life Sci. 2018 208 96 101 10.1016/j.lfs.2018.07.016 30017668
233. Malek-Ahmadi M. Beach T. Obradov A. Sue L. Belden C. Davis K. Walker D.G. Lue L. Adem A. Sabbagh M.N. Increased Alzheimer’s disease neuropathology is associated with type 2 diabetes and ApoE ε4 carrier status Curr. Alzheimer Res. 2013 10 654 659 10.2174/15672050113109990006 23627755
234. Curtis D. Bakaya K. Sharma L. Bandyopadhyay S. Weighted burden analysis of exome-sequenced late-onset Alzheimer’s cases and controls provides further evidence for a role for PSEN1 and suggests involvement of the PI3K/Akt/GSK-3β and WNT signalling pathways Ann. Hum. Genet. 2020 84 291 302 10.1111/ahg.12375 32020597
235. Reynolds C.H. Garwood C.J. Wray S. Price C. Kellie S. Perera T. Zvelebil M. Yang A. Sheppard P.W. Varndell I.M. Phosphorylation regulates tau interactions with Src homology 3 domains of phosphatidylinositol 3-kinase, phospholipase Cgamma1, Grb2, and Src family kinases J. Biol. Chem. 2008 283 18177 18186 10.1074/jbc.M709715200 18467332
236. Baudier J. Cole R.D. Interactions between the microtubule-associated tau proteins and S100b regulate tau phosphorylation by the Ca2+/calmodulin-dependent protein kinase II J. Biol. Chem. 1988 263 5876 5883 10.1016/S0021-9258(18)60647-7 2833519
237. Yamaguchi F. Umeda Y. Shimamoto S. Tsuchiya M. Tokumitsu H. Tokuda M. Kobayashi R. S100 proteins modulate protein phosphatase 5 function: A link between CA2+ signal transduction and protein dephosphorylation J. Biol. Chem. 2012 287 13787 13798 10.1074/jbc.M111.329771 22399290
238. Huttunen H.J. Kuja-Panula J. Sorci G. Agneletti A.L. Donato R. Rauvala H. Coregulation of neurite outgrowth and cell survival by amphoterin and S100 proteins through receptor for advanced glycation end products (RAGE) activation J. Biol. Chem. 2000 275 40096 40105 10.1074/jbc.M006993200 11007787
239. Esposito G. Scuderi C. Lu J. Savani C. De Filippis D. Iuvone T. Steardo L. Jr. Sheen V. Steardo L. S100B induces tau protein hyperphosphorylation via Dickopff-1 up-regulation and disrupts the Wnt pathway in human neural stem cells J. Cell. Mol. Med. 2008 12 914 927 10.1111/j.1582-4934.2008.00159.x 18494933
240. Van Eldik L.J. Wainwright M.S. The Janus face of glial-derived S100B: Beneficial and detrimental functions in the brain Restor. Neurol. Neurosci. 2003 21 97 108 14530573
241. Brown J.L. Roberts W.K. Evidence that approximately eighty per cent of the soluble proteins from Ehrlich ascites cells are Nalpha-acetylated J. Biol. Chem. 1976 251 1009 1014 10.1016/S0021-9258(17)33793-6 1249063
242. Allfrey V.G. Mirsky A.E. Structural Modifications of Histones and their Possible Role in the Regulation of RNA Synthesis Science 1964 144 559 10.1126/science.144.3618.559 17836360
243. Levenson J.M. O’Riordan K.J. Brown K.D. Trinh M.A. Molfese D.L. Sweatt J.D. Regulation of histone acetylation during memory formation in the hippocampus J. Biol. Chem. 2004 279 40545 40559 10.1074/jbc.M402229200 15273246
244. Behnia R. Panic B. Whyte J.R. Munro S. Targeting of the Arf-like GTPase Arl3p to the Golgi requires N-terminal acetylation and the membrane protein Sys1p Nat. Cell Biol. 2004 6 405 413 10.1038/ncb1120 15077113
245. Scott D.C. Monda J.K. Bennett E.J. Harper J.W. Schulman B.A. N-terminal acetylation acts as an avidity enhancer within an interconnected multiprotein complex Science 2011 334 674 678 10.1126/science.1209307 21940857
246. Ferreon J.C. Jain A. Choi K.-J. Tsoi P.S. MacKenzie K.R. Jung S.Y. Ferreon A.C. Acetylation disfavors tau phase separation Int. J. Mol. Sci. 2018 19 1360 10.3390/ijms19051360
247. Cohen T.J. Guo J.L. Hurtado D.E. Kwong L.K. Mills I.P. Trojanowski J.Q. Lee V.M. The acetylation of tau inhibits its function and promotes pathological tau aggregation Nat. Commun. 2011 2 252 10.1038/ncomms1255 21427723
248. Cohen T.J. Friedmann D. Hwang A.W. Marmorstein R. Lee V.M. The microtubule-associated tau protein has intrinsic acetyltransferase activity Nat. Struct. Mol. Biol. 2013 20 756 762 10.1038/nsmb.2555 23624859
249. Irwin D.J. Cohen T.J. Grossman M. Arnold S.E. Xie S.X. Lee V.M. Trojanowski J.Q. Acetylated tau, a novel pathological signature in Alzheimer’s disease and other tauopathies Brain 2012 135 Pt 3 807 818 10.1093/brain/aws013 22366796
250. Min S.W. Cho S.H. Zhou Y. Schroeder S. Haroutunian V. Seeley W.W. Huang E.J. Shen Y. Masliah E. Mukherjee C. Acetylation of tau inhibits its degradation and contributes to tauopathy Neuron 2010 67 953 966 10.1016/j.neuron.2010.08.044 20869593
251. Cohen T.J. Constance B.H. Hwang A.W. James M. Yuan C.-X. Intrinsic tau acetylation is coupled to auto-proteolytic tau fragmentation PLoS ONE 2016 11 e0158470 10.1371/journal.pone.0158470 27383765
252. Cook C. Carlomagno Y. Gendron T.F. Dunmore J. Scheffel K. Stetler C. Davis M. Dickson D. Jarpe M. DeTure M. Acetylation of the KXGS motifs in tau is a critical determinant in modulation of tau aggregation and clearance Hum. Mol. Genet. 2014 23 104 116 10.1093/hmg/ddt402 23962722
253. Ding H. Dolan P.J. Johnson G.V. Histone deacetylase 6 interacts with the microtubule-associated protein tau J. Neurochem. 2008 106 2119 2130 10.1111/j.1471-4159.2008.05564.x 18636984
254. Ogryzko V.V. Schiltz R.L. Russanova V. Howard B.H. Nakatani Y. The transcriptional coactivators p300 and CBP are histone acetyltransferases Cell 1996 87 953 959 10.1016/S0092-8674(00)82001-2 8945521
255. Chen H. Lin R.J. Xie W. Wilpitz D. Evans R.M. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase Cell 1999 98 675 686 10.1016/S0092-8674(00)80054-9 10490106
256. Rouaux C. Jokic N. Mbebi C. Boutillier S. Loeffler J.P. Boutillier A.L. Critical loss of CBP/p300 histone acetylase activity by caspase-6 during neurodegeneration EMBO J. 2003 22 6537 6549 10.1093/emboj/cdg615 14657026
257. Verdel A. Curtet S. Brocard M.-P. Rousseaux S. Lemercier C. Yoshida M. Khochbin S. Active maintenance of mHDA2/mHDAC6 histone-deacetylase in the cytoplasm Curr. Biol. 2000 10 747 749 10.1016/S0960-9822(00)00542-X 10873806
258. Sen A. Nelson T.J. Alkon D.L. ApoE4 and Aβ oligomers reduce BDNF expression via HDAC nuclear translocation J. Neurosci. 2015 35 7538 7551 10.1523/JNEUROSCI.0260-15.2015 25972179
259. Parmigiani R. Xu W. Venta-Perez G. Erdjument-Bromage H. Yaneva M. Tempst P. Marks P. HDAC6 is a specific deacetylase of peroxiredoxins and is involved in redox regulation Proc. Natl. Acad. Sci. USA 2008 105 9633 9638 10.1073/pnas.0803749105 18606987
260. Cook C. Gendron T.F. Scheffel K. Carlomagno Y. Dunmore J. DeTure M. Petrucelli L. Loss of HDAC6, a novel CHIP substrate, alleviates abnormal tau accumulation Hum. Mol. Genet. 2012 21 2936 2945 10.1093/hmg/dds125 22492994
261. Zhang B. West E.J. Van K.C. Gurkoff G.G. Zhou J. Zhang X.-M. Kozikowski A.P. Lyeth B.G. HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats Brain Res. 2008 1226 181 191 10.1016/j.brainres.2008.05.085 18582446
262. Kim H.J. Rowe M. Ren M. Hong J.S. Chen P.S. Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: Multiple mechanisms of action J Pharm. Exp. 2007 321 892 901 10.1124/jpet.107.120188 17371805
263. Vaziri H. Dessain S.K. Ng Eaton E. Imai S.I. Frye R.A. Pandita T.K. Guarente L. Weinberg R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase Cell 2001 107 149 159 10.1016/S0092-8674(01)00527-X 11672523
264. Langley E. Pearson M. Faretta M. Bauer U.M. Frye R.A. Minucci S. Pelicci P.G. Kouzarides T. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence EMBO J. 2002 21 2383 2396 10.1093/emboj/21.10.2383 12006491
265. Julien C. Tremblay C. Emond V. Lebbadi M. Salem N. Jr. Bennett D.A. Calon F. Sirtuin 1 reduction parallels the accumulation of tau in Alzheimer disease J. Neuropathol. Exp. Neurol. 2009 68 48 58 10.1097/NEN.0b013e3181922348 19104446
266. Zakhary S.M. Ayubcha D. Dileo J.N. Jose R. Leheste J.R. Horowitz J.M. Torres G. Distribution analysis of deacetylase SIRT1 in rodent and human nervous systems Anat. Rec. 2010 293 1024 1032 10.1002/ar.21116
267. Pallas M. Pizarro J.G. Gutierrez-Cuesta J. Crespo-Biel N. Alvira D. Tajes M. Yeste-Velasco M. Folch J. Canudas A.M. Sureda F.X. Modulation of SIRT1 expression in different neurodegenerative models and human pathologies Neuroscience 2008 154 1388 1397 10.1016/j.neuroscience.2008.04.065 18538940
268. Min S.W. Sohn P.D. Li Y. Devidze N. Johnson J.R. Krogan N.J. Masliah E. Mok S.A. Gestwicki J.E. Gan L. SIRT1 Deacetylates Tau and Reduces Pathogenic Tau Spread in a Mouse Model of Tauopathy J. Neurosci. 2018 38 3680 3688 10.1523/JNEUROSCI.2369-17.2018 29540553
269. Gao J. Wang W.Y. Mao Y.W. Graff J. Guan J.S. Pan L. Mak G. Kim D. Su S.C. Tsai L.H. A novel pathway regulates memory and plasticity via SIRT1 and miR-134 Nature 2010 466 1105 1109 10.1038/nature09271 20622856
270. Lazarus B.D. Love D.C. Hanover J.A. Recombinant O-GlcNAc transferase isoforms: Identification of O-GlcNAcase, yes tyrosine kinase, and tau as isoform-specific substrates Glycobiology 2006 16 415 421 10.1093/glycob/cwj078 16434389
271. Kreppel L.K. Blomberg M.A. Hart G.W. Dynamic glycosylation of nuclear and cytosolic proteins. Cloning and characterization of a unique O-GlcNAc transferase with multiple tetratricopeptide repeats J. Biol. Chem. 1997 272 9308 9315 10.1074/jbc.272.14.9308 9083067
272. Yu C.H. Si T. Wu W.H. Hu J. Du J.T. Zhao Y.F. Li Y.M. O-GlcNAcylation modulates the self-aggregation ability of the fourth microtubule-binding repeat of tau Biochem. Biophys. Res. Commun. 2008 375 59 62 10.1016/j.bbrc.2008.07.101 18671940
273. Liu F. Iqbal K. Grundke-Iqbal I. Hart G.W. Gong C.-X. O-GlcNAcylation regulates phosphorylation of tau: A mechanism involved in Alzheimer’s disease Proc. Natl. Acad. Sci. USA 2004 101 10804 10809 10.1073/pnas.0400348101 15249677
274. Kato T. Inui Y. Nakamura A. Ito K. Brain fluorodeoxyglucose (FDG) PET in dementia Ageing Res. Rev. 2016 30 73 84 10.1016/j.arr.2016.02.003 26876244
275. Lim S. Haque M.M. Nam G. Ryoo N. Rhim H. Kim Y.K. Monitoring of Intracellular Tau Aggregation Regulated by OGA/OGT Inhibitors Int. J. Mol. Sci. 2015 16 20212 20224 10.3390/ijms160920212 26343633
276. Koga H. Kaushik S. Cuervo A.M. Protein homeostasis and aging: The importance of exquisite quality control Ageing Res. Rev. 2011 10 205 215 10.1016/j.arr.2010.02.001 20152936
277. Morawe T. Hiebel C. Kern A. Behl C. Protein homeostasis, aging and Alzheimer’s disease Mol. Neurobiol. 2012 46 41 54 10.1007/s12035-012-8246-0 22361852
278. Glickman M.H. Ciechanover A. The ubiquitin-proteasome proteolytic pathway: Destruction for the sake of construction Physiol. Rev. 2002 82 373 428 10.1152/physrev.00027.2001 11917093
279. Dikic I. Robertson M. Ubiquitin ligases and beyond BMC Biol. 2012 10 22 10.1186/1741-7007-10-22 22420755
280. Shimura H. Schwartz D. Gygi S.P. Kosik K.S. CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival J. Biol. Chem. 2004 279 4869 4876 10.1074/jbc.M305838200 14612456
281. Kanack A. Vittal V. Haver H. Keppel T. Gundry R.L. Klevit R.E. Scaglione K.M. UbcH5 Interacts with Substrates to Participate in Lysine Selection with the E3 Ubiquitin Ligase CHIP Biochemistry 2020 59 2078 2088 10.1021/acs.biochem.0c00084 32401531
282. Ye Y. Klenerman D. Finley D. N-terminal ubiquitination of amyloidogenic proteins triggers removal of their oligomers by the proteasome holoenzyme J. Mol. Biol. 2020 432 585 596 10.1016/j.jmb.2019.08.021 31518613
283. Ravalin M. Theofilas P. Basu K. Opoku-Nsiah K.A. Assimon V.A. Medina-Cleghorn D. Chen Y.F. Bohn M.F. Arkin M. Grinberg L.T. Specificity for latent C termini links the E3 ubiquitin ligase CHIP to caspases Nat. Chem. Biol. 2019 15 786 794 10.1038/s41589-019-0322-6 31320752
284. Vittal V. Shi L. Wenzel D.M. Scaglione K.M. Duncan E.D. Basrur V. Elenitoba-Johnson K.S. Baker D. Paulson H.L. Brzovic P.S. Intrinsic disorder drives N-terminal ubiquitination by Ube2w Nat. Chem. Biol. 2015 11 83 89 10.1038/nchembio.1700 25436519
285. Petrucelli L. Dickson D. Kehoe K. Taylor J. Snyder H. Grover A. De Lucia M. McGowan E. Lewis J. Prihar G. CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation Hum. Mol. Genet. 2004 13 703 714 10.1093/hmg/ddh083 14962978
286. Moore D.J. West A.B. Dikeman D.A. Dawson V.L. Dawson T.M. Parkin mediates the degradation-independent ubiquitination of Hsp70 J. Neurochem. 2008 105 1806 1819 10.1111/j.1471-4159.2008.05261.x 18248624
287. Sassone J. Serratto G. Valtorta F. Silani V. Passafaro M. Ciammola A. The synaptic function of parkin Brain 2017 140 2265 2272 10.1093/brain/awx006 28335015
288. Singh K. Han K. Tilve S. Wu K. Geller H.M. Sack M.N. Parkin targets NOD2 to regulate astrocyte endoplasmic reticulum stress and inflammation Glia 2018 66 2427 2437 10.1002/glia.23482 30378174
289. Williams E.T. Glauser L. Tsika E. Jiang H. Islam S. Moore D.J. Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting Hum. Mol. Genet. 2018 27 3189 3205 10.1093/hmg/ddy224 29893854
290. Sun T. Ding W. Xu T. Ao X. Yu T. Li M. Liu Y. Zhang X. Hou L. Wang J. Parkin Regulates Programmed Necrosis and Myocardial Ischemia/Reperfusion Injury by Targeting Cyclophilin-D Antioxid. Redox Signal. 2019 31 1177 1193 10.1089/ars.2019.7734 31456416
291. Hatakeyama S. Matsumoto M. Kamura T. Murayama M. Chui D.H. Planel E. Takahashi R. Nakayama K.I. Takashima A. U-box protein carboxyl terminus of Hsc70-interacting protein (CHIP) mediates poly-ubiquitylation preferentially on four-repeat Tau and is involved in neurodegeneration of tauopathy J. Neurochem. 2004 91 299 307 10.1111/j.1471-4159.2004.02713.x 15447663
292. Flach K. Ramminger E. Hilbrich I. Arsalan-Werner A. Albrecht F. Herrmann L. Goedert M. Arendt T. Holzer M. Axotrophin/MARCH7 acts as an E3 ubiquitin ligase and ubiquitinates tau protein in vitro impairing microtubule binding Biochim. Biophys. Acta 2014 1842 1527 1538 10.1016/j.bbadis.2014.05.029 24905733
293. Babu J.R. Geetha T. Wooten M.W. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation J. Neurochem. 2005 94 192 203 10.1111/j.1471-4159.2005.03181.x 15953362
294. Wang T. Wang W. Wang Q. Xie R. Landay A. Chen D. The E3 ubiquitin ligase CHIP in normal cell function and in disease conditions Ann. N. Y. Acad. Sci. 2020 1460 3 10 10.1111/nyas.14206 31414713
295. Rui Y.-N. Xu Z. Patel B. Chen Z. Chen D. Tito A. David G. Sun Y. Stimming E.F. Bellen H.J. Huntingtin functions as a scaffold for selective macroautophagy Nat. Cell Biol. 2015 17 262 275 10.1038/ncb3101 25686248
296. Geetha T. Jiang J. Wooten M.W. Lysine 63 polyubiquitination of the nerve growth factor receptor TrkA directs internalization and signaling Mol. Cell 2005 20 301 312 10.1016/j.molcel.2005.09.014 16246731
297. Wooten M.W. Geetha T. Seibenhener M.L. Babu J.R. Diaz-Meco M.T. Moscat J. The p62 scaffold regulates nerve growth factor-induced NF-kappaB activation by influencing TRAF6 polyubiquitination J. Biol. Chem. 2005 280 35625 35629 10.1074/jbc.C500237200 16079148
298. Seibenhener M.L. Geetha T. Wooten M.W. Sequestosome 1/p62-more than just a scaffold FEBS Lett. 2007 581 175 179 10.1016/j.febslet.2006.12.027 17188686
299. Bjørkøy G. Lamark T. Brech A. Outzen H. Perander M. Øvervatn A. Stenmark H. Johansen T. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death J. Cell Biol. 2005 171 603 614 10.1083/jcb.200507002 16286508
300. Clausen T.H. Lamark T. Isakson P. Finley K. Larsen K.B. Brech A. Overvatn A. Stenmark H. Bjorkoy G. Simonsen A. p62/SQSTM1 and ALFY interact to facilitate the formation of p62 bodies/ALIS and their degradation by autophagy Autophagy 2010 6 330 344 10.4161/auto.6.3.11226 20168092
301. Hori T. Osaka F. Chiba T. Miyamoto C. Okabayashi K. Shimbara N. Kato S. Tanaka K. Covalent modification of all members of human cullin family proteins by NEDD8 Oncogene 1999 18 6829 6834 10.1038/sj.onc.1203093 10597293
302. Kamitani T. Kito K. Fukuda-Kamitani T. Yeh E.T. Targeting of NEDD8 and its conjugates for proteasomal degradation by NUB1 J. Biol. Chem. 2001 276 46655 46660 10.1074/jbc.M108636200 11585840
303. Richet E. Pooler A.M. Rodriguez T. Novoselov S.S. Schmidtke G. Groettrup M. Hanger D.P. Cheetham M.E. van der Spuy J. NUB1 modulation of GSK3beta reduces tau aggregation Hum. Mol. Genet. 2012 21 5254 5267 10.1093/hmg/dds376 22965877
304. Guarascio R. Salih D. Yasvoina M. Edwards F.A. Cheetham M.E. van der Spuy J. Negative Regulator of Ubiquitin-Like Protein 1 modulates the autophagy-lysosomal pathway via p62 to facilitate the extracellular release of tau following proteasome impairment Hum. Mol. Genet. 2020 29 80 96 10.1093/hmg/ddz255 31691796
305. Bukau B. Horwich A.L. The Hsp70 and Hsp60 chaperone machines Cell 1998 92 351 366 10.1016/S0092-8674(00)80928-9 9476895
306. Tavaria M. Gabriele T. Kola I. Anderson R.L. A hitchhiker’s guide to the human Hsp70 family Cell Stress Chaperones 1996 1 23 28 10.1379/1466-1268(1996)001<0023:AHSGTT>2.3.CO;2 9222585
307. Jinwal U.K. Akoury E. Abisambra J.F. O’Leary III J.C. Thompson A.D. Blair L.J. Jin Y. Bacon J. Nordhues B.A. Cockman M. Imbalance of Hsp70 family variants fosters tau accumulation FASEB J. 2013 27 1450 1459 10.1096/fj.12-220889 23271055
308. Liu Z.-C. Fu Z.-Q. Song J. Zhang J.-Y. Wei Y.-P. Chu J. Han L. Qu N. Wang J.-Z. Tian Q. Bip enhanced the association of GSK-3β with tau during ER stress both in vivo and in vitro J. Alzheimer’s Dis. 2012 29 727 740 10.3233/JAD-2012-111898 22460328
309. Sarkar M. Kuret J. Lee G. Two motifs within the tau microtubule-binding domain mediate its association with the hsc70 molecular chaperone J. Neurosci. Res. 2008 86 2763 2773 10.1002/jnr.21721 18500754
310. Rauch J.N. Zuiderweg E.R. Gestwicki J.E. Non-canonical Interactions between Heat Shock Cognate Protein 70 (Hsc70) and Bcl2-associated Anthanogene (BAG) Co-Chaperones Are Important for Client Release J. Biol. Chem. 2016 291 19848 19857 10.1074/jbc.M116.742502 27474739
311. Elliott E. Tsvetkov P. Ginzburg I. BAG-1 associates with Hsc70.Tau complex and regulates the proteasomal degradation of Tau protein J. Biol. Chem. 2007 282 37276 37284 10.1074/jbc.M706379200 17954934
312. Patterson K.R. Ward S.M. Combs B. Voss K. Kanaan N.M. Morfini G. Brady S.T. Gamblin T.C. Binder L.I. Heat shock protein 70 prevents both tau aggregation and the inhibitory effects of preexisting tau aggregates on fast axonal transport Biochemistry 2011 50 10300 10310 10.1021/bi2009147 22039833
313. Abisambra J.F. Jinwal U.K. Suntharalingam A. Arulselvam K. Brady S. Cockman M. Jin Y. Zhang B. Dickey C.A. DnaJA1 antagonizes constitutive Hsp70-mediated stabilization of tau J. Mol. Biol. 2012 421 653 661 10.1016/j.jmb.2012.02.003 22343013
314. Young J.C. Hartl F.U. Chaperones and transcriptional regulation by nuclear receptors Nat. Struct. Biol. 2002 9 640 642 10.1038/nsb0902-640 12198482
315. Oroz J. Chang B.J. Wysoczanski P. Lee C.-T. Pérez-Lara Á. Chakraborty P. Hofele R.V. Baker J.D. Blair L.J. Biernat J. Structure and pro-toxic mechanism of the human Hsp90/PPIase/Tau complex Nat. Commun. 2018 9 1 13 10.1038/s41467-018-06880-0 29317637
316. Fontaine S.N. Rauch J.N. Nordhues B.A. Assimon V.A. Stothert A.R. Jinwal U.K. Sabbagh J.J. Chang L. Stevens S.M. Zuiderweg E.R. Isoform-selective genetic inhibition of constitutive cytosolic Hsp70 activity promotes client tau degradation using an altered co-chaperone complement J. Biol. Chem. 2015 290 13115 13127 10.1074/jbc.M115.637595 25864199
317. Ali Y.O. Allen H.M. Yu L. Li-Kroeger D. Bakhshizadehmahmoudi D. Hatcher A. McCabe C. Xu J. Bjorklund N. Taglialatela G. NMNAT2: HSP90 complex mediates proteostasis in proteinopathies PLoS Biol. 2016 14 e1002472 10.1371/journal.pbio.1002472 27254664
318. Jinwal U.K. Koren J. Borysov S.I. Schmid A.B. Abisambra J.F. Blair L.J. Johnson A.G. Jones J.R. Shults C.L. O’Leary J.C. The Hsp90 cochaperone, FKBP51, increases Tau stability and polymerizes microtubules J. Neurosci. 2010 30 591 599 10.1523/JNEUROSCI.4815-09.2010 20071522
319. Woodford M.R. Sager R.A. Marris E. Dunn D.M. Blanden A.R. Murphy R.L. Rensing N. Shapiro O. Panaretou B. Prodromou C. Tumor suppressor Tsc1 is a new Hsp90 co-chaperone that facilitates folding of kinase and non-kinase clients EMBO J. 2017 36 3650 3665 10.15252/embj.201796700 29127155
320. Tortosa E. Santa-Maria I. Moreno F. Lim F. Perez M. Avila J. Binding of Hsp90 to tau promotes a conformational change and aggregation of tau protein J. Alzheimer’s Dis. 2009 17 319 325 10.3233/JAD-2009-1049 19363271
321. Blair L.J. Nordhues B.A. Hill S.E. Scaglione K.M. O’Leary J.C. Fontaine S.N. Breydo L. Zhang B. Li P. Wang L. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau J. Clin. Investig. 2013 123 4158 4169 10.1172/JCI69003 23999428
322. Shelton L.B. Baker J.D. Zheng D. Sullivan L.E. Solanki P.K. Webster J.M. Sun Z. Sabbagh J.J. Nordhues B.A. Koren J. Hsp90 activator Aha1 drives production of pathological tau aggregates Proc. Natl. Acad. Sci. USA 2017 114 9707 9712 10.1073/pnas.1707039114 28827321
323. Freilich R. Betegon M. Tse E. Mok S.-A. Julien O. Agard D.A. Southworth D.R. Takeuchi K. Gestwicki J.E. Competing protein-protein interactions regulate binding of Hsp27 to its client protein tau Nat. Commun. 2018 9 1 11 10.1038/s41467-018-07012-4 29317637
324. Shimura H. Miura-Shimura Y. Kosik K.S. Binding of tau to heat shock protein 27 leads to decreased concentration of hyperphosphorylated tau and enhanced cell survival J. Biol. Chem. 2004 279 17957 17962 10.1074/jbc.M400351200 14963027
325. Poon S. Easterbrook-Smith S.B. Rybchyn M.S. Carver J.A. Wilson M.R. Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state Biochemistry 2000 39 15953 15960 10.1021/bi002189x 11123922
326. Shepherd C.E. Affleck A.J. Bahar A.Y. Carew-Jones F. Halliday G.M. Intracellular and secreted forms of clusterin are elevated early in Alzheimer’s disease and associate with both Abeta and tau pathology Neurobiol. Aging 2020 89 129 131 10.1016/j.neurobiolaging.2019.10.025 31813628
327. Zhou Y. Hayashi I. Wong J. Tugusheva K. Renger J.J. Zerbinatti C. Intracellular clusterin interacts with brain isoforms of the bridging integrator 1 and with the microtubule-associated protein Tau in Alzheimer’s disease PLoS ONE 2014 9 e103187 10.1371/journal.pone.0103187 25051234
328. Schmid F.X. Mayr L.M. Mucke M. Schonbrunner E.R. Prolyl isomerases: Role in protein folding Adv. Protein Chem. 1993 44 25 66 8317297
329. Morgan A.A. Rubenstein E. Proline: The distribution, frequency, positioning, and common functional roles of proline and polyproline sequences in the human proteome PLoS ONE 2013 8 e53785 10.1371/journal.pone.0053785 23372670
330. Goode B.L. Denis P.E. Panda D. Radeke M.J. Miller H.P. Wilson L. Feinstein S.C. Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly Mol. Biol. Cell 1997 8 353 365 10.1091/mbc.8.2.353 9190213
331. Bielska A.A. Zondlo N.J. Hyperphosphorylation of tau induces local polyproline II helix Biochemistry 2006 45 5527 5537 10.1021/bi052662c 16634634
332. Koren J. Jinwal U.K. Davey Z. Kiray J. Arulselvam K. Dickey C.A. Bending tau into shape: The emerging role of peptidyl-prolyl isomerases in tauopathies Mol. Neurobiol. 2011 44 65 70 10.1007/s12035-011-8182-4 21523562
333. Chambraud B. Sardin E. Giustiniani J. Dounane O. Schumacher M. Goedert M. Baulieu E.E. A role for FKBP52 in Tau protein function Proc. Natl. Acad. Sci. USA 2010 107 2658 2663 10.1073/pnas.0914957107 20133804
334. Lu P.-J. Wulf G. Zhou X.Z. Davies P. Lu K.P. The prolyl isomerase Pin1 restores the function of Alzheimer-associated phosphorylated tau protein Nature 1999 399 784 788 10.1038/21650 10391244
335. Gruber C.W. Cemazar M. Heras B. Martin J.L. Craik D.J. Protein disulfide isomerase: The structure of oxidative folding Trends Biochem. Sci. 2006 31 455 464 10.1016/j.tibs.2006.06.001 16815710
336. Xu L.R. Liu X.L. Chen J. Liang Y. Protein disulfide isomerase interacts with tau protein and inhibits its fibrillization PLoS ONE 2013 8 e76657 10.1371/journal.pone.0076657 24098548
337. Wegmann S. Eftekharzadeh B. Tepper K. Zoltowska K.M. Bennett R.E. Dujardin S. Laskowski P.R. MacKenzie D. Kamath T. Commins C. Tau protein liquid-liquid phase separation can initiate tau aggregation EMBO J. 2018 37 e98049 10.15252/embj.201798049 29472250
338. Wang K. Liu J.Q. Zhong T. Liu X.L. Zeng Y. Qiao X. Xie T. Chen Y. Gao Y.Y. Tang B. Phase Separation and Cytotoxicity of Tau are Modulated by Protein Disulfide Isomerase and S-nitrosylation of this Molecular Chaperone J. Mol. Biol. 2020 432 2141 2163 10.1016/j.jmb.2020.02.013 32087196
339. Uehara T. Nakamura T. Yao D. Shi Z.Q. Gu Z. Ma Y. Masliah E. Nomura Y. Lipton S.A. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration Nature 2006 441 513 517 10.1038/nature04782 16724068
340. Honjo Y. Horibe T. Torisawa A. Ito H. Nakanishi A. Mori H. Komiya T. Takahashi R. Kawakami K. Protein disulfide isomerase P5-immunopositive inclusions in patients with Alzheimer’s disease J. Alzheimers Dis. 2014 38 601 609 10.3233/JAD-130632 24037032
341. Blair L.J. Baker J.D. Sabbagh J.J. Dickey C.A. The emerging role of peptidyl-prolyl isomerase chaperones in tau oligomerization, amyloid processing, and Alzheimer’s disease J. Neurochem. 2015 133 1 13 10.1111/jnc.13033 25628064
342. Peak S.L. Gracia L. Lora G. Jinwal U.K. Hsp90-interacting Co-chaperones and their Family Proteins in Tau Regulation: Introducing a Novel Role for Cdc37L1 Neuroscience 2021 453 312 323 10.1016/j.neuroscience.2020.11.020 33246057
343. Amadoro G. Corsetti V. Atlante A. Florenzano F. Capsoni S. Bussani R. Mercanti D. Calissano P. Interaction between NH2-tau fragment and Aβ in Alzheimer’s disease mitochondria contributes to the synaptic deterioration Neurobiol. Aging 2012 33 833.e1 833.e25 10.1016/j.neurobiolaging.2011.08.001
344. Elrod J.W. Molkentin J.D. Physiologic functions of cyclophilin D and the mitochondrial permeability transition pore Circ. J. 2013 77 1111 1122 10.1253/circj.CJ-13-0321 23538482
345. Schinzel A.C. Takeuchi O. Huang Z. Fisher J.K. Zhou Z. Rubens J. Hetz C. Danial N.N. Moskowitz M.A. Korsmeyer S.J. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia Proc. Natl. Acad. Sci. USA 2005 102 12005 12010 10.1073/pnas.0505294102 16103352
346. Baines C.P. Kaiser R.A. Purcell N.H. Blair N.S. Osinska H. Hambleton M.A. Brunskill E.W. Sayen M.R. Gottlieb R.A. Dorn G.W. Loss of cyclophilin D reveals a critical role for mitochondrial permeability transition in cell death Nature 2005 434 658 662 10.1038/nature03434 15800627
347. Guo C. Sun L. Chen X. Zhang D. Oxidative stress, mitochondrial damage and neurodegenerative diseases Neural Regen. Res. 2013 8 2003 25206509
348. Berridge M.J. Dysregulation of neural calcium signaling in Alzheimer disease, bipolar disorder and schizophrenia Prion 2013 7 2 13 10.4161/pri.21767 22895098
349. Abeti R. Abramov A.Y. Mitochondrial Ca2+ in neurodegenerative disorders Pharmacol. Res. 2015 99 377 381 10.1016/j.phrs.2015.05.007 26013908
350. Du H. Guo L. Fang F. Chen D. Sosunov A.A. McKhann G.M. Yan Y. Wang C. Zhang H. Molkentin J.D. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer’s disease Nat. Med. 2008 14 1097 1105 10.1038/nm.1868 18806802
351. Du H. Guo L. Zhang W. Rydzewska M. Yan S. Cyclophilin D deficiency improves mitochondrial function and learning/memory in aging Alzheimer disease mouse model Neurobiol. Aging 2011 32 398 406 10.1016/j.neurobiolaging.2009.03.003 19362755
352. Jara C. Cerpa W. Tapia-Rojas C. Quintanilla R.A. Tau deletion prevents cognitive impairment and mitochondrial dysfunction age-associated by a mechanism dependent on Cyclophilin-D (CypD) Front. Neurosci. 2020 14 1480
353. Pérez M.J. Jara C. Quintanilla R.A. Contribution of tau pathology to mitochondrial impairment in neurodegeneration Front. Neurosci. 2018 12 441 10.3389/fnins.2018.00441 30026680
354. Shimohama S. Apoptosis in Alzheimer’s disease—An update Apoptosis 2000 5 9 16 10.1023/A:1009625323388 11227497
355. Strasser A. O’Connor L. Dixit V.M. Apoptosis signaling Annu. Rev. Biochem. 2000 69 217 245 10.1146/annurev.biochem.69.1.217 10966458
356. Chung C.-W. Song Y.-H. Kim I.-K. Yoon W.-J. Ryu B.-R. Jo D.-G. Woo H.-N. Kwon Y.-K. Kim H.-H. Gwag B.-J. Proapoptotic effects of tau cleavage product generated by caspase-3 Neurobiol. Dis. 2001 8 162 172 10.1006/nbdi.2000.0335 11162250
357. Cotman C.W. Poon W.W. Rissman R.A. Blurton-Jones M. The role of caspase cleavage of tau in Alzheimer disease neuropathology J. Neuropathol. Exp. Neurol. 2005 64 104 112 10.1093/jnen/64.2.104 15751224
358. Zilka N. Kovacech B. Barath P. Kontsekova E. Novák M. The Self-Perpetuating tau Truncation Circle Portland Press Ltd. London, UK 2012
359. Miao E.A. Rajan J.V. Aderem A. Caspase-1-induced pyroptotic cell death Immunol. Rev. 2011 243 206 214 10.1111/j.1600-065X.2011.01044.x 21884178
360. Chu J. Lauretti E. Praticò D. Caspase-3-dependent cleavage of Akt modulates tau phosphorylation via GSK3β kinase: Implications for Alzheimer’s disease Mol. Psychiatry 2017 22 1002 1008 10.1038/mp.2016.214 28138159
361. Glushakova O.Y. Glushakov A.O. Borlongan C.V. Valadka A.B. Hayes R.L. Glushakov A.V. Role of Caspase-3-Mediated Apoptosis in Chronic Caspase-3-Cleaved Tau Accumulation and Blood–Brain Barrier Damage in the Corpus Callosum after Traumatic Brain Injury in Rats J. Neurotrauma 2018 35 157 173 10.1089/neu.2017.4999 28637381
362. Horowitz P.M. Patterson K.R. Guillozet-Bongaarts A.L. Reynolds M.R. Carroll C.A. Weintraub S.T. Bennett D.A. Cryns V.L. Berry R.W. Binder L.I. Early N-terminal changes and caspase-6 cleavage of tau in Alzheimer’s disease J. Neurosci. 2004 24 7895 7902 10.1523/JNEUROSCI.1988-04.2004 15356202
363. Guo H. Albrecht S. Bourdeau M. Petzke T. Bergeron C. LeBlanc A.C. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer’s disease Am. J. Pathol. 2004 165 523 531 10.1016/S0002-9440(10)63317-2 15277226
364. Zhao H. Zhao W. Lok K. Wang Z. Yin M. A Synergic Role of Caspase-6 and Caspase-3 in Tau Truncation at D421 Induced by H2O2 Cell. Mol. Neurobiol. 2014 34 369 378 10.1007/s10571-013-0021-x 24363090
365. Albrecht S. Bogdanovic N. Ghetti B. Winblad B. LeBlanc A.C. Caspase-6 activation in familial Alzheimer disease brains carrying amyloid precursor protein or presenilin I or presenilin II mutations J. Neuropathol. Exp. Neurol. 2009 68 1282 1293 10.1097/NEN.0b013e3181c1da10 19915487
366. Wang X.J. Cao Q. Zhang Y. Su X.D. Activation and regulation of caspase-6 and its role in neurodegenerative diseases Annu. Rev. Pharm. Toxicol. 2015 55 553 572 10.1146/annurev-pharmtox-010814-124414
367. Gervais F.G. Xu D. Robertson G.S. Vaillancourt J.P. Zhu Y. Huang J. LeBlanc A. Smith D. Rigby M. Shearman M.S. Involvement of caspases in proteolytic cleavage of Alzheimer’s amyloid-beta precursor protein and amyloidogenic A beta peptide formation Cell 1999 97 395 406 10.1016/S0092-8674(00)80748-5 10319819
368. Pellegrini L. Passer B.J. Tabaton M. Ganjei J.K. D’Adamio L. Alternative, non-secretase processing of Alzheimer’s beta-amyloid precursor protein during apoptosis by caspase-6 and -8 J. Biol. Chem. 1999 274 21011 21016 10.1074/jbc.274.30.21011 10409650
369. Lu D.C. Rabizadeh S. Chandra S. Shayya R.F. Ellerby L.M. Ye X. Salvesen G.S. Koo E.H. Bredesen D.E. A second cytotoxic proteolytic peptide derived from amyloid beta-protein precursor Nat. Med. 2000 6 397 404 10.1038/74656 10742146
370. Park S.A. Shaked G.M. Bredesen D.E. Koo E.H. Mechanism of cytotoxicity mediated by the C31 fragment of the amyloid precursor protein Biochem. Biophys. Res. Commun. 2009 388 450 455 10.1016/j.bbrc.2009.08.042 19679105
371. Gonçalves A.V. Margolis S.R. Quirino G.F. Mascarenhas D.P. Rauch I. Nichols R.D. Ansaldo E. Fontana M.F. Vance R.E. Zamboni D.S. Gasdermin-D and Caspase-7 are the key Caspase-1/8 substrates downstream of the NAIP5/NLRC4 inflammasome required for restriction of Legionella pneumophila PLoS Pathog. 2019 15 e1007886 10.1371/journal.ppat.1007886 31251782
372. Ayers K.L. Mirshahi U.L. Wardeh A.H. Murray M.F. Hao K. Glicksberg B.S. Li S. Carey D.J. Chen R. A loss of function variant in CASP7 protects against Alzheimer’s disease in homozygous APOE epsilon4 allele carriers BMC Genom. 2016 17 Suppl. 2 445 10.1186/s12864-016-2725-z
373. Zhang X. Zhu C. Beecham G. Vardarajan B.N. Ma Y. Lancour D. Farrell J.J. Chung J. Alzheimer’s Disease Sequencing P. Mayeux R. A rare missense variant of CASP7 is associated with familial late-onset Alzheimer’s disease Alzheimers Dement 2019 15 441 452 10.1016/j.jalz.2018.10.005 30503768
374. Muzio M. Stockwell B.R. Stennicke H.R. Salvesen G.S. Dixit V.M. An induced proximity model for caspase-8 activation J. Biol. Chem. 1998 273 2926 2930 10.1074/jbc.273.5.2926 9446604
375. Stennicke H.R. Jurgensmeier J.M. Shin H. Deveraux Q. Wolf B.B. Yang X. Zhou Q. Ellerby H.M. Ellerby L.M. Bredesen D. Pro-caspase-3 is a major physiologic target of caspase-8 J. Biol. Chem. 1998 273 27084 27090 10.1074/jbc.273.42.27084 9765224
376. Rohn T.T. Head E. Nesse W.H. Cotman C.W. Cribbs D.H. Activation of caspase-8 in the Alzheimer’s disease brain Neurobiol. Dis. 2001 8 1006 1016 10.1006/nbdi.2001.0449 11741396
377. Rehker J. Rodhe J. Nesbitt R.R. Boyle E.A. Martin B.K. Lord J. Karaca I. Naj A. Jessen F. Helisalmi S. Caspase-8, association with Alzheimer’s Disease and functional analysis of rare variants PLoS ONE 2017 12 e0185777 28985224
378. O’Brien R.J. Xu D. Petralia R.S. Steward O. Huganir R.L. Worley P. Synaptic clustering of AMPA receptors by the extracellular immediate-early gene product Narp Neuron 1999 23 309 323 10.1016/S0896-6273(00)80782-5 10399937
379. Allen N.J. Bennett M.L. Foo L.C. Wang G.X. Chakraborty C. Smith S.J. Barres B.A. Astrocyte glypicans 4 and 6 promote formation of excitatory synapses via GluA1 AMPA receptors Nature 2012 486 410 414 10.1038/nature11059 22722203
380. Groc L. Gustafsson B. Hanse E. AMPA signalling in nascent glutamatergic synapses: There and not there! Trends Neurosci. 2006 29 132 139 10.1016/j.tins.2006.01.005 16443288
381. Farhy-Tselnicker I. van Casteren A.C. Lee A. Chang V.T. Aricescu A.R. Allen N.J. Astrocyte-secreted glypican 4 regulates release of neuronal pentraxin 1 from axons to induce functional synapse formation Neuron 2017 96 428 445.e13 10.1016/j.neuron.2017.09.053 29024665
382. DeGregorio-Rocasolano N. Gasull T. Trullas R. Overexpression of neuronal pentraxin 1 is involved in neuronal death evoked by low K+ in cerebellar granule cells J. Biol. Chem. 2001 276 796 803 10.1074/jbc.M007967200 11031272
383. Enguita M. DeGregorio-Rocasolano N. Abad A. Trullas R. Glycogen synthase kinase 3 activity mediates neuronal pentraxin 1 expression and cell death induced by potassium deprivation in cerebellar granule cells Mol. Pharmacol. 2005 67 1237 1246 10.1124/mol.104.007062 15630079
384. Abad M.A. Enguita M. De Gregorio-Rocasolano N. Ferrer I. Trullas R. Neuronal pentraxin 1 contributes to the neuronal damage evoked by amyloid-β and is overexpressed in dystrophic neurites in Alzheimer’s brain J. Neurosci. 2006 26 12735 12747 10.1523/JNEUROSCI.0575-06.2006 17151277
385. Martinez-Vicente M. Sovak G. Cuervo A.M. Protein degradation and aging Exp. Gerontol. 2005 40 622 633 10.1016/j.exger.2005.07.005 16125351
386. Gafni J. Ellerby L.M. Calpain activation in Huntington’s disease J. Neurosci. 2002 22 4842 4849 10.1523/JNEUROSCI.22-12-04842.2002 12077181
387. Gafni J. Hermel E. Young J.E. Wellington C.L. Hayden M.R. Ellerby L.M. Inhibition of calpain cleavage of huntingtin reduces toxicity: Accumulation of calpain/caspase fragments in the nucleus J. Biol. Chem. 2004 279 20211 20220 10.1074/jbc.M401267200 14981075
388. Anderson J.P. Walker D.E. Goldstein J.M. De Laat R. Banducci K. Caccavello R.J. Barbour R. Huang J. Kling K. Lee M. Phosphorylation of Ser-129 is the dominant pathological modification of α-synuclein in familial and sporadic Lewy body disease J. Biol. Chem. 2006 281 29739 29752 10.1074/jbc.M600933200 16847063
389. Berke S.J.S. Schmied F.A.F. Brunt E.R. Ellerby L.M. Paulson H.L. Caspase-mediated proteolysis of the polyglutamine disease protein ataxin-3 J. Neurochem. 2004 89 908 918 10.1111/j.1471-4159.2004.02369.x 15140190
390. Goti D. Katzen S.M. Mez J. Kurtis N. Kiluk J. Ben-Haïem L. Jenkins N.A. Copeland N.G. Kakizuka A. Sharp A.H. A mutant ataxin-3 putative-cleavage fragment in brains of Machado-Joseph disease patients and transgenic mice is cytotoxic above a critical concentration J. Neurosci. 2004 24 10266 10279 10.1523/JNEUROSCI.2734-04.2004 15537899
391. Forloni G. Angeretti N. Chiesa R. Monzani E. Salmona M. Bugiani O. Tagliavini F. Neurotoxicity of a prion protein fragment Nature 1993 362 543 546 10.1038/362543a0 8464494
392. Soto C. Unfolding the role of protein misfolding in neurodegenerative diseases Nat. Rev. Neurosci. 2003 4 49 60 10.1038/nrn1007 12511861
393. Novak M. Kabat J. Wischik C.M. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer’s disease paired helical filament EMBO J. 1993 12 365 370 10.1002/j.1460-2075.1993.tb05665.x 7679073
394. Wischik C.M. Novak M. Edwards P.C. Klug A. Tichelaar W. Crowther R.A. Structural characterization of the core of the paired helical filament of Alzheimer disease Proc. Natl. Acad. Sci. USA 1988 85 4884 4888 10.1073/pnas.85.13.4884 2455299
395. Wischik C.M. Novak M. Thogersen H.C. Edwards P.C. Runswick M.J. Jakes R. Walker J.E. Milstein C. Roth M. Klug A. Isolation of a fragment of tau derived from the core of the paired helical filament of Alzheimer disease Proc. Natl. Acad. Sci. USA 1988 85 4506 4510 10.1073/pnas.85.12.4506 3132715
396. Quinn J.P. Corbett N.J. Kellett K.A. Hooper N.M. Tau proteolysis in the pathogenesis of tauopathies: Neurotoxic fragments and novel biomarkers J. Alzheimer’s Dis. 2018 63 13 33 10.3233/JAD-170959 29630551
397. Zilka N. Filipcik P. Koson P. Fialova L. Skrabana R. Zilkova M. Rolkova G. Kontsekova E. Novak M. Truncated tau from sporadic Alzheimer’s disease suffices to drive neurofibrillary degeneration in vivo FEBS Lett. 2006 580 3582 3588 10.1016/j.febslet.2006.05.029 16753151
398. Igaz L.M. Kwong L.K. Chen-Plotkin A. Winton M.J. Unger T.L. Xu Y. Neumann M. Trojanowski J.Q. Lee V.M. Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies J. Biol. Chem. 2009 284 8516 8524 10.1074/jbc.M809462200 19164285
399. Filipcik P. Zilka N. Bugos O. Kucerak J. Koson P. Novak P. Novak M. First transgenic rat model developing progressive cortical neurofibrillary tangles Neurobiol. Aging 2012 33 1448 1456 10.1016/j.neurobiolaging.2010.10.015 21196063
400. Tennstaedt A. Popsel S. Truebestein L. Hauske P. Brockmann A. Schmidt N. Irle I. Sacca B. Niemeyer C.M. Brandt R. Human high temperature requirement serine protease A1 (HTRA1) degrades tau protein aggregates J. Biol. Chem. 2012 287 20931 20941 10.1074/jbc.M111.316232 22535953
401. Glading A. Bodnar R. Reynolds I. Shiraha H. Satish L. Potter D. Blair H. Wells A. Epidermal growth factor activates m-calpain (calpain II), at least in part, by extracellular signal-regulated kinase-mediated phosphorylation Mol. Cell. Biol. 2004 24 2499 2512 10.1128/MCB.24.6.2499-2512.2004 14993287
402. Yang L.S. Ksiezak-Reding H. Calpain-induced proteolysis of normal human tau and tau associated with paired helical filaments Eur. J. Biochem. 1995 233 9 17 10.1111/j.1432-1033.1995.009_1.x 7588778
403. Baudry M. Bi X. Calpain-1 and Calpain-2: The Yin and Yang of Synaptic Plasticity and Neurodegeneration Trends Neurosci 2016 39 235 245 10.1016/j.tins.2016.01.007 26874794
404. Kurbatskaya K. Phillips E.C. Croft C.L. Dentoni G. Hughes M.M. Wade M.A. Al-Sarraj S. Troakes C. O’Neill M.J. Perez-Nievas B.G. Upregulation of calpain activity precedes tau phosphorylation and loss of synaptic proteins in Alzheimer’s disease brain Acta Neuropathol. Commun. 2016 4 34 10.1186/s40478-016-0299-2 27036949
405. Park S.Y. Ferreira A. The generation of a 17 kDa neurotoxic fragment: An alternative mechanism by which tau mediates beta-amyloid-induced neurodegeneration J. Neurosci. 2005 25 5365 5375 10.1523/JNEUROSCI.1125-05.2005 15930385
406. Garg S. Timm T. Mandelkow E.M. Mandelkow E. Wang Y. Cleavage of Tau by calpain in Alzheimer’s disease: The quest for the toxic 17 kD fragment Neurobiol. Aging 2011 32 1 14 10.1016/j.neurobiolaging.2010.09.008 20961659
407. Matsumoto S.E. Motoi Y. Ishiguro K. Tabira T. Kametani F. Hasegawa M. Hattori N. The twenty-four KDa C-terminal tau fragment increases with aging in tauopathy mice: Implications of prion-like properties Hum. Mol. Genet. 2015 24 6403 6416 10.1093/hmg/ddv351 26374846
408. Cicognola C. Satir T.M. Brinkmalm G. Matecko-Burmann I. Agholme L. Bergstrom P. Becker B. Zetterberg H. Blennow K. Hoglund K. Tauopathy-Associated Tau Fragment Ending at Amino Acid 224 Is Generated by Calpain-2 Cleavage J. Alzheimers Dis. 2020 74 1143 1156 10.3233/JAD-191130 32144989
409. Cicognola C. Brinkmalm G. Wahlgren J. Portelius E. Gobom J. Cullen N.C. Hansson O. Parnetti L. Constantinescu R. Wildsmith K. Novel tau fragments in cerebrospinal fluid: Relation to tangle pathology and cognitive decline in Alzheimer’s disease Acta Neuropathol. 2019 137 279 296 10.1007/s00401-018-1948-2 30547227
410. Zhang Z. Song M. Liu X. Kang S.S. Kwon I.S. Duong D.M. Seyfried N.T. Hu W.T. Liu Z. Wang J.Z. Cleavage of tau by asparagine endopeptidase mediates the neurofibrillary pathology in Alzheimer’s disease Nat. Med. 2014 20 1254 1262 10.1038/nm.3700 25326800
411. Wang Z.-H. Liu P. Liu X. Manfredsson F.P. Sandoval I.M. Yu S.P. Wang J.-Z. Ye K. Delta-secretase phosphorylation by SRPK2 enhances its enzymatic activity, provoking pathogenesis in Alzheimer’s disease Mol. Cell 2017 67 812 825.e5 10.1016/j.molcel.2017.07.018 28826672
412. Wang P. Joberty G. Buist A. Vanoosthuyse A. Stancu I.C. Vasconcelos B. Pierrot N. Faelth-Savitski M. Kienlen-Campard P. Octave J.N. Tau interactome mapping based identification of Otub1 as Tau deubiquitinase involved in accumulation of pathological Tau forms in vitro and in vivo Acta Neuropathol. 2017 133 731 749 10.1007/s00401-016-1663-9 28083634
413. Dall E. Brandstetter H. Structure and function of legumain in health and disease Biochimie 2016 122 126 150 10.1016/j.biochi.2015.09.022 26403494
414. Basurto-Islas G. Grundke-Iqbal I. Tung Y.C. Liu F. Iqbal K. Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease J. Biol. Chem. 2013 288 17495 17507 10.1074/jbc.M112.446070 23640887
415. Harrigan J.A. Jacq X. Martin N.M. Jackson S.P. Deubiquitylating enzymes and drug discovery: Emerging opportunities Nat. Rev. Drug Discov. 2018 17 57 78 10.1038/nrd.2017.152 28959952
416. Kontaxi C. Piccardo P. Gill A.C. Lysine-Directed Post-translational Modifications of Tau Protein in Alzheimer’s Disease and Related Tauopathies Front. Mol. Biosci. 2017 4 56 10.3389/fmolb.2017.00056 28848737
417. Letronne F. Laumet G. Ayral A.M. Chapuis J. Demiautte F. Laga M. Vandenberghe M.E. Malmanche N. Leroux F. Eysert F. ADAM30 Downregulates APP-Linked Defects Through Cathepsin D Activation in Alzheimer’s Disease EBioMedicine 2016 9 278 292 10.1016/j.ebiom.2016.06.002 27333034
418. Khurana V. Elson-Schwab I. Fulga T.A. Sharp K.A. Loewen C.A. Mulkearns E. Tyynelä J. Scherzer C.R. Feany M.B. Lysosomal dysfunction promotes cleavage and neurotoxicity of tau in vivo PLoS Genet. 2010 6 e1001026 10.1371/journal.pgen.1001026 20664788
419. Egberts F. Heinrich M. Jensen J.M. Winoto-Morbach S. Pfeiffer S. Wickel M. Schunck M. Steude J. Saftig P. Proksch E. Cathepsin D is involved in the regulation of transglutaminase 1 and epidermal differentiation J. Cell Sci. 2004 117 Pt 11 2295 2307 10.1242/jcs.01075 15126630
420. Banay-Schwartz M. Bracco F. DeGuzman T. Lajtha A. Developmental changes in the breakdown of brain tubulin by cerebral cathepsin D Neurochem. Res. 1983 8 51 61 10.1007/BF00965653 6856017
421. Banay-Schwartz M. Dahl D. Hui K.S. Lajtha A. The breakdown of the individual neurofilament proteins by cathepsin D Neurochem. Res. 1987 12 361 367 10.1007/BF00993246 3600962
422. Woessner J.F. Jr. Shamberger R.J. Jr. Purification and properties of cathepsin D from bovine uterus J. Biol. Chem. 1971 246 1951 1960 10.1016/S0021-9258(19)77174-9 5549596
423. Wolf M. Clark-Lewis I. Buri C. Langen H. Lis M. Mazzucchelli L. Cathepsin D specifically cleaves the chemokines macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, and SLC that are expressed in human breast cancer Am. J. Pathol. 2003 162 1183 1190 10.1016/S0002-9440(10)63914-4 12651610
424. Hiraiwa M. Martin B.M. Kishimoto Y. Conner G.E. Tsuji S. O’Brien J.S. Lysosomal proteolysis of prosaposin, the precursor of saposins (sphingolipid activator proteins): Its mechanism and inhibition by ganglioside Arch. Biochem. Biophys. 1997 341 17 24 10.1006/abbi.1997.9958 9143348
425. Kenessey A. Nacharaju P. Ko L.W. Yen S.H. Degradation of tau by lysosomal enzyme cathepsin D: Implication for Alzheimer neurofibrillary degeneration J. Neurochem. 1997 69 2026 2038 10.1046/j.1471-4159.1997.69052026.x 9349548
426. Benuck M. Marks N. Hashim G.A. Metabolic instability of myelin proteins. Breakdown of basic protein induced by brain cathepsin D Eur. J. Biochem. 1975 52 615 621 10.1111/j.1432-1033.1975.tb04033.x 70349
427. Sadik G. Kaji H. Takeda K. Yamagata F. Kameoka Y. Hashimoto K. Miyanaga K. Shinoda T. In vitro processing of amyloid precursor protein by cathepsin D Int. J. Biochem. Cell Biol. 1999 31 1327 1337 10.1016/S1357-2725(99)00053-9 10605825
428. Heinrich M. Neumeyer J. Jakob M. Hallas C. Tchikov V. Winoto-Morbach S. Wickel M. Schneider-Brachert W. Trauzold A. Hethke A. Cathepsin D links TNF-induced acid sphingomyelinase to Bid-mediated caspase-9 and -3 activation Cell Death Differ 2004 11 550 563 10.1038/sj.cdd.4401382 14739942
429. Papassotiropoulos A. Bagli M. Kurz A. Kornhuber J. Forstl H. Maier W. Pauls J. Lautenschlager N. Heun R. A genetic variation of cathepsin D is a major risk factor for Alzheimer’s disease Ann. Neurol. 2000 47 399 403 10.1002/1531-8249(200003)47:3<399::AID-ANA22>3.0.CO;2-5 10716266
430. Poepsel S. Sprengel A. Sacca B. Kaschani F. Kaiser M. Gatsogiannis C. Raunser S. Clausen T. Ehrmann M. Determinants of amyloid fibril degradation by the PDZ protease HTRA1 Nat. Chem. Biol. 2015 11 862 869 10.1038/nchembio.1931 26436840
431. Arai T. Guo J.P. McGeer P.L. Proteolysis of non-phosphorylated and phosphorylated tau by thrombin J. Biol. Chem. 2005 280 5145 5153 10.1074/jbc.M409234200 15542598
432. Marshall R.S. Vierstra R.D. Dynamic regulation of the 26S proteasome: From synthesis to degradation Front. Mol. Biosci. 2019 6 40 10.3389/fmolb.2019.00040 31231659
433. Zhang J.Y. Liu S.J. Li H.L. Wang J.Z. Microtubule-associated protein tau is a substrate of ATP/Mg(2+)-dependent proteasome protease system J. Neural. Transm. 2005 112 547 555 10.1007/s00702-004-0196-x 15372326
434. Kanayama H.O. Tamura T. Ugai S. Kagawa S. Tanahashi N. Yoshimura T. Tanaka K. Ichihara A. Demonstration that a human 26S proteolytic complex consists of a proteasome and multiple associated protein components and hydrolyzes ATP and ubiquitin-ligated proteins by closely linked mechanisms Eur. J. Biochem. 1992 206 567 578 10.1111/j.1432-1033.1992.tb16961.x 1317798
435. Voges D. Zwickl P. Baumeister W. The 26S proteasome: A molecular machine designed for controlled proteolysis Annu. Rev. Biochem. 1999 68 1015 1068 10.1146/annurev.biochem.68.1.1015 10872471
436. Bard J.A.M. Goodall E.A. Greene E.R. Jonsson E. Dong K.C. Martin A. Structure and Function of the 26S Proteasome Annu. Rev. Biochem. 2018 87 697 724 10.1146/annurev-biochem-062917-011931 29652515
437. Borodovsky A. Kessler B.M. Casagrande R. Overkleeft H.S. Wilkinson K.D. Ploegh H.L. A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14 EMBO J. 2001 20 5187 5196 10.1093/emboj/20.18.5187 11566882
438. Lee B.-H. Lu Y. Prado M.A. Shi Y. Tian G. Sun S. Elsasser S. Gygi S.P. King R.W. Finley D. USP14 deubiquitinates proteasome-bound substrates that are ubiquitinated at multiple sites Nature 2016 532 398 401 10.1038/nature17433 27074503
439. Keck S. Nitsch R. Grune T. Ullrich O. Proteasome inhibition by paired helical filament-tau in brains of patients with Alzheimer’s disease J. Neurochem. 2003 85 115 122 10.1046/j.1471-4159.2003.01642.x 12641733
440. Myeku N. Clelland C.L. Emrani S. Kukushkin N.V. Yu W.H. Goldberg A.L. Duff K.E. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling Nat. Med. 2016 22 46 53 10.1038/nm.4011 26692334
441. Thibaudeau T.A. Anderson R.T. Smith D.M. A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers Nat. Commun. 2018 9 1 14 10.1038/s41467-018-03509-0 29317637
442. Sengupta S. Horowitz P.M. Karsten S.L. Jackson G.R. Geschwind D.H. Fu Y. Berry R.W. Binder L.I. Degradation of tau protein by puromycin-sensitive aminopeptidase in vitro Biochemistry 2006 45 15111 15119 10.1021/bi061830d 17154549
443. Karsten S.L. Sang T.K. Gehman L.T. Chatterjee S. Liu J. Lawless G.M. Sengupta S. Berry R.W. Pomakian J. Oh H.S. A genomic screen for modifiers of tauopathy identifies puromycin-sensitive aminopeptidase as an inhibitor of tau-induced neurodegeneration Neuron 2006 51 549 560 10.1016/j.neuron.2006.07.019 16950154
444. Yang G. Zhou R. Zhou Q. Guo X. Yan C. Ke M. Lei J. Shi Y. Structural basis of Notch recognition by human gamma-secretase Nature 2019 565 192 197 10.1038/s41586-018-0813-8 30598546
445. Zhou R. Yang G. Guo X. Zhou Q. Lei J. Shi Y. Recognition of the amyloid precursor protein by human gamma-secretase Science 2019 363 eaaw0930 10.1126/science.aaw0930 30630874
446. Zhang S. Cai F. Wu Y. Bozorgmehr T. Wang Z. Zhang S. Huang D. Guo J. Shen L. Rankin C. A presenilin-1 mutation causes Alzheimer disease without affecting Notch signaling Mol. Psychiatry 2020 25 603 613 10.1038/s41380-018-0101-x 29915376
447. Russo C. Schettini G. Saido T.C. Hulette C. Lippa C. Lannfelt L. Ghetti B. Gambetti P. Tabaton M. Teller J.K. Presenilin-1 mutations in Alzheimer’s disease Nature 2000 405 531 532 10.1038/35014735 10850703
448. Takashima A. Murayama M. Murayama O. Kohno T. Honda T. Yasutake K. Nihonmatsu N. Mercken M. Yamaguchi H. Sugihara S. Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau Proc. Natl. Acad. Sci. USA 1998 95 9637 9641 10.1073/pnas.95.16.9637 9689133
449. Kelleher R.J. 3rd Shen J. Presenilin-1 mutations and Alzheimer’s disease Proc. Natl. Acad. Sci. USA 2017 114 629 631 10.1073/pnas.1619574114 28082723
450. Gordon-Weeks P.R. Fournier A.E. Neuronal cytoskeleton in synaptic plasticity and regeneration J. Neurochem. 2014 129 206 212 10.1111/jnc.12502 24147810
451. Goldstein A.Y. Wang X. Schwarz T.L. Axonal transport and the delivery of pre-synaptic components Curr. Opin. Neurobiol. 2008 18 495 503 10.1016/j.conb.2008.10.003 18950710
452. Witte H. Bradke F. The role of the cytoskeleton during neuronal polarization Curr. Opin. Neurobiol. 2008 18 479 487 10.1016/j.conb.2008.09.019 18929658
453. Alonso A.d.C. Zaidi T. Novak M. Barra H.S. Grundke-Iqbal I. Iqbal K. Interaction of tau isoforms with Alzheimer’s disease abnormally hyperphosphorylated tau and in VitroPhosphorylation into the disease-like protein J. Biol. Chem. 2001 276 37967 37973 10.1074/jbc.M105365200 11495914
454. Paonessa F. Evans L.D. Solanki R. Larrieu D. Wray S. Hardy J. Jackson S.P. Livesey F.J. Microtubules deform the nuclear membrane and disrupt nucleocytoplasmic transport in tau-mediated frontotemporal dementia Cell Rep. 2019 26 582 593.e5 10.1016/j.celrep.2018.12.085 30650353
455. Seiberlich V. Goldbaum O. Zhukareva V. Richter-Landsberg C. The small molecule inhibitor PR-619 of deubiquitinating enzymes affects the microtubule network and causes protein aggregate formation in neural cells: Implications for neurodegenerative diseases Biochim. Biophys. Acta Mol. Cell Res. 2012 1823 2057 2068 10.1016/j.bbamcr.2012.04.011
456. Souter S. Lee G. Microtubule-associated protein tau in human prostate cancer cells: Isoforms, phosphorylation, and interactions J. Cell. Biochem. 2009 108 555 564 10.1002/jcb.22287 19681044
457. Lai R.Y. Harrington C.R. Wischik C.M. Absence of a role for phosphorylation in the tau pathology of Alzheimer’s disease Biomolecules 2016 6 19 10.3390/biom6020019
458. Alonso A.d.C. Grundke-Iqbal I. Barra H.S. Iqbal K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: Sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau Proc. Natl. Acad. Sci. USA 1997 94 298 303 10.1073/pnas.94.1.298 8990203
459. Harada A. Teng J. Takei Y. Oguchi K. Hirokawa N. MAP2 is required for dendrite elongation, PKA anchoring in dendrites, and proper PKA signal transduction J. Cell Biol. 2002 158 541 549 10.1083/jcb.200110134 12163474
460. Kim Y. Jang Y.N. Kim J.Y. Kim N. Noh S. Kim H. Queenan B.N. Bellmore R. Mun J.Y. Park H. Microtubule-associated protein 2 mediates induction of long-term potentiation in hippocampal neurons FASEB J. 2020 34 6965 6983 10.1096/fj.201902122RR 32237183
461. Gumy L.F. Katrukha E.A. Grigoriev I. Jaarsma D. Kapitein L.C. Akhmanova A. Hoogenraad C.C. MAP2 Defines a Pre-axonal Filtering Zone to Regulate KIF1- versus KIF5-Dependent Cargo Transport in Sensory Neurons Neuron 2017 94 347 362.e7 10.1016/j.neuron.2017.03.046 28426968
462. Brouhard G.J. Rice L.M. Microtubule dynamics: An interplay of biochemistry and mechanics Nat. Rev. Mol. Cell Biol. 2018 19 451 463 10.1038/s41580-018-0009-y 29674711
463. Weisenberg R.C. Deery W.J. Dickinson P.J. Tubulin-nucleotide interactions during the polymerization and depolymerization of microtubules Biochemistry 1976 15 4248 4254 10.1021/bi00664a018 963034
464. Panda D. Goode B.L. Feinstein S.C. Wilson L. Kinetic stabilization of microtubule dynamics at steady state by tau and microtubule-binding domains of tau Biochemistry 1995 34 11117 11127 10.1021/bi00035a017 7669769
465. Drechsel D.N. Hyman A. Cobb M.H. Kirschner M. Modulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau Mol. Biol. Cell 1992 3 1141 1154 10.1091/mbc.3.10.1141 1421571
466. Hayashi I. Wilde A. Mal T.K. Ikura M. Structural basis for the activation of microtubule assembly by the EB1 and p150Glued complex Mol. Cell 2005 19 449 460 10.1016/j.molcel.2005.06.034 16109370
467. Go C.D. Knight J.D. Rajasekharan A. Rathod B. Hesketh G.G. Abe K.T. Youn J.-Y. Samavarchi-Tehrani P. Zhang H. Zhu L.Y. A proximity-dependent biotinylation map of a human cell: An interactive web resource bioRxiv 2021 10.1101/796391
468. Askham J.M. Vaughan K.T. Goodson H.V. Morrison E.E. Evidence that an interaction between EB1 and p150Glued is required for the formation and maintenance of a radial microtubule array anchored at the centrosome Mol. Biol. Cell 2002 13 3627 3645 10.1091/mbc.e02-01-0061 12388762
469. Yang C. Wu J. De Heus C. Grigoriev I. Liv N. Yao Y. Smal I. Meijering E. Klumperman J. Qi R.Z. EB1 and EB3 regulate microtubule minus end organization and Golgi morphology J. Cell Biol. 2017 216 3179 3198 10.1083/jcb.201701024 28814570
470. Ramirez-Rios S. Denarier E. Prezel E. Vinit A. Stoppin-Mellet V. Devred F. Barbier P. Peyrot V. Sayas C.L. Avila J. Tau antagonizes end-binding protein tracking at microtubule ends through a phosphorylation-dependent mechanism Mol. Biol. Cell 2016 27 2924 2934 10.1091/mbc.E16-01-0029 27466319
471. Sayas C.L. Medina M. Cuadros R. Ollá I. García E. Pérez M. Ferrer I. Hernández F. Avila J. Role of tau N-terminal motif in the secretion of human tau by End Binding proteins PLoS ONE 2019 14 e0210864 10.1371/journal.pone.0210864 30668577
472. Malki I. Cantrelle F.X. Sottejeau Y. Lippens G. Lambert J.C. Landrieu I. Regulation of the interaction between the neuronal BIN 1 isoform 1 and Tau proteins–role of the SH 3 domain FEBS J. 2017 284 3218 3229 10.1111/febs.14185 28755476
473. Chapuis J. Hansmannel F. Gistelinck M. Mounier A. Van Cauwenberghe C. Kolen K. Geller F. Sottejeau Y. Harold D. Dourlen P. Increased expression of BIN1 mediates Alzheimer genetic risk by modulating tau pathology Mol. Psychiatry 2013 18 1225 1234 10.1038/mp.2013.1 23399914
474. Wu T. Shi Z. Baumgart T. Mutations in BIN1 associated with centronuclear myopathy disrupt membrane remodeling by affecting protein density and oligomerization PLoS ONE 2014 9 e93060 10.1371/journal.pone.0093060 24755653
475. Wechsler-Reya R. Sakamuro D. Zhang J. Duhadaway J. Prendergast G.C. Structural analysis of the human BIN1 gene. Evidence for tissue-specific transcriptional regulation and alternate RNA splicing J. Biol. Chem. 1997 272 31453 31458 10.1074/jbc.272.50.31453 9395479
476. Seshadri S. Fitzpatrick A.L. Ikram M.A. DeStefano A.L. Gudnason V. Boada M. Bis J.C. Smith A.V. Carassquillo M.M. Lambert J.C. Genome-wide analysis of genetic loci associated with Alzheimer disease JAMA 2010 303 1832 1840 10.1001/jama.2010.574 20460622
477. Kingwell K. Alzheimer disease: BIN1 variant increases risk of Alzheimer disease through tau Nat. Rev. Neurol. 2013 9 184 10.1038/nrneurol.2013.34 23458971
478. Dharmalingam E. Haeckel A. Pinyol R. Schwintzer L. Koch D. Kessels M.M. Qualmann B. F-BAR proteins of the syndapin family shape the plasma membrane and are crucial for neuromorphogenesis J. Neurosci. 2009 29 13315 13327 10.1523/JNEUROSCI.3973-09.2009 19846719
479. Wang Q. Navarro M.V. Peng G. Molinelli E. Goh S.L. Judson B.L. Rajashankar K.R. Sondermann H. Molecular mechanism of membrane constriction and tubulation mediated by the F-BAR protein Pacsin/Syndapin Proc. Natl. Acad. Sci. USA 2009 106 12700 12705 10.1073/pnas.0902974106 19549836
480. Kessels M.M. Qualmann B. Syndapins integrate N-WASP in receptor-mediated endocytosis EMBO J. 2002 21 6083 6094 10.1093/emboj/cdf604 12426380
481. Plomann M. Lange R. Vopper G. Cremer H. Heinlein U.A. Scheff S. Baldwin S.A. Leitges M. Cramer M. Paulsson M. PACSIN, a brain protein that is upregulated upon differentiation into neuronal cells Eur. J. Biochem. 1998 256 201 211 10.1046/j.1432-1327.1998.2560201.x 9746365
482. Pérez-Otaño I. Luján R. Tavalin S.J. Plomann M. Modregger J. Liu X.-B. Jones E.G. Heinemann S.F. Lo D.C. Ehlers M.D. Endocytosis and synaptic removal of NR3A-containing NMDA receptors by PACSIN1/syndapin1 Nat. Neurosci. 2006 9 611 621 10.1038/nn1680 16617342
483. Carmignoto G. Vicini S. Activity-dependent decrease in NMDA receptor responses during development of the visual cortex Science 1992 258 1007 1011 10.1126/science.1279803 1279803
484. Hestrin S. Developmental regulation of NMDA receptor-mediated synaptic currents at a central synapse Nature 1992 357 686 689 10.1038/357686a0 1377360
485. Sheng M. Cummings J. Roldan L.A. Jan Y.N. Jan L.Y. Changing subunit composition of heteromeric NMDA receptors during development of rat cortex Nature 1994 368 144 147 10.1038/368144a0 8139656
486. Yamagishi A. Masuda M. Ohki T. Onishi H. Mochizuki N. A novel actin bundling/filopodium-forming domain conserved in insulin receptor tyrosine kinase substrate p53 and missing in metastasis protein J. Biol. Chem. 2004 279 14929 14936 10.1074/jbc.M309408200 14752106
487. Scita G. Confalonieri S. Lappalainen P. Suetsugu S. IRSp53: Crossing the road of membrane and actin dynamics in the formation of membrane protrusions Trends Cell Biol. 2008 18 52 60 10.1016/j.tcb.2007.12.002 18215522
488. Kang J. Park H. Kim E. IRSp53/BAIAP2 in dendritic spine development, NMDA receptor regulation, and psychiatric disorders Neuropharmacology 2016 100 27 39 10.1016/j.neuropharm.2015.06.019 26275848
489. Disanza A. Mantoani S. Hertzog M. Gerboth S. Frittoli E. Steffen A. Berhoerster K. Kreienkamp H.-J. Milanesi F. Di Fiore P.P. Regulation of cell shape by Cdc42 is mediated by the synergic actin-bundling activity of the Eps8–IRSp53 complex Nat. Cell Biol. 2006 8 1337 1347 10.1038/ncb1502 17115031
490. Okamura-Oho Y. Miyashita T. Yamada M. Distinctive tissue distribution and phosphorylation of IRSp53 isoforms Biochem. Biophys. Res. Commun. 2001 289 957 960 10.1006/bbrc.2001.6102 11741283
491. Fujiwara T. Mammoto A. Kim Y. Takai Y. Rho small G-protein-dependent binding of mDia to an Src homology 3 domain-containing IRSp53/BAIAP2 Biochem. Biophys. Res. Commun. 2000 271 626 629 10.1006/bbrc.2000.2671 10814512
492. Choi J. Ko J. Racz B. Burette A. Lee J.-R. Kim S. Na M. Lee H.W. Kim K. Weinberg R.J. Regulation of dendritic spine morphogenesis by insulin receptor substrate 53, a downstream effector of Rac1 and Cdc42 small GTPases J. Neurosci. 2005 25 869 879 10.1523/JNEUROSCI.3212-04.2005 15673667
493. Fromer M. Pocklington A.J. Kavanagh D.H. Williams H.J. Dwyer S. Gormley P. Georgieva L. Rees E. Palta P. Ruderfer D.M. De novo mutations in schizophrenia implicate synaptic networks Nature 2014 506 179 184 10.1038/nature12929 24463507
494. Purcell S.M. Moran J.L. Fromer M. Ruderfer D. Solovieff N. Roussos P. O’dushlaine C. Chambert K. Bergen S.E. Kähler A. A polygenic burden of rare disruptive mutations in schizophrenia Nature 2014 506 185 190 10.1038/nature12975 24463508
495. Levy D. Ronemus M. Yamrom B. Lee Y.-h. Leotta A. Kendall J. Marks S. Lakshmi B. Pai D. Ye K. Rare de novo and transmitted copy-number variation in autistic spectrum disorders Neuron 2011 70 886 897 10.1016/j.neuron.2011.05.015 21658582
496. Toma C. Hervás A. Balmaña N. Vilella E. Aguilera F. Cuscó I. del Campo M. Caballero R. De Diego-Otero Y. Ribasés M. Association study of six candidate genes asymmetrically expressed in the two cerebral hemispheres suggests the involvement of BAIAP2 in autism J. Psychiatr. Res. 2011 45 280 282 10.1016/j.jpsychires.2010.09.001 20888579
497. Liu L. Sun L. Li Z.-H. Li H.-M. Wei L.-P. Wang Y.-F. Qian Q.-J. BAIAP2 exhibits association to childhood ADHD especially predominantly inattentive subtype in Chinese Han subjects Behav. Brain Funct. 2013 9 1 9 10.1186/1744-9081-9-48 23295062
498. Herrmann L. Wiegmann C. Arsalan-Werner A. Hilbrich I. Jager C. Flach K. Suttkus A. Lachmann I. Arendt T. Holzer M. Hook proteins: Association with Alzheimer pathology and regulatory role of hook3 in amyloid beta generation PLoS ONE 2015 10 e0119423 10.1371/journal.pone.0119423 25799409
499. Goitre L. Trapani E. Trabalzini L. Retta S.F. The Ras superfamily of small GTPases: The unlocked secrets Ras Signal. 2014 1120 1 18
500. Carazo-Salas R.E. Guarguaglini G. Gruss O.J. Segref A. Karsenti E. Mattaj I.W. Generation of GTP-bound Ran by RCC1 is required for chromatin-induced mitotic spindle formation Nature 1999 400 178 181 10.1038/22133 10408446
501. Bao X. Liu H. Liu X. Ruan K. Zhang Y. Zhang Z. Hu Q. Liu Y. Akram S. Zhang J. Mitosis-specific acetylation tunes Ran effector binding for chromosome segregation J. Mol. Cell Biol. 2018 10 18 32 10.1093/jmcb/mjx045 29040603
502. Melchior F. Paschal B. Evans J. Gerace L. Inhibition of nuclear protein import by nonhydrolyzable analogues of GTP and identification of the small GTPase Ran/TC4 as an essential transport factor J. Cell Biol. 1993 123 1649 1659 10.1083/jcb.123.6.1649 8276887
503. Görlich D. Pante N. Kutay U. Aebi U. Bischoff F. Identification of different roles for RanGDP and RanGTP in nuclear protein import EMBO J. 1996 15 5584 5594 10.1002/j.1460-2075.1996.tb00943.x 8896452
504. Rudack T. Jenrich S. Brucker S. Vetter I.R. Gerwert K. Kötting C. Catalysis of GTP hydrolysis by small GTPases at atomic detail by integration of X-ray crystallography, experimental, and theoretical IR spectroscopy J. Biol. Chem. 2015 290 24079 24090 10.1074/jbc.M115.648071 26272610
505. Fleming L.M. Weisgraber K.H. Strittmatter W.J. Troncoso J.C. Johnson G.V. Differential binding of apolipoprotein E isoforms to tau and other cytoskeletal proteins Exp. Neurol. 1996 138 252 260 10.1006/exnr.1996.0064 8620924
506. Yu Y. Kuang Y.L. Lei D. Zhai X. Zhang M. Krauss R.M. Ren G. Polyhedral 3D structure of human plasma very low density lipoproteins by individual particle cryo-electron tomography1 J. Lipid Res. 2016 57 1879 1888 10.1194/jlr.M070375 27538822
507. Dawson P.A. Rudel L.L. Intestinal cholesterol absorption Curr Opin Lipidol 1999 10 315 320 10.1097/00041433-199908000-00005 10482134
508. Otvos J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy Clin. Lab. 2002 48 171 180 11934219
509. Rall S.C. Jr. Weisgraber K.H. Mahley R.W. Human apolipoprotein E. The complete amino acid sequence J. Biol. Chem. 1982 257 4171 4178 10.1016/S0021-9258(18)34702-1 7068630
510. Heinsinger N.M. Gachechiladze M.A. Rebeck G.W. Apolipoprotein E Genotype Affects Size of ApoE Complexes in Cerebrospinal Fluid J. Neuropathol. Exp. Neurol. 2016 75 918 924 10.1093/jnen/nlw067 27516118
511. Roses A.D. Saunders A.M. APOE is a major susceptibility gene for Alzheimer’s disease Curr. Opin. Biotechnol. 1994 5 663 667 10.1016/0958-1669(94)90091-4 7765750
512. Strittmatter W.J. Saunders A.M. Goedert M. Weisgraber K.H. Dong L.M. Jakes R. Huang D.Y. Pericak-Vance M. Schmechel D. Roses A.D. Isoform-specific interactions of apolipoprotein E with microtubule-associated protein tau: Implications for Alzheimer disease Proc. Natl. Acad. Sci. USA 1994 91 11183 11186 10.1073/pnas.91.23.11183 7972031
513. Bullido M.J. Aldudo J. Frank A. Coria F. Avila J. Valdivieso F. A polymorphism in the tau gene associated with risk for Alzheimer’s disease Neurosci. Lett. 2000 278 49 52 10.1016/S0304-3940(99)00893-9 10643798
514. Yu L. Boyle P.A. Leurgans S. Schneider J.A. Bennett D.A. Disentangling the effects of age and APOE on neuropathology and late life cognitive decline Neurobiol. Aging 2014 35 819 826 10.1016/j.neurobiolaging.2013.10.074 24199961
515. Dhaenens C.-M. Van Brussel E. Schraen-Maschke S. Pasquier F. Delacourte A. Sablonnière B. Association study of three polymorphisms of kinesin light-chain 1 gene with Alzheimer’s disease Neurosci. Lett. 2004 368 290 292 10.1016/j.neulet.2004.07.040 15364413
516. Rahman A. Friedman D.S. Goldstein L.S. Two kinesin light chain genes in mice: Identification and characterization of the encoded proteins J. Biol. Chem. 1998 273 15395 15403 10.1074/jbc.273.25.15395 9624122
517. Konecna A. Frischknecht R. Kinter J. Ludwig A. Steuble M. Meskenaite V. Indermühle M. Engel M. Cen C. Mateos J.-M. Calsyntenin-1 docks vesicular cargo to kinesin-1 Mol. Biol. Cell 2006 17 3651 3663 10.1091/mbc.e06-02-0112 16760430
518. Araki Y. Kawano T. Taru H. Saito Y. Wada S. Miyamoto K. Kobayashi H. Ishikawa H.O. Ohsugi Y. Yamamoto T. The novel cargo Alcadein induces vesicle association of kinesin-1 motor components and activates axonal transport EMBO J. 2007 26 1475 1486 10.1038/sj.emboj.7601609 17332754
519. Vagnoni A. Perkinton M.S. Gray E.H. Francis P.T. Noble W. Miller C.C. Calsyntenin-1 mediates axonal transport of the amyloid precursor protein and regulates Aβ production Hum. Mol. Genet. 2012 21 2845 2854 10.1093/hmg/dds109 22434822
520. Vagnoni A. Rodriguez L. Manser C. De Vos K.J. Miller C.C. Phosphorylation of kinesin light chain 1 at serine 460 modulates binding and trafficking of calsyntenin-1 J. Cell Sci. 2011 124 1032 1042 10.1242/jcs.075168 21385839
521. Mórotz G.M. Glennon E.B. Greig J. Lau D.H. Bhembre N. Mattedi F. Muschalik N. Noble W. Vagnoni A. Miller C.C. Kinesin light chain-1 serine-460 phosphorylation is altered in Alzheimer’s disease and regulates axonal transport and processing of the amyloid precursor protein Acta Neuropathol. Commun. 2019 7 1 13 10.1186/s40478-019-0857-5 30606247
522. Morel M. Héraud C. Nicaise C. Suain V. Brion J.-P. Levels of kinesin light chain and dynein intermediate chain are reduced in the frontal cortex in Alzheimer’s disease: Implications for axoplasmic transport Acta Neuropathol. 2012 123 71 84 10.1007/s00401-011-0901-4 22094641
523. Falzone T.L. Gunawardena S. McCleary D. Reis G.F. Goldstein L.S. Kinesin-1 transport reductions enhance human tau hyperphosphorylation, aggregation and neurodegeneration in animal models of tauopathies Hum. Mol. Genet. 2010 19 4399 4408 10.1093/hmg/ddq363 20817925
524. Schroer T.A. Dynactin Annu. Rev. Cell Dev. Biol. 2004 20 759 779 10.1146/annurev.cellbio.20.012103.094623 15473859
525. Ayloo S. Lazarus J.E. Dodda A. Tokito M. Ostap E.M. Holzbaur E.L. Dynactin functions as both a dynamic tether and brake during dynein-driven motility Nat. Commun. 2014 5 1 11 10.1038/ncomms5807 25185702
526. Lill R. Nargang F.E. Neupert W. Biogenesis of mitochondrial proteins Curr. Opin. Cell Biol. 1996 8 505 512 10.1016/S0955-0674(96)80028-7 8791452
527. Chai Y.L. Xing H. Chong J.R. Francis P.T. Ballard C.G. Chen C.P. Lai M.K. Mitochondrial translocase of the outer membrane alterations may underlie dysfunctional oxidative phosphorylation in Alzheimer’s disease J. Alzheimer’s Dis. 2018 61 793 801 10.3233/JAD-170613 29254089
528. Neupert W. Herrmann J.M. Translocation of proteins into mitochondria Annu. Rev. Biochem. 2007 76 723 749 10.1146/annurev.biochem.76.052705.163409 17263664
529. Petersen C.A.H. Alikhani N. Behbahani H. Wiehager B. Pavlov P.F. Alafuzoff I. Leinonen V. Ito A. Winblad B. Glaser E. The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae Proc. Natl. Acad. Sci. USA 2008 105 13145 13150 10.1073/pnas.0806192105 18757748
530. Gawaz M. Douglas M. Klingenberg M. Structure-function studies of adenine nucleotide transport in mitochondria. II. Biochemical analysis of distinct AAC1 and AAC2 proteins in yeast J. Biol. Chem. 1990 265 14202 14208 10.1016/S0021-9258(18)77287-6 2167309
531. Krüger J. Hinttala R. Majamaa K. Remes A.M. Mitochondrial DNA haplogroups in early-onset Alzheimer’s disease and frontotemporal lobar degeneration Mol. Neurodegener. 2010 5 1 6 10.1186/1750-1326-5-8 20205790
532. Copeland W.C. Inherited mitochondrial diseases of DNA replication Annu. Rev. Med. 2008 59 131 146 10.1146/annurev.med.59.053006.104646 17892433
533. Sasaki K. Shimura H. Itaya M. Tanaka R. Mori H. Mizuno Y. Kosik K.S. Tanaka S. Hattori N. Excitatory amino acid transporter 2 associates with phosphorylated tau and is localized in neurofibrillary tangles of tauopathic brains FEBS Lett. 2009 583 2194 2200 10.1016/j.febslet.2009.06.015 19527721
534. Benussi L. Ghidoni R. Paterlini A. Nicosia F. Alberici A.C. Signorini S. Barbiero L. Binetti G. Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation Exp. Cell Res. 2005 308 78 84 10.1016/j.yexcr.2005.04.021 15904919
535. Cheng F. Vivacqua G. Yu S. The role of alpha-synuclein in neurotransmission and synaptic plasticity J. Chem. Neuroanat. 2011 42 242 248 10.1016/j.jchemneu.2010.12.001 21167933
536. Pranke I.M. Morello V. Bigay J. Gibson K. Verbavatz J.-M. Antonny B. Jackson C.L. α-Synuclein and ALPS motifs are membrane curvature sensors whose contrasting chemistry mediates selective vesicle binding J. Cell Biol. 2011 194 89 103 10.1083/jcb.201011118 21746853
537. Jin H. Kanthasamy A. Ghosh A. Yang Y. Anantharam V. Kanthasamy A.G. α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity J. Neurosci. 2011 31 2035 2051 10.1523/JNEUROSCI.5634-10.2011 21307242
538. Clayton D.F. George J.M. Synucleins in synaptic plasticity and neurodegenerative disorders J. Neurosci. Res. 1999 58 120 129 10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.0.CO;2-E 10491577
539. Burré J. Sharma M. Tsetsenis T. Buchman V. Etherton M.R. Südhof T.C. α-Synuclein promotes SNARE-complex assembly in vivo and in vitro Science 2010 329 1663 1667 10.1126/science.1195227 20798282
540. Hamilton R.L. Lewy bodies in Alzheimer’s disease: A neuropathological review of 145 cases using α-synuclein immunohistochemistry Brain Pathol. 2000 10 378 384 10.1111/j.1750-3639.2000.tb00269.x 10885656
541. Arai Y. Yamazaki M. Mori O. Muramatsu H. Asano G. Katayama Y. α-Synuclein-positive structures in cases with sporadic Alzheimer’s disease: Morphology and its relationship to tau aggregation Brain Res. 2001 888 287 296 10.1016/S0006-8993(00)03082-1 11150486
542. Giasson B.I. Forman M.S. Higuchi M. Golbe L.I. Graves C.L. Kotzbauer P.T. Trojanowski J.Q. Lee V.M.-Y. Initiation and synergistic fibrillization of tau and alpha-synuclein Science 2003 300 636 640 10.1126/science.1082324 12714745
543. Oikawa T. Nonaka T. Terada M. Tamaoka A. Hisanaga S.-i. Hasegawa M. α-Synuclein fibrils exhibit gain of toxic function, promoting tau aggregation and inhibiting microtubule assembly J. Biol. Chem. 2016 291 15046 15056 10.1074/jbc.M116.736355 27226637
544. Duka T. Duka V. Joyce J.N. Sidhu A. α-Synuclein contributes to GSK-3β-catalyzed Tau phosphorylation in Parkinson’s disease models FASEB J. 2009 23 2820 2830 10.1096/fj.08-120410 19369384
545. Doetsch F. Caille I. Lim D.A. Garcia-Verdugo J.M. Alvarez-Buylla A. Subventricular zone astrocytes are neural stem cells in the adult mammalian brain Cell 1999 97 703 716 10.1016/S0092-8674(00)80783-7 10380923
546. Seward M.E. Swanson E. Norambuena A. Reimann A. Cochran J.N. Li R. Roberson E.D. Bloom G.S. Amyloid-β signals through tau to drive ectopic neuronal cell cycle re-entry in Alzheimer’s disease J. Cell Sci. 2013 126 1278 1286 10.1242/jcs.1125880 23345405
547. Frost B. Hemberg M. Lewis J. Feany M.B. Tau promotes neurodegeneration through global chromatin relaxation Nat. Neurosci. 2014 17 357 366 10.1038/nn.3639 24464041
548. Hernández-Ortega K. Garcia-Esparcia P. Gil L. Lucas J.J. Ferrer I. Altered machinery of protein synthesis in Alzheimer’s: From the nucleolus to the ribosome Brain Pathol. 2016 26 593 605 10.1111/bpa.12335 26512942
549. Barbato C. Corbi N. Canu N. Fanciulli M. Serafino A. Ciotti M. Libri V. Bruno T. Amadoro G. De Angelis R. Rb binding protein Che-1 interacts with Tau in cerebellar granule neurons. Modulation during neuronal apoptosis Mol. Cell Neurosci 2003 24 1038 1050 10.1016/j.mcn.2003.08.002 14697667
550. Ueberham U. Rohn S. Ueberham E. Wodischeck S. Hilbrich I. Holzer M. Bruckner M.K. Gruschka H. Arendt T. Pin1 promotes degradation of Smad proteins and their interaction with phosphorylated tau in Alzheimer’s disease Neuropathol. Appl. Neurobiol. 2014 40 815 832 10.1111/nan.12163 24964035
551. Bruno T. De Angelis R. De Nicola F. Barbato C. Di Padova M. Corbi N. Libri V. Benassi B. Mattei E. Chersi A. Che-1 affects cell growth by interfering with the recruitment of HDAC1 by Rb Cancer Cell 2002 2 387 399 10.1016/S1535-6108(02)00182-4 12450794
552. Wrighton K.H. Lin X. Feng X.H. Phospho-control of TGF-beta superfamily signaling Cell Res. 2009 19 8 20 10.1038/cr.2008.327 19114991
553. Zheng J.Y. Sun J. Ji C.M. Shen L. Chen Z.J. Xie P. Sun Y.Z. Yu R.T. Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer’s disease (APP/PS1) mice by inhibiting TGF-beta/Smad2/STAT3 signaling Neurobiol. Aging 2017 54 112 132 10.1016/j.neurobiolaging.2017.03.002 28366226
554. Fan Q. He W. Gayen M. Benoit M.R. Luo X. Hu X. Yan R. Activated CX3CL1/Smad2 Signals Prevent Neuronal Loss and Alzheimer’s Tau Pathology-Mediated Cognitive Dysfunction J. Neurosci. 2020 40 1133 1144 10.1523/JNEUROSCI.1333-19.2019 31822518
555. Baig S. van Helmond Z. Love S. Tau hyperphosphorylation affects Smad 2/3 translocation Neuroscience 2009 163 561 570 10.1016/j.neuroscience.2009.06.045 19555739
556. Anderson P. Kedersha N. Stress granules: The Tao of RNA triage Trends Biochem. Sci. 2008 33 141 150 10.1016/j.tibs.2007.12.003 18291657
557. Liu-Yesucevitz L. Bassell G.J. Gitler A.D. Hart A.C. Klann E. Richter J.D. Warren S.T. Wolozin B. Local RNA translation at the synapse and in disease J. Neurosci. 2011 31 16086 16093 10.1523/JNEUROSCI.4105-11.2011 22072660
558. Bai B. Hales C.M. Chen P.C. Gozal Y. Dammer E.B. Fritz J.J. Wang X. Xia Q. Duong D.M. Street C. U1 small nuclear ribonucleoprotein complex and RNA splicing alterations in Alzheimer’s disease Proc. Natl. Acad. Sci. USA 2013 110 16562 16567 10.1073/pnas.1310249110 24023061
559. Berson A. Barbash S. Shaltiel G. Goll Y. Hanin G. Greenberg D.S. Ketzef M. Becker A.J. Friedman A. Soreq H. Cholinergic-associated loss of hnRNP-A/B in Alzheimer’s disease impairs cortical splicing and cognitive function in mice EMBO Mol. Med. 2012 4 730 742 10.1002/emmm.201100995 22628224
560. Bishof I. Dammer E.B. Duong D.M. Kundinger S.R. Gearing M. Lah J.J. Levey A.I. Seyfried N.T. RNA-binding proteins with basic-acidic dipeptide (BAD) domains self-assemble and aggregate in Alzheimer’s disease J. Biol. Chem. 2018 293 11047 11066 10.1074/jbc.RA118.001747 29802200
561. Vanderweyde T. Apicco D.J. Youmans-Kidder K. Ash P.E.A. Cook C. Lummertz da Rocha E. Jansen-West K. Frame A.A. Citro A. Leszyk J.D. Interaction of tau with the RNA-Binding Protein TIA1 Regulates tau Pathophysiology and Toxicity Cell Rep. 2016 15 1455 1466 10.1016/j.celrep.2016.04.045 27160897
562. Pomeranz Krummel D.A. Oubridge C. Leung A.K. Li J. Nagai K. Crystal structure of human spliceosomal U1 snRNP at 5.5 A resolution Nature 2009 458 475 480 10.1038/nature07851 19325628
563. Bai B. Chen P.C. Hales C.M. Wu Z. Pagala V. High A.A. Levey A.I. Lah J.J. Peng J. Integrated approaches for analyzing U1-70K cleavage in Alzheimer’s disease J. Proteome Res. 2014 13 4526 4534 10.1021/pr5003593 24902715
564. Diner I. Hales C.M. Bishof I. Rabenold L. Duong D.M. Yi H. Laur O. Gearing M. Troncoso J. Thambisetty M. Aggregation properties of the small nuclear ribonucleoprotein U1-70K in Alzheimer disease J. Biol. Chem. 2014 289 35296 35313 10.1074/jbc.M114.562959 25355317
565. Raj T. Li Y.I. Wong G. Humphrey J. Wang M. Ramdhani S. Wang Y.C. Ng B. Gupta I. Haroutunian V. Integrative transcriptome analyses of the aging brain implicate altered splicing in Alzheimer’s disease susceptibility Nat. Genet. 2018 50 1584 1592 10.1038/s41588-018-0238-1 30297968
566. Del Gatto-Konczak F. Bourgeois C.F. Le Guiner C. Kister L. Gesnel M.-C. Stévenin J. Breathnach R. The RNA-binding protein TIA-1 is a novel mammalian splicing regulator acting through intron sequences adjacent to a 5′ splice site Mol. Cell. Biol. 2000 20 6287 6299 10.1128/MCB.20.17.6287-6299.2000 10938105
567. Gilks N. Kedersha N. Ayodele M. Shen L. Stoecklin G. Dember L.M. Anderson P. Stress granule assembly is mediated by prion-like aggregation of TIA-1 Mol. Biol. Cell 2004 15 5383 5398 10.1091/mbc.e04-08-0715 15371533
568. Vanderweyde T. Yu H. Varnum M. Liu-Yesucevitz L. Citro A. Ikezu T. Duff K. Wolozin B. Contrasting pathology of the stress granule proteins TIA-1 and G3BP in tauopathies J. Neurosci. 2012 32 8270 8283 10.1523/JNEUROSCI.1592-12.2012 22699908
569. Jiang L. Ash P.E.A. Maziuk B.F. Ballance H.I. Boudeau S. Abdullatif A.A. Orlando M. Petrucelli L. Ikezu T. Wolozin B. TIA1 regulates the generation and response to toxic tau oligomers Acta Neuropathol. 2019 137 259 277 10.1007/s00401-018-1937-5 30465259
570. Apicco D.J. Ash P.E.A. Maziuk B. LeBlang C. Medalla M. Al Abdullatif A. Ferragud A. Botelho E. Ballance H.I. Dhawan U. Reducing the RNA binding protein TIA1 protects against tau-mediated neurodegeneration in vivo Nat. Neurosci. 2018 21 72 80 10.1038/s41593-017-0022-z 29273772
571. McKerracher L. Chamoux M. Arregui C.O. Role of laminin and integrin interactions in growth cone guidance Mol. Neurobiol. 1996 12 95 116 10.1007/BF02740648 8818145
572. Teng F.Y. Tang B.L. Axonal regeneration in adult CNS neurons-signaling molecules and pathways J. Neurochem. 2006 96 1501 1508 10.1111/j.1471-4159.2006.03663.x 16476081
573. McKenna N.J. O’Malley B.W. Combinatorial control of gene expression by nuclear receptors and coregulators Cell 2002 108 465 474 10.1016/S0092-8674(02)00641-4 11909518
574. Ochsner S.A. Abraham D. Martin K. Ding W. McOwiti A. Kankanamge W. Wang Z. Andreano K. Hamilton R.A. Chen Y. The Signaling Pathways Project, an integrated ‘omics knowledgebase for mammalian cellular signaling pathways Sci. Data 2019 6 252 10.1038/s41597-019-0193-4 31672983
575. Mielke K. Herdegen T. JNK and p38 stresskinases—Degenerative effectors of signal-transduction-cascades in the nervous system Prog. Neurobiol. 2000 61 45 60 10.1016/S0301-0082(99)00042-8 10759064
576. Berridge M.J. Calcium hypothesis of Alzheimer’s disease Pflug. Arch. 2010 459 441 449 10.1007/s00424-009-0736-1
577. Cau Y. Valensin D. Mori M. Draghi S. Botta M. Structure, function, involvement in diseases and targeting of 14-3-3 proteins: An update Curr. Med. Chem. 2018 25 5 21 10.2174/0929867324666170426095015 28462702
578. Cornell B. Toyo-Oka K. 14-3-3 proteins in brain development: Neurogenesis, neuronal migration and neuromorphogenesis Front. Mol. Neurosci. 2017 10 318 10.3389/fnmol.2017.00318 29075177
579. Foote M. Zhou Y. 14-3-3 proteins in neurological disorders Int. J. Biochem. Mol. Biol. 2012 3 152 22773956
580. Agarwal-Mawal A. Qureshi H.Y. Cafferty P.W. Yuan Z. Han D. Lin R. Paudel H.K. 14-3-3 connects glycogen synthase kinase-3 beta to tau within a brain microtubule-associated tau phosphorylation complex J. Biol. Chem. 2003 278 12722 12728 10.1074/jbc.M211491200 12551948
581. Sadik G. Tanaka T. Kato K. Yamamori H. Nessa B.N. Morihara T. Takeda M. Phosphorylation of tau at Ser214 mediates its interaction with 14-3-3 protein: Implications for the mechanism of tau aggregation J. Neurochem. 2009 108 33 43 10.1111/j.1471-4159.2008.05716.x 19014373
582. Rosenquist M. 14-3-3 proteins in apoptosis Braz. J. Med. Biol. Res. 2003 36 403 408 10.1590/S0100-879X2003000400001 12700817
583. Jang S.W. Liu X. Fu H. Rees H. Yepes M. Levey A. Ye K. Interaction of Akt-phosphorylated SRPK2 with 14-3-3 mediates cell cycle and cell death in neurons J. Biol. Chem. 2009 284 24512 24525 10.1074/jbc.M109.026237 19592491
584. Chen Y. Chen X. Yao Z. Shi Y. Xiong J. Zhou J. Su Z. Huang Y. 14-3-3/Tau interaction and Tau amyloidogenesis J. Mol. Neurosci. 2019 68 620 630 10.1007/s12031-019-01325-9 31062171
585. McShea A. Zelasko D.A. Gerst J.L. Smith M.A. Signal transduction abnormalities in Alzheimer’s disease: Evidence of a pathogenic stimuli Brain Res. 1999 815 237 242 10.1016/S0006-8993(98)01135-4 9878757
586. Venezia V. Russo C. Repetto E. Salis S. Dolcini V. Genova F. Nizzari M. Mueller U. Schettini G. Apoptotic cell death influences the signaling activity of the amyloid precursor protein through ShcA and Grb2 adaptor proteins in neuroblastoma SH-SY5Y cells J. Neurochem. 2004 90 1359 1370 10.1111/j.1471-4159.2004.02618.x 15341520
587. Roder H.M. Eden P.A. Ingram V.M. Brain protein kinase PK40erk converts TAU into a PHF-like form as found in Alzheimer’s disease Biochem. Biophys. Res. Commun. 1993 193 639 647 10.1006/bbrc.1993.1672 8512563
588. Uhlén M. Fagerberg L. Hallström B.M. Lindskog C. Oksvold P. Mardinoglu A. Sivertsson Å. Kampf C. Sjöstedt E. Asplund A. Tissue-based map of the human proteome Science 2015 347 1260419 10.1126/science.1260419 25613900
589. O’Brien J.S. Carson G.S. Seo H.-C. Hiraiwa M. Kishimoto Y. Identification of prosaposin as a neurotrophic factor Proc. Natl. Acad. Sci. USA 1994 91 9593 9596 10.1073/pnas.91.20.9593 7937812
590. Coleman J.L. Ngo T. Schmidt J. Mrad N. Liew C.K. Jones N.M. Graham R.M. Smith N.J. Metalloprotease cleavage of the N terminus of the orphan G protein–coupled receptor GPR37L1 reduces its constitutive activity Sci. Signal. 2016 9 ra36 10.1126/scisignal.aad1089 27072655
591. Vaz-Silva J. Gomes P. Jin Q. Zhu M. Zhuravleva V. Quintremil S. Meira T. Silva J. Dioli C. Soares-Cunha C. Endolysosomal degradation of Tau and its role in glucocorticoid-driven hippocampal malfunction EMBO J. 2018 37 e99084 10.15252/embj.201899084 30166454
592. Raiborg C. Stenmark H. The ESCRT machinery in endosomal sorting of ubiquitylated membrane proteins Nature 2009 458 445 452 10.1038/nature07961 19325624
593. Sheehan P. Zhu M. Beskow A. Vollmer C. Waites C.L. Activity-Dependent Degradation of Synaptic Vesicle Proteins Requires Rab35 and the ESCRT Pathway J. Neurosci. 2016 36 8668 8686 10.1523/JNEUROSCI.0725-16.2016 27535913
594. Nixon R.A. Yang D.-S. Autophagy failure in Alzheimer’s disease—Locating the primary defect Neurobiol. Dis. 2011 43 38 45 10.1016/j.nbd.2011.01.021 21296668
595. Green K.N. Billings L.M. Roozendaal B. McGaugh J.L. LaFerla F.M. Glucocorticoids increase amyloid-β and tau pathology in a mouse model of Alzheimer’s disease J. Neurosci. 2006 26 9047 9056 10.1523/JNEUROSCI.2797-06.2006 16943563
596. Gireud-Goss M. Reyes S. Tewari R. Patrizz A. Howe M.D. Kofler J. Waxham M.N. McCullough L.D. Bean A.J. The ubiquitin ligase UBE4B regulates amyloid precursor protein ubiquitination, endosomal trafficking, and amyloid β42 generation and secretion Mol. Cell. Neurosci. 2020 108 103542 10.1016/j.mcn.2020.103542 32841720
597. Ittner L.M. Ke Y.D. Gotz J. Phosphorylated Tau interacts with c-Jun N-terminal kinase-interacting protein 1 (JIP1) in Alzheimer disease J. Biol. Chem. 2009 284 20909 20916 10.1074/jbc.M109.014472 19491104
598. Ozdemir A.Y. Rom I. Kovalevich J. Yen W. Adiga R. Dave R.S. Langford D. PINCH in the cellular stress response to tau-hyperphosphorylation PLoS ONE 2013 8 e58232 10.1371/journal.pone.0058232 23554879
599. Li S. Bordoy R. Stanchi F. Moser M. Braun A. Kudlacek O. Wewer U.M. Yurchenco P.D. Fassler R. PINCH1 regulates cell-matrix and cell-cell adhesions, cell polarity and cell survival during the peri-implantation stage J. Cell Sci. 2005 118 Pt 13 2913 2921 10.1242/jcs.02422 15976450
600. Rearden A. Hurford R. Luu N. Kieu E. Sandoval M. Perez-Liz G. Del Valle L. Powell H. Langford T.D. Novel expression of PINCH in the central nervous system and its potential as a biomarker for human immunodeficiency virus-associated neurodegeneration J. Neurosci. Res. 2008 86 2535 2542 10.1002/jnr.21701 18459134
601. Jang H.J. Yang Y.R. Kim J.K. Choi J.H. Seo Y.K. Lee Y.H. Lee J.E. Ryu S.H. Suh P.G. Phospholipase C-gamma1 involved in brain disorders Adv. Biol. Regu.l 2013 53 51 62 10.1016/j.jbior.2012.09.008 23063587
602. Kang D.-S. Kim I.S. Baik J.-H. Kim D. Cocco L. Suh P.-G. The function of PLCγ1 in developing mouse mDA system Adv. Biol. Regul. 2020 75 100654 10.1016/j.jbior.2019.100654 31558431
603. Hayashi H. Campenot R.B. Vance D.E. Vance J.E. Protection of neurons from apoptosis by apolipoprotein E-containing lipoproteins does not require lipoprotein uptake and involves activation of phospholipase Cgamma1 and inhibition of calcineurin J. Biol. Chem. 2009 284 29605 29613 10.1074/jbc.M109.039560 19717566
604. Shimohama S. Matsushima H. Fujimoto S. Takenawa T. Taniguchi T. Kameyama M. Kimura J. Differential involvement of phospholipase C isozymes in Alzheimer’s disease Gerontology 1995 41 Suppl. 1 13 19 10.1159/000213716 8537014
605. Hampel H. Ewers M. Bürger K. Annas P. Mörtberg A. Bogstedt A. Frölich L. Schröder J. Schönknecht P. Riepe M.W. Lithium trial in Alzheimer’s disease: A randomized, single-blind, placebo-controlled, multicenter 10-week study J. Clin. Psychiatry 2009 70 922 931 10.4088/JCP.08m04606 19573486
606. Pagan F. Hebron M. Valadez E.H. Torres-Yaghi Y. Huang X. Mills R.R. Wilmarth B.M. Howard H. Dunn C. Carlson A. Nilotinib effects in Parkinson’s disease and dementia with Lewy bodies J. Parkinson’s Dis. 2016 6 503 517 10.3233/JPD-160867 27434297
607. Nygaard H.B. Wagner A.F. Bowen G.S. Good S.P. MacAvoy M.G. Strittmatter K.A. Kaufman A.C. Rosenberg B.J. Sekine-Konno T. Varma P. A phase Ib multiple ascending dose study of the safety, tolerability, and central nervous system availability of AZD0530 (saracatinib) in Alzheimer’s disease Alzheimer’s Res. Ther. 2015 7 1 11 10.1186/s13195-015-0119-0 26584966
608. Van Dyck C.H. Nygaard H.B. Chen K. Donohue M.C. Raman R. Rissman R.A. Brewer J.B. Koeppe R.A. Chow T.W. Rafii M.S. Effect of AZD0530 on cerebral metabolic decline in Alzheimer disease: A randomized clinical trial JAMA Neurol. 2019 76 1219 1229 10.1001/jamaneurol.2019.2050 31329216
609. Del Ser T. Steinwachs K.C. Gertz H.J. Andres M.V. Gomez-Carrillo B. Medina M. Vericat J.A. Redondo P. Fleet D. Leon T. Treatment of Alzheimer’s disease with the GSK-3 inhibitor tideglusib: A pilot study J. Alzheimer’s Dis. 2013 33 205 215 10.3233/JAD-2012-120805 22936007
610. Lovestone S. Boada M. Dubois B. Hüll M. Rinne J.O. Huppertz H.-J. Calero M. Andres M.V. Gómez-Carrillo B. Leon T. A phase II trial of tideglusib in Alzheimer’s disease J. Alzheimer’s Dis. 2015 45 75 88 10.3233/JAD-141959 25537011
611. Tolosa E. Litvan I. Höglinger G.U. Burn D. Lees A. Andrés M.V. Gómez-Carrillo B. León T. Del Ser T. Investigators T. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy Mov. Disord. 2014 29 470 478 10.1002/mds.25824 24532007
612. Höglinger G.U. Huppertz H.J. Wagenpfeil S. Andrés M.V. Belloch V. León T. Del Ser T. Investigators T.M. Gmez J. Tijero B. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial Mov. Disord. 2014 29 479 487 10.1002/mds.25815 24488721
613. Tariot P.N. Schneider L.S. Cummings J. Thomas R.G. Raman R. Jakimovich L.J. Loy R. Bartocci B. Fleisher A. Ismail M.S. Chronic divalproex sodium to attenuate agitation and clinical progression of Alzheimer disease Arch. Gen. Psychiatry 2011 68 853 861 10.1001/archgenpsychiatry.2011.72 21810649
614. Leclair-Visonneau L. Rouaud T. Debilly B. Durif F. Houeto J.-L. Kreisler A. Defebvre L. Lamy E. Volteau C. Nguyen J.-M. Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy Clin. Neurol. Neurosurg. 2016 146 35 39 10.1016/j.clineuro.2016.04.021 27136096
615. Fleisher A. Truran D. Mai J. Langbaum J. Aisen P. Cummings J. Jack C. Weiner M. Thomas R. Schneider L. Chronic divalproex sodium use and brain atrophy in Alzheimer disease Neurology 2011 77 1263 1271 10.1212/WNL.0b013e318230a16c 21917762
616. Huisa B.N. Thomas R.G. Jin S. Oltersdorf T. Taylor C. Feldman H.H. Memantine and acetylcholinesterase inhibitor use in Alzheimer’s disease clinical trials: Potential for confounding by indication J. Alzheimer’s Dis. 2019 67 707 713 10.3233/JAD-180684 30636733
617. Malpas C.B. Vivash L. Genc S. Saling M.M. Desmond P. Steward C. Hicks R.J. Callahan J. Brodtmann A. Collins S. A phase IIa randomized control trial of VEL015 (Sodium Selenate) in mild-moderate Alzheimer’s disease J. Alzheimer’s Dis. 2016 54 223 232 10.3233/JAD-160544 27447428
618. VandeVrede L. Dale M.L. Fields S. Frank M. Hare E. Heuer H.W. Keith K. Koestler M. Ljubenkov P.A. McDermott D. Open-Label Phase 1 Futility Studies of Salsalate and Young Plasma in Progressive Supranuclear Palsy Mov. Disord. Clin. Pract. 2020 7 440 447 10.1002/mdc3.12940 32373661
619. Peng Y. Hu Y. Xu S. Li P. Li J. Lu L. Yang H. Feng N. Wang L. Wang X. L-3-n-butylphthalide reduces tau phosphorylation and improves cognitive deficits in AβPP/PS1-Alzheimer’s transgenic mice J. Alzheimer’s Dis. 2012 29 379 391 10.3233/JAD-2011-111577 22233765
620. Rohn T.T. Kokoulina P. Eaton C.R. Poon W.W. Caspase activation in transgenic mice with Alzheimer-like pathology: Results from a pilot study utilizing the caspase inhibitor, Q-VD-OPh Int. J. Clin. Exp. Med. 2009 2 300 20057974
621. Flores J. Noël A. Foveau B. Beauchet O. LeBlanc A.C. Pre-symptomatic Caspase-1 inhibitor delays cognitive decline in a mouse model of Alzheimer disease and aging Nat. Commun. 2020 11 1 14 10.1038/s41467-020-18405-9 31911652
622. Flores J. Noël A. Foveau B. Lynham J. Lecrux C. LeBlanc A.C. Caspase-1 inhibition alleviates cognitive impairment and neuropathology in an Alzheimer’s disease mouse model Nat. Commun. 2018 9 1 14 10.1038/s41467-018-06449-x 29317637
623. Selenica M.-L. Benner L. Housley S.B. Manchec B. Lee D.C. Nash K.R. Kalin J. Bergman J.A. Kozikowski A. Gordon M.N. Histone deacetylase 6 inhibition improves memory and reduces total tau levels in a mouse model of tau deposition Alzheimer’s Res. Ther. 2014 6 1 12 10.1186/alzrt241 24382028
624. Fan S.-J. Huang F.-I. Liou J.-P. Yang C.-R. The novel histone de acetylase 6 inhibitor, MPT0G211, ameliorates tau phosphorylation and cognitive deficits in an Alzheimer’s disease model Cell Death Dis. 2018 9 1 14 10.1038/s41419-018-0688-5 29298988
625. Lee H.-Y. Fan S.-J. Huang F.-I. Chao H.-Y. Hsu K.-C. Lin T.E. Yeh T.-K. Lai M.-J. Li Y.-H. Huang H.-L. 5-Aroylindoles act as selective histone deacetylase 6 inhibitors ameliorating Alzheimer’s disease phenotypes J. Med. Chem. 2018 61 7087 7102 10.1021/acs.jmedchem.8b00151 30028616
626. Onishi T. Maeda R. Terada M. Sato S. Fujii T. Ito M. Hashikami K. Kawamoto T. Tanaka M. A novel orally active HDAC6 inhibitor T-518 shows a therapeutic potential for Alzheimer’s disease and tauopathy in mice Sci. Rep. 2021 11 1 11 10.1038/s41598-021-94923-w 33414495
627. Dickey C.A. Kamal A. Lundgren K. Klosak N. Bailey R.M. Dunmore J. Ash P. Shoraka S. Zlatkovic J. Eckman C.B. The high-affinity HSP90-CHIP complex recognizes and selectively degrades phosphorylated tau client proteins J. Clin. Investig. 2007 117 648 658 10.1172/JCI29715 17304350
628. Miyata Y. Li X. Lee H.-F. Jinwal U.K. Srinivasan S.R. Seguin S.P. Young Z.T. Brodsky J.L. Dickey C.A. Sun D. Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels ACS Chem. Neurosci. 2013 4 930 939 10.1021/cn300210g 23472668
629. Abisambra J. Jinwal U.K. Miyata Y. Rogers J. Blair L. Li X. Seguin S.P. Wang L. Jin Y. Bacon J. Allosteric heat shock protein 70 inhibitors rapidly rescue synaptic plasticity deficits by reducing aberrant tau Biol. Psychiatry 2013 74 367 374 10.1016/j.biopsych.2013.02.027 23607970
630. Hardy J.A. Higgins G.A. Alzheimer’s disease: The amyloid cascade hypothesis Science 1992 256 184 186 10.1126/science.1566067 1566067
631. Selkoe D.J. Hardy J. The amyloid hypothesis of Alzheimer’s disease at 25 years EMBO Mol. Med. 2016 8 595 608 10.15252/emmm.201606210 27025652
632. van der Kant R. Langness V.F. Herrera C.M. Williams D.A. Fong L.K. Leestemaker Y. Steenvoorden E. Rynearson K.D. Brouwers J.F. Helms J.B. Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-β in iPSC-derived Alzheimer’s disease neurons Cell Stem Cell 2019 24 363 375.e9 10.1016/j.stem.2018.12.013 30686764
633. Young J.E. Fong L.K. Frankowski H. Petsko G.A. Small S.A. Goldstein L.S. Stabilizing the retromer complex in a human stem cell model of Alzheimer’s disease reduces TAU phosphorylation independently of amyloid precursor protein Stem Cell Rep. 2018 10 1046 1058 10.1016/j.stemcr.2018.01.031 29503090
634. Bhaskar K. Konerth M. Kokiko-Cochran O.N. Cardona A. Ransohoff R.M. Lamb B.T. Regulation of tau pathology by the microglial fractalkine receptor Neuron 2010 68 19 31 10.1016/j.neuron.2010.08.023 20920788
635. Johnson K.A. Schultz A. Betensky R.A. Becker J.A. Sepulcre J. Rentz D. Mormino E. Chhatwal J. Amariglio R. Papp K. Tau positron emission tomographic imaging in aging and early A lzheimer disease Ann. Neurol. 2016 79 110 119 10.1002/ana.24546 26505746
636. Schöll M. Lockhart S.N. Schonhaut D.R. O’Neil J.P. Janabi M. Ossenkoppele R. Baker S.L. Vogel J.W. Faria J. Schwimmer H.D. PET imaging of tau deposition in the aging human brain Neuron 2016 89 971 982 10.1016/j.neuron.2016.01.028 26938442
637. Grothe M.J. Barthel H. Sepulcre J. Dyrba M. Sabri O. Teipel S.J. Alzheimer’s Disease Neuroimaging Initiative. In vivo staging of regional amyloid deposition Neurology 2017 89 2031 2038 10.1212/WNL.0000000000004643 29046362
638. Jansen W.J. Ossenkoppele R. Knol D.L. Tijms B.M. Scheltens P. Verhey F.R. Visser P.J. Aalten P. Aarsland D. Alcolea D. Prevalence of cerebral amyloid pathology in persons without dementia: A meta-analysis JAMA 2015 313 1924 1938 10.1001/jama.2015.4668 25988462
639. Gonzalez M.W. Kann M.G. Chapter 4: Protein interactions and disease PLoS Comput. Biol. 2012 8 e1002819 10.1371/journal.pcbi.1002819 23300410
640. Morris M. Maeda S. Vossel K. Mucke L. The many faces of tau Neuron 2011 70 410 426 10.1016/j.neuron.2011.04.009 21555069

